<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Improving adverse drug event reporting by healthcare professionals - Shalviri, G - 2024 | Cochrane Library</title> <meta content="Improving adverse drug event reporting by healthcare professionals - Shalviri, G - 2024 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012594.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Improving adverse drug event reporting by healthcare professionals - Shalviri, G - 2024 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012594.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012594.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Improving adverse drug event reporting by healthcare professionals" name="citation_title"/> <meta content="Gloria Shalviri" name="citation_author"/> <meta content="Shalviri_g@yahoo.com" name="citation_author_email"/> <meta content="Niayesh Mohebbi" name="citation_author"/> <meta content="Tehran University of Medical Sciences" name="citation_author_institution"/> <meta content="Fariba Mirbaha" name="citation_author"/> <meta content="Tehran University of Medical Sciences" name="citation_author_institution"/> <meta content="Reza Majdzadeh" name="citation_author"/> <meta content="Bahareh Yazdizadeh" name="citation_author"/> <meta content="Tehran University of Medical Sciences" name="citation_author_institution"/> <meta content="Kheirollah Gholami" name="citation_author"/> <meta content="Tehran University of Medical Sciences" name="citation_author_institution"/> <meta content="Liesl Grobler" name="citation_author"/> <meta content="Monash University" name="citation_author_institution"/> <meta content="Christopher J Rose" name="citation_author"/> <meta content="Weng Yee Chin" name="citation_author"/> <meta content="The University of Hong Kong" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD012594.pub2" name="citation_doi"/> <meta content="2024" name="citation_date"/> <meta content="2024/10/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012594.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012594.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012594.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Adverse Drug Reaction Reporting Systems [statistics &amp; numerical data]; Bias; Controlled Before-After Studies; *Drug-Related Side Effects and Adverse Reactions [epidemiology, prevention &amp; control]; *Health Personnel; Interrupted Time Series Analysis; *Medication Errors [prevention &amp; control, statistics &amp; numerical data]; Non-Randomized Controlled Trials as Topic; Randomized Controlled Trials as Topic" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012594.pub2&amp;doi=10.1002/14651858.CD012594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="1ljSZou6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012594\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012594\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012594\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012594\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ru","th","ko","fa","fr"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD012594.pub2",title:"Improving adverse drug event reporting by healthcare professionals",firstPublishedDate:"Oct 29, 2024 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Central Editorial Service",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012594.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012594.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012594.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012594.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012594.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012594.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012594.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012594.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012594.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012594.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2570 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012594.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-sec-0088"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-sec-0075"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/appendices#CD012594-sec-0093"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/supinfo/CD012594-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/supinfo/CD012594-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2024 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Improving adverse drug event reporting by healthcare professionals</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/information#CD012594-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Gloria Shalviri</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/information#CD012594-cr-0005">Niayesh Mohebbi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/information#CD012594-cr-0006">Fariba Mirbaha</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/information#CD012594-cr-0007">Reza Majdzadeh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/information#CD012594-cr-0008">Bahareh Yazdizadeh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/information#CD012594-cr-0009">Kheirollah Gholami</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/information#CD012594-cr-0010">Liesl Grobler</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/information#CD012594-cr-0011">Christopher J Rose</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012594.pub2/information#CD012594-cr-0012">Weng Yee Chin</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/information/en#CD012594-sec-0106">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 October 2024 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012594.pub2">https://doi.org/10.1002/14651858.CD012594.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012594-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012594-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012594-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012594-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012594-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012594-abs-0010">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD012594-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012594-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012594-abs-0001" lang="en"> <section id="CD012594-sec-0001"> <h3 class="title" id="CD012594-sec-0001">Background</h3> <p>Adverse drug events, encompassing both adverse drug reactions and medication errors, pose a significant threat to health, leading to illness and, in severe cases, death. Timely and voluntary reporting of adverse drug events by healthcare professionals plays a crucial role in mitigating the morbidity and mortality linked to unexpected reactions and improper medication usage. </p> </section> <section id="CD012594-sec-0002"> <h3 class="title" id="CD012594-sec-0002">Objectives</h3> <p>To assess the effectiveness of different interventions aimed at healthcare professionals to improve the reporting of adverse drug events. </p> </section> <section id="CD012594-sec-0003"> <h3 class="title" id="CD012594-sec-0003">Search methods</h3> <p>We searched CENTRAL, Embase, MEDLINE and several other electronic databases and trials registers, including ClinicalTrials.gov and WHO ICTRP, from inception until 14 October 2022. We also screened reference lists in the included studies and relevant systematic reviews. </p> </section> <section id="CD012594-sec-0004"> <h3 class="title" id="CD012594-sec-0004">Selection criteria</h3> <p>We included randomised trials, non‐randomised controlled studies, controlled before‐after studies, interrupted time series studies (ITS) and repeated measures studies, assessing the effect of any intervention aimed at healthcare professionals and designed to increase adverse drug event reporting. Eligible comparators were healthcare professionals' usual reporting practice or a different intervention or interventions designed to improve adverse drug event reporting rate. We excluded studies of interventions targeted at adverse event reporting following immunisation. Our primary outcome measures were the total number of adverse drug event reports (including both adverse drug reaction reports and medication error reports) and the number of false adverse drug event reports (encompassing both adverse drug reaction reports and medication error reports) submitted by healthcare professionals. Secondary outcomes were the number of serious, high‐causality, unexpected or previously unknown, and new drug‐related adverse drug event reports submitted by healthcare professionals. We used GRADE to assess the certainty of evidence. </p> </section> <section id="CD012594-sec-0005"> <h3 class="title" id="CD012594-sec-0005">Data collection and analysis</h3> <p>We followed standard methods recommended by Cochrane and the Cochrane Effective Practice and Organisation of Care (EPOC) Group. We extracted and reanalysed ITS study data and imputed treatment effect estimates (including standard errors or confidence intervals) for the randomised studies. </p> </section> <section id="CD012594-sec-0006"> <h3 class="title" id="CD012594-sec-0006">Main results</h3> <p>We included 15 studies (eight RCTs, six ITS, and one non‐randomised cross‐over study) with approximately 62,389 participants. All studies were conducted in high‐income countries in large tertiary care hospitals. There was a high risk of performance bias in the controlled studies due to the nature of the interventions. None of the ITS studies had a control arm, so we could not be sure of the detected effects being independent of other changes. None of the studies reported on the number of false adverse drug event reports submitted. </p> <p>There is low‐certainty evidence suggesting that an education session, together with reminder card and adverse drug reaction (ADR) report form, may substantially improve the rate of ADR reporting by healthcare professionals when compared to usual practice (i.e. spontaneous reporting with or without some training provided by regional pharmacosurveillance units). These educational interventions increased the number of ADR reports in total (RR 3.00, 95% CI 1.53 to 5.90; 5 studies, 21,655 participants), serious ADR reports (RR 3.30, 95% CI 1.51 to 7.21; 5 studies, 21,655 participants), high‐causality ADR reports (RR 2.48, 95% CI 1.11 to 5.57; 5 studies, 21,655 participants), unexpected ADR reports (RR 4.72, 95% CI 1.75 to 12.76; 4 studies, 15,085 participants) and new drug‐related ADR reports (RR 8.68, 95% CI 3.40 to 22.13; 2 studies, 7884 participants). </p> <p>Additionally, low‐certainty evidence suggests that, compared to usual practice (i.e. spontaneous reporting), making it easier to report ADRs by using a standardised discharge form with added ADR items may slightly improve the total number of ADR reports submitted (RR 2.06, 95% CI 1.11 to 3.83; 1 study, 5967 participants). The discharge form tested was based on the ‘Diagnosis Related Groups’ (DRG) system for recording patient diagnoses, and the medical and surgical procedures received during their hospital stay. </p> <p>Due to very low‐certainty evidence, we do not know if the following interventions have any effect on the total number of adverse drug event reports (including both ADR and ME reports) submitted by healthcare professionals: </p> <p>‐ sending informational letters or emails to GPs and nurses;</p> <p>‐ multifaceted interventions, including financial and non‐financial incentives, fines, education and reminder cards; </p> <p>‐ implementing government regulations together with financial incentives;</p> <p>‐ including ADR report forms in quarterly bulletins and prescription pads;</p> <p>‐ providing a hyperlink to the reporting form in hospitals' electronic patient records;</p> <p>‐ improving the reporting method by re‐engineering a web‐based electronic error reporting system; </p> <p>‐ the presence of a clinical pharmacist in a hospital setting actively identifying adverse drug events and advocating for the identification and reporting of adverse drug events. </p> </section> <section id="CD012594-sec-0007"> <h3 class="title" id="CD012594-sec-0007">Authors' conclusions</h3> <p>Compared to usual practice (i.e. spontaneous reporting with or without some training from regional pharmacosurveillance units), low‐certainty evidence suggests that the number of ADR reports submitted may substantially increase following an education session, paired with reminder card and ADR report form, and may slightly increase with the use of a standardised discharge form method that makes it easier for healthcare professionals to report ADRs. </p> <p>The evidence for other interventions identified in this review, such as informational letters or emails and financial incentives, is uncertain. </p> <p>Future studies need to assess the benefits (increase in the number of adverse drug event reports) and harms (increase in the number of false adverse drug event reports) of any intervention designed to improve healthcare professionals' reporting of adverse drug events. Interventions to increase the number of submitted adverse drug event reports that are suitable for use in low‐ and middle‐income countries should be developed and rigorously evaluated. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012594-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012594-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012594-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012594-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012594-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012594-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012594-abs-0011">한국어</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012594-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD012594-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012594-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012594-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012594-abs-0002" lang="en"> <h3>Improving healthcare professionals' reporting of adverse drug reactions and medication errors </h3> <p><b>Key messages</b> </p> <p>‐ Healthcare professionals have a responsibility to report unexpected and harmful responses to medicines. These responses are known as 'adverse drug events', a term that includes both adverse drug reactions (ADRs) and medication errors (MEs). </p> <p>‐ An education session (outreach, in‐person workshops or via telephone), along with providing a reminder card and ADR report form, may substantially increase the number of ADR reports submitted. </p> <p>‐ Using a standardised discharge form with additional ADR items that is designed to make it easier to report ADRs may slightly increase the number of ADR reports submitted. </p> <p>‐ Future studies need to assess the benefit (increase in the number of adverse drug event reports submitted) and harm (increase in the number of false adverse drug event reports submitted) of any intervention designed to improve healthcase professionals' reporting of adverse drug events. </p> <p>‐ Interventions suitable for use in low‐ and middle‐income countries need to be developed and rigorously evaluated. </p> <p><b>What did we want to find out?</b> </p> <p>This Cochrane review investigated whether interventions for healthcare professionals are effective for improving at their reporting of adverse drug events. Adverse drug events include any adverse drug reaction (ADR) and any medication error (ME). </p> <p><b>What did we do?</b> </p> <p>We looked at evidence from a range of different types of studies to find out if interventions aimed at healthcare professionals could increase the number of adverse drug event reports they make. We compared the total number of adverse drug event reports (which included both ADR and ME reports) submitted by healthcare professionals. We were also interested in the number of false adverse drug event reports they made. As well as the total number of reports, we looked separately at the number of reports submitted for adverse drug events that were categorised as serious, high‐causality (i.e. very likely to be caused by the drug), unexpected (i.e. previously unknown) or related to recent drugs (i.e. only used in the last five years). </p> <p><b>What did we find?</b> </p> <p>This review included 15 studies (62,389 participants) that compared the effect of various interventions aimed at healthcare professionals to increase the number of adverse drug event reports they make. All the studies were carried out in high‐income countries. None of the studies looked at whether these interventions led to more false adverse drug event reports. </p> <p>Compared to usual practice (spontaneous reporting and some training from regional units that monitor the safety of medicines), an education session about why and how to report adverse events, plus reminder of the session content and provision of an ADR report form, may increase the number of ADR reports made by healthcare professionals. </p> <p>Compared to usual practice (spontaneous reporting), using a standardised discharge form with additional ADR items about when the ADR occurred and how it developed may also slightly improve the number of ADR reports made. The standardised form tested was based on the ‘Diagnosis Related Groups’ system for recording patient diagnoses and the medical and surgical procedures patients receive during their hospital stay. </p> <p>We are very uncertain about the effectiveness of other interventions that were tested in the studies, including: </p> <p>‐ sending informational letters or emails to GPs and nurses;</p> <p>‐ interventions with multiple aspects, including financial and non‐financial incentives, fines, education and reminder cards; </p> <p>‐ implementing government regulations together with financial incentives;</p> <p>‐ including ADR report forms in quarterly bulletins and prescription pads;</p> <p>‐ providing a hyperlink to the reporting form in hospitals' electronic patient records;</p> <p>‐ improving the reporting method by re‐engineering the web‐based electronic error reporting system; </p> <p>‐ the presence of a clinical pharmacist in hospital who actively identifies adverse drug events and encourages the identification and reporting of adverse drug events. </p> <p><b>How up to date is this review?</b> </p> <p>The evidence in this review is based on searches up to October 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012594-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012594-sec-0088"></div> <h3 class="title" id="CD012594-sec-0089">Implications for practice</h3> <section id="CD012594-sec-0089"> <p>Low‐certainty evidence suggests that two of the interventions tested in the studies may be useful for increasing the number of ADR reports submitted by healthcare professionals: an education session together with reminder card and adverse drug reaction (ADR) report form may substantially increase the number of ADR reports, and making it easier to report ADRs by using a modified standard discharge form may slightly increase ADR reports. The local applicability of these interventions and how the interventions might be implemented in different settings needs to be assessed. All other interventions identified in the eligible studies, such as informational letters or emails, government regulations and financial incentives, and multifacted interventions warrant further rigorous evaluation in real‐world practice settings as the certainty of the evidence for these interventions is very low. </p> </section> <h3 class="title" id="CD012594-sec-0090">Implications for research</h3> <section id="CD012594-sec-0090"> <p> <ul id="CD012594-list-0021"> <li> <p>Although randomised controlled trials provide the most robust evidence of effectiveness, it may be more feasible and pragmatic to assess the effectiveness of interventions to improve adverse drug event (ADE) reporting using carefully controlled observational study designs. For example, the effectiveness of a clinical pharmacist actively identifying and encouraging the identification and reporting of ADEs in a hospital setting (the intervention) could be assessed using an interrupted time series study design. Two or more prespecified geographic regions, where data from routine systems is readily available and where interventions can be implemented across a very wide jurisdiction, would be identified. The intervention could be implemented in some hospitals in the regions and not in others (these would serve as the control group). Routine data from all the hospitals would be collected at three or more time points prior to the implementation of the intervention and at three or more time points after the intervention. The type of intervention being assessed would determine the study setting and number of sites to be included. </p> </li> <li> <p>Most of the studies in the current body of evidence are focused on physicians. While future studies should continue to focus on testing the effectiveness of the various interventions for physicians, studies should also focus on other healthcare professionals, such as nurses and general practitioners. </p> </li> <li> <p>Studies might also consider investigating the effectiveness of these interventions in both inpatient and outpatient settings. </p> </li> <li> <p>Studies should assess any intervention in terms of both the benefit (increase in the number of ADE reports) and potential harm (increase in the number of false ADE reports). </p> </li> <li> <p>Countries around the world have different pharmacovigilance infrastructures and capacities, different disease burdens and distribution, different medical care cultures, different medical education programmes, and vastly different economic status, so interventions to increase the reporting rate of ADEs need to be developed and tested in more countries, particularly low‐ and middle‐income countries. </p> </li> <li> <p>This review focused on interventions to enhance ADE reporting in healthcare providers only. However, other relevant populations (e.g. patients and students) are also significant contributors to this information, and reviews of interventions targeted at enhancing their reporting rates are also valuable. </p> </li> <li> <p>Healthcare professional students (e.g. medical, nursing and pharmacy students) are a crucial target population for interventions that enhance ADE reporting. Identifying effective educational interventions is an important area for medical education research to help inform future curriculum development. </p> </li> <li> <p>We excluded many studies, with relevant interventions targeted at relevant participants (healthcare professionals), from this review due to having an ineligible study design. Depending on the availability and integrity of the data, it may be possible to re‐analyse the data from uncontrolled before‐after studies and retrospective observational studies using interrupted time series or repeated‐measures analyses. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012594-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012594-sec-0008"></div> <div class="table" id="CD012594-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Education session plus reminder card and ADR report form versus usual practice</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participants:</b> physicians and pharmacists </p> <p><b>Intervention:</b> education session (in‐person workshop or via telephone), reminder card and ADR report form </p> <p><b>Comparator:</b> usual practice (spontaneous reporting; briefing and standard training given by regional pharmacosurveillance unit) </p> <p><b>Setting:</b> hospitals and outpatient centres in Northern Portugal and Spain </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Risk ratio*</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks<sup>‡</sup> </b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> <p><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk with usual practice</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with education session plus reminder card and report form</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of ADE reports (including ADR reports and ME reports): number of ADR reports </p> <p>Follow‐up: 13 to 16 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.00 (1.53 to 5.90)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 ADR reports per 1000 practitioner years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240 ADR reports per 1000 practitioner years (122 to 472)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21,665 (5 cRCTs)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An education session, together with reminder card and ADR report form, may improve the reporting rate of ADRs. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of false ADE reports (including false ADR reports and false ME reports)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of serious ADE reports (including serious ADR reports and serious ME reports)</p> <p>Follow‐up: 13 to 16 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.30 (1.51 to 7.21)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 ADR reports per 1000 practitioner years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 ADR reports per 1000 practitioner years (15 to 72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21,665 (5 cRCTs)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An education session, together with reminder card and ADR report form, may improve the reporting rate of serious ADRs. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of high‐causality ADE reports (including high‐causality ADR reports and high‐causality ME reports) </p> <p>Follow‐up: 13 to 16 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.48 (1.11 to 5.57)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 ADR reports per 1000 practitioner years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 ADR reports per 1000 practitioner years (22 to 111)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21,665 (5 cRCTs)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An education session, together with reminder card and ADR report form, may improve the reporting rate of high‐causality ADRs. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of unexpected ADE reports (including unexpected ADR reports and unexpected ME reports) </p> <p>Follow‐up: 13 to 16 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4.72 (1.75 to 12.76)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 ADR reports per 1000 practitioner years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 ADR reports per 1000 practitioner years (35 to 255)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,085 (4 cRCTs)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An education session, together with reminder card and ADR report form, may improve the reporting rate of unexpected ADRs </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of new‐drug‐related ADE reports (including drug‐related ADR reports and drug‐related ME reports) </p> <p>Follow‐up: 13 to 16 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8.68 (3.40 to 22.13)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 ADR reports per 1000 practitioner years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 ADR reports per 1000 practitioner years (17 to 111)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7884 (2 cRCTs)<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An education session, together with reminder card and ADR report form, may improve the reporting rate of new‐drug‐related ADRs. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ADE: adverse drug event; ADR: adverse drug reaction; CI: confidence interval; cRCT: cluster‐randomised controlled trial; ME: medication error; vs: versus </p> <p>*Risk ratios &gt; 1 are associated with more ADRs with education session plus reminder card and ADR report form versus usual practice. </p> <p><sup>‡</sup>Illustrative comparative risks are presented as numbers of ADRs per 1000 practitioner years and are rounded to whole numbers. </p> <p><sup>1</sup><a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a> (physicians, education group session); <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a> (pharmacists, education group session); <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a> (physicians; same intervention clusters from <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a> randomised a second time to telephone interview or workshop); <a href="./references#CD012594-bbs2-0010" title="ISRCTN91140684. An educational intervention to improve adverse drug reactions reporting among Galician physicians. https://www.isrctn.com/ISRCTN91140684 (first received 7 May 2009). Lopez-GonzalezE , HerdeiroMT , Pineiro-LamasM , FigueirasA , Grephepi group. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Safety2015;38(2):189-96. ">Lopez‐Gonzalez 2015</a> (physicians, education group session); <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a> (pharmacists, telephone interview or workshop) </p> <p><sup>2</sup><a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a> (physicians); <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a> (pharmacists); <a href="./references#CD012594-bbs2-0010" title="ISRCTN91140684. An educational intervention to improve adverse drug reactions reporting among Galician physicians. https://www.isrctn.com/ISRCTN91140684 (first received 7 May 2009). Lopez-GonzalezE , HerdeiroMT , Pineiro-LamasM , FigueirasA , Grephepi group. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Safety2015;38(2):189-96. ">Lopez‐Gonzalez 2015</a> (physicians); <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a> (pharmacists) </p> <p><sup>3</sup><a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a> </p> <p><sup>4</sup>Downgraded once for serious risk of bias (performance bias and potential selection bias due to baseline differences in reporting rates between intervention and control group; see <a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a>); downgraded once for serious inconsistency: I<sup>2</sup> = 95%. The inconsistency might be explained by the mode of delivery of the education (i.e. telephone vs interactive group session vs workshop) or the different target audience (physicians vs pharmacist), but we are uncertain of this; no serious imprecision; no serious indirectness; no publication bias. </p> <p><sup>5</sup>Downgraded once for serious risk of bias (performance bias and potential selection bias due to baseline differences in reporting rates between intervention and control group; see <a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a>); downgraded once for serious inconsistency: I<sup>2</sup> = 96%. The inconsistency might be explained by the mode of delivery of the education (i.e. telephone vs interactive group session vs workshop) or the different target audience (physicians vs. pharmacist), or both, but we are uncertain of this; no serious imprecision; no serious indirectness; no publication bias. </p> <p><sup>6</sup>Downgraded once for serious risk of bias (performance bias and potential selection bias due to baseline differences in reporting rates between intervention and control group; see <a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a>); downgraded once for serious inconsistency: I<sup>2</sup> = 100%. The inconsistency might be explained by the mode of delivery of the educational outreach (i.e. telephone vs interactive group session vs workshop) or the different target audience (physicians vs pharmacist), but we are uncertain of this; no serious imprecision; no serious indirectness; no publication bias. </p> <p><sup>7</sup>Downgraded once for serious risk of bias (performance bias and potential selection bias due to baseline differences in reporting rates between intervention and control group; see <a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a>); downgraded once for serious inconsistency: I<sup>2</sup> = 64%. The inconsistency might be explained by the mode of delivery of the education (i.e. telephone vs interactive group session vs workshop) or the different target audience (physicians vs pharmacist), but we are uncertain of this; no serious imprecision; no serious indirectness; no publication bias. </p> <p><sup>8</sup>Downgraded once for serious risk of performance bias and potential selection bias due to baseline differences in reporting rates between intervention and control group (see <a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>); no serious inconsistency; downgraded once for serious imprecision (wide confidence intervals so uncertain of the true estimate of effect); no serious indirectness; no publication bias </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012594-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Informational letter or email versus usual practice</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participants:</b> general practitioners and nurses </p> <p><b>Intervention:</b> informational letter or email </p> <p><b>Comparator:</b> usual practice (spontaneous reporting) </p> <p><b>Setting:</b> primary healthcare units in Sweden </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Rate ratio<sup>*</sup> </b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative rates</b><sup>‡</sup><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Exposure</b><sup>†</sup><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed rate with usual practice</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding rate with informational letter or email</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of ADE reports (including ADR reports and ME reports): number of ADR reports after one year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.28 (0.42 to 3.91)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 ADR reports per 100 practitioner years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 ADR reports per 100 practitioner years (34 to 313)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>268 primary healthcare unit years (2 RCTs)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if informational letters or emails to GPs and nurses increase the total number of ADR reports because the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of false ADE reports (including false ADR reports and false ME reports)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of serious ADE reports (including serious ADR reports and serious ME reports): number of serious ADR reports after one year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.79 (0.69 to 4.65)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 ADR reports per 100 practitioner years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 ADR reports per 100 practitioner years (7 to 47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>268 primary healthcare unit years (2 RCTs)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if informational letters or emails to GPs and nurses increase serious ADR reports because the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of high‐causality ADE reports (including high‐causality ADR reports and high‐causality ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of unexpected ADE reports (including unexpected ADR reports and unexpected ME reports): number of unexpected ADR reports after one year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.46 (0.92 to 2.30)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 ADR reports per 100 practitioner years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 ADR reports per 100 practitioner years (18 to 46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>268 primary healthcare unit years (2 RCTs)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if informational letters or emails to GPs and nurses increase the number of unexpected ADR reports as the certainty of the evidence is very low. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of new drug‐related ADE reports (including drug‐related ADR reports and drug‐related ME reports): number of new drug‐related ADR reports after one year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.58 (1.12 to 5.92)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 ADR reports per 100 practitioner years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 ADR reports per 100 practitioner years (6 to 30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>268 primary healthcare unit years (2 RCTs)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if informational letters or emails to GPs and nurses increase the total number of new drug‐related ADR reports because the evidence is very uncertain. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ADE: adverse drug event; ADR: adverse drug reaction; CI: confidence interval; RCT: randomised controlled trials; ME: medication error; vs: versus </p> <p><sup>*</sup>Rate ratios &gt; 1 are associated with more ADRs with informational letter or email versus usual practice. </p> <p><sup>†</sup>Unit of exposure is primary healthcare unit years. </p> <p><sup>‡</sup>Illustrative comparative rates are presented as numbers of ADR reports per 100 practitioner years and are rounded to whole numbers. </p> <p><sup>1</sup><a href="./references#CD012594-bbs2-0008" title="JohanssonML , BrunlofG , EdwardC , WallerstedtSM . Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports. European Journal of Clinical Pharmacology2009;65(5):511-4. ">Johansson 2009</a>; <a href="./references#CD012594-bbs2-0009" title="JohanssonML , HaggS , WallerstedtSM . Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study. BMC Clinical Pharmacology2011;11:14. ">Johansson 2011</a> </p> <p><sup>2</sup>Downgraded once for serious risk of bias (performance bias and potential contamination bias); no serious inconsistency; downgraded twice for very serious imprecision: wide confidence intervals that cross the line of no effect (in the case of total number of ADR reports, number of serious ADR reports and number of unexpected ADR reports), small event rate (total of 242 ADR reports from 268 units in 2007 and 2008, total of 35 serious ADR reports from 268 units in 2007 and 2008, total of 85 unexpected ADR reports from 268 units in 2007 and 2008); no serious indirectness; no publication bias </p> <p><sup>3</sup>Downgraded once for serious risk of bias (performance bias and potential contamination bias); no serious inconsistency; downgraded twice for very serious imprecision: wide confidence intervals, small event rate (total of 16 new drug‐related ADRs reported from 268 units in 2007 and 2008); no serious indirectness; no publication bias </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012594-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Multifaceted interventions versus usual practice</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participants:</b> physicians and pharmacists </p> <p><b>Intervention:</b> multifaceted intervention (including financial incentives, fines, non‐financial incentives, education, reminders) </p> <p><b>Comparator:</b> usual practice (spontaneous reporting) </p> <p><b>Setting:</b> hospital </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative numbers of ADES<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative numbers of ADEs</b><sup>‡</sup><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Mean study duration (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed number with usual practice</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding number with multifaceted intervention</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of ADE reports (including ADR reports and ME reports): number of ADR reports after one year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4.29 (0.32 to 56.76)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 ADR reports per 1000 practitioners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>343 ADR reports per 1000 practitioners (26 to 4541)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.5 years (2)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if multifaceted interventions increase the total number of ADR reports in physicians and pharmacists one year after implementation because the evidence is very uncertain.<sup>3</sup> </p> <p>Data after two years in footnotes<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of false ADE reports (including false ADR reports and false ME reports)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of serious ADE reports (including serious ADR reports and serious ME reports): number of serious ADR reports after one year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.10 (0.29 to 15.20)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 ADR reports per 1000 practitioners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 ADR reports per 1000 practitioners (3 to 150)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.5 years (2)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if multifaceted interventions increase the total number of serious ADR reports in physicians and pharmacists one year after implementation because the evidence is very uncertain. </p> <p>Data after two years in footnotes<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of high‐causality ADE reports (including high‐causality ADR reports and high‐causality ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of unexpected ADE reports (including unexpected ADR reports and unexpected ME reports): unexpected or previously unknown ADR reports after one year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.02 to 22.75)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 ADR reports per 1000 practitioners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 ADR reports per 1000 practitioners (0 to 455)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0 years (1)<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if multifaceted interventions increase the total number of unexpected (previously unknown) ADR reports in physicians and pharmacists one year after implementation because the evidence is very uncertain </p> <p>Data after two years in footnotes<sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of new drug‐related ADE reports (including drug‐related ADR reports and drug‐related ME reports): number of new drug‐ related ADR reports after one year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.65 (0.20 to 13.77)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 ADR reports per 1000 practitioners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 ADR reports per 1000 practitioners (1 to 69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.5 years (2)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if multifaceted interventions increase the total number of new‐drug‐related ADR reports in physicians and pharmacists one year after implementation, because the evidence is very uncertain. </p> <p>Data after two years in footnotes<sup>9</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ADE: adverse drug event; ADR: adverse drug reaction; CI: confidence interval; ITS: interrupted time series; ME: medication error; vs: versus </p> <p><sup>*</sup>Relative numbers of ADRs &gt; 1 are associated with more ADRs with multifaceted intervention versus usual practice. </p> <p><sup>‡</sup>Illustrative comparative numbers of ADRs are presented as numbers of ADRs after 1 and 2 years in a setting with 1000 practitioners. </p> <p><sup>1</sup>Meta‐analysis of data from <a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>: financial incentive (1% of physician salary) for spontaneous reporting of ADRs plus fine (double the amount of the incentive) for not reporting or missing an ADR (study timeline ‐ 2006 to 2009 (pre‐intervention), 2009 to 2011 (financial incentive), 2012 to 2014 (financial incentive plus government regulations for antimicrobial agents), December 2014 (last time point), total 108 observations); and <a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>: financial incentives (1% of physicians salary) for spontaneous reporting of ADRs, twice‐yearly education meeting, reminder cards and list of the most important ADRs (study timeline ‐ January 1998 (first point); December 2002 (intervention implemented); December 2005 (last time point); a total of 96 observations) </p> <p><sup>2</sup>Both studies are observational ITS studies, so GRADE starts at low; downgraded once for serious risk of bias (high risk of bias for domain: intervention independent of other changes; there are no compelling arguments that the intervention occurred independently of other changes over time and the outcome was not influenced by other confounding variables or historic events during study period); downgraded once for serious inconsistency (I<sup>2</sup> = 92% for year 1 and 81% for year 2, inconsistency between the studies may be explained by the fact that one study was conducted in China and the other in Spain, but not certain of this); no serious indirectness; downgraded once for serious imprecision (wide confidence intervals that cross the line of no effect); no other considerations. </p> <p><sup>3</sup>Data from <a href="./references#CD012594-bbs2-0001" title="AliS , EgunsolaO , Al-DossariDS , Al-ZaagiIA . Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Therapeutic Advances in Drug Safety2018;9(10):585-90. [DOI: 10.1177/2042098618790209]">Ali 2018</a> (intervention included implementation of financial and non‐financial incentives, i.e. employee of the month award, letters of appreciation, a day's leave, performance excellence award of extra month’s salary and a certificate) could not be included in the meta‐analysis as the length of follow‐up was much shorter (study timelines ‐ 2 years; a total of 24 observations) than <a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a> (8 years; 108 observations) and <a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a> (7 years; 96 observations). Data from <a href="./references#CD012594-bbs2-0001" title="AliS , EgunsolaO , Al-DossariDS , Al-ZaagiIA . Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Therapeutic Advances in Drug Safety2018;9(10):585-90. [DOI: 10.1177/2042098618790209]">Ali 2018</a> shows relative numbers of ADR reports after 1 year: 6.99, 95% CI 3.43 to 10.54; prior to intervention ‐ 80 ADR reports per 1000 practitioners, post intervention implementation ‐ 560 ADR reports per 1000 practitioners (274 to 843); very low certainty evidence as based on observational ITS study, so GRADE starts at low; downgraded once for serious risk of bias (high risk of bias for other bias ‐ seasonality not adjusted for; and intervention independent of other changes <i>‐</i> there are no compelling arguments that the intervention occurred independently of other changes over time and the outcome was not influenced by other confounding variables or historic events during study period); no serious inconsistency; no serious indirectness; no serious imprecision; no other considerations. </p> <p><sup>4</sup>Total number of ADE reports (including ADR reports and ME reports): <b>relative number of ADR reports after 2 years</b> 8.11 (95% CI 0.61 to 107.93); assumed number with usual practice 160 expected ADR reports per 1000 practitioners, corresponding number with multifaceted intervention 1298 expected ADR reports per 1000 practitioners (98 to 17,269), mean study duration 6.5 years, 2 studies<sup>1</sup> ; certainty of the evidence: very low (see footnote<sup>2</sup>) </p> <p><sup>5</sup><b>Relative number of serious ADR reports after 2 years</b>: 2.57 (95% CI 0.22 to 29.93); prior to intervention ‐ 20 ADR reports per 1000 practitioners, post intervention ‐ 51 ADR reports per 1000 practitioners (4 to 599) mean study duration 6.5 years (<a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>; <a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>); very low certainty evidence (see footnote<sup>2</sup>) </p> <p><sup>6</sup><a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a> </p> <p><sup>7</sup>Observational ITS study, so GRADE starts at low; downgraded once for serious risk of bias (high risk of bias for domain: intervention independent of other changes; there are no compelling arguments that the intervention occurred independently of other changes over time and the outcome was not influenced by other confounding variables or historic events during study period); no serious inconsistency; no serious indirectness; downgraded once for serious imprecision (wide confidence intervals that cross the line of no effect); no other considerations. </p> <p><sup>8</sup><b>Relative number of unexpected (previously unknown) ADR reports after 2 years</b>: 0.67 (95% CI 0.01 to 61.55); prior to intervention ‐ 40 ADR reports per 1000 practitioners; post intervention implementation ‐ 27 ADR reports per 1000 practitioners (0 to 2462); mean study duration 7.0 years (<a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>); very low certainty evidence (see footnote<sup>7</sup>) </p> <p><sup>9</sup><b>Relative number of new drug‐related ADR reports after 2 years</b>: 1.86 (95% CI 0.16 to 21.59); prior to intervention ‐ 10 ADR reports per 1000 practitioners; post intervention implementation ‐ 19 ADR reports per 1000 practitioners (2 to 216); mean study duration 6.5 years (<a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>; <a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>); very low certainty evidence (see footnote<sup>2</sup>) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012594-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Government regulations plus financial incentives versus usual practice</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participants:</b> healthcare professionals </p> <p><b>Intervention:</b> financial incentive, fines, plus government regulation, mandatory monitoring, and reporting of ADRs (timeline: 2009 to 2011 (financial incentive or fine); 2012 to 2014 (financial incentive or fine plus government regulations for antimicrobial agents) </p> <p><b>Comparator:</b> spontaneous reporting (2006 to 2009: pre‐intervention) </p> <p><b>Setting:</b> hospital </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative numbers of ADEs<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative numbers of ADEs</b><sup>‡</sup><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Mean study duration (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed number with usual practice</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding number with multifaceted intervention</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of ADE reports (including ADR reports and ME reports): Total number of ADR reports after one year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.43 (0.54 to 3.79)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 ADR reports per 1000 practitioners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114 ADR reports per 1000 practitioners (43 to 303)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0 years (1)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We do not know if government regulations and financial incentives increase the total number of ADR reports by physicians one year after implementation of these interventions because the evidence is very uncertain. </p> <p>Data after two years in footnotes<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of false ADE reports (including false ADR reports and false ME reports)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of serious ADE reports (including serious ADR reports and serious ME reports)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of high‐causality ADE reports (including high‐causality ADR reports and high‐causality ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of unexpected ADE reports (including unexpected ADR reports and unexpected ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of new drug‐related ADE reports (including drug‐related ADR reports and drug‐related ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ADE: adverse drug event; ADR: adverse drug reaction; CI: confidence interval; cRCT: cluster randomised controlled trials; ME: medication error; vs: versus </p> <p><sup>*</sup>Relative numbers of ADRs &gt; 1 are associated with more ADRs with multifaceted intervention versus usual practice. </p> <p><sup>‡</sup>Illustrative comparative numbers of ADRs are presented as numbers of ADRs after 1 and 2 years in a setting with 1000 practitioners. </p> <p><sup>1</sup><a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>: financial incentive (1% of physician salary) for spontaneous reporting of ADRs plus fine (double the amount of the incentive) for not reporting or missing an ADR plus government regulation of antimicrobial use including detailed ADR classification, mandatory monitoring, and reporting of ADRs associated with antimicrobial agents; (timeline ‐ 2006 to 2009 (pre‐intervention); 2009 to 2011 (financial incentive); 2012 to 2014 (financial incentive plus government regulations for antimicrobial agents); December 2014 (last time point); total of 108 observations) </p> <p><sup>2</sup>Observational ITS study so GRADE starts at low; downgraded by one for risk of bias (high risk of bias for domain: Intervention independent of other changes; there are no compelling arguments that the intervention occurred independently of other changes over time and the outcome was not influenced by other confounding variables or historic events during study period); no serious inconsistency; no serious indirectness; downgraded once for serious imprecision (wide confidence intervals that cross the line of no effect); no other considerations. </p> <p><sup>3</sup>Total number of ADE reports, including ADR reports and ME reports: number of ADR reports after 2 years 1.02 (95% CI 0.24 to 4.32, mean study duration: 8 years, 1 study<sup>1</sup>; assumed number of ADR reports with usual practice 160 ADR reports per 1000 practitioners, corresponding number of ADR reports with multifaceted intervention 163 ADR reports per 1000 practitioners (38 to 346); certainty of the evidence: very low<sup>2</sup> </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012594-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Improving access to ADR report forms versus usual practice</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participants:</b> healthcare professionals </p> <p><b>Intervention:</b> improved access to ADE reporting (standardised discharge form method; yellow card ADR report form in bulletin and prescription pad; online hyperlink to ADR report form) </p> <p><b>Comparator:</b> spontaneous reporting </p> <p><b>Setting:</b> hospital </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)<sup>*</sup> </b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative rates and numbers of ADEs</b><sup>‡</sup><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants or mean study duration (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed rate or number with usual practice</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding rate or number with improving access</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of ADE reports, including ADR reports and ME reports</p> <p>Data from cRCT</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.06 (1.11 to 3.83)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 ADR reports per 1000 practitioner years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165 ADR reports per 1000 practitioner years (89 to 306)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5967 (1)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use of a standardised discharge form (for recording patient diagnoses, medical and surgical acts received during hospital stay; based on the ‘Diagnosis Related Groups’ (DRG) system) with additional ADR items (time of occurrence and evolution) may slightly increase the number of ADR reports. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of ADE reports, including ADR reports and ME reports</p> <p>Data from ITS study after one‐year follow up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.95 (1.33 to 2.85)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 ADR reports per 1000 practitioners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156 ADR reports per 1000 practitioners (106 to 228)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.4 years (2)<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very Low<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if including yellow card ADR report form in quarterly bulletins and prescription pads or providing a hyperlink to the ADR report form in hospitals' electronic patient records may lead to more ADRs being reported after one year because the evidence is very uncertain. </p> <p>Data after two years in footnote<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of false ADE reports (including false ADR reports and false ME reports)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of serious ADE reports (including serious ADR reports and serious ME reports)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of high‐causality ADE reports (including high‐causality ADR reports and high‐causality ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of unexpected ADE reports (including unexpected ADR reports and unexpected ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of new‐drug‐related ADE reports (including new‐drug‐related ADR reports and new‐drug‐related ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ADE: adverse drug event; ADR: adverse drug reaction; CI: confidence interval; cRCT: cluster randomised controlled trial; ITS: interrupted time series; ME: medication error; vs: versus </p> <p><sup>*</sup>Relative treatment effects are expressed as risk ratios and, for ITS analyses, relative expected numbers of ADRs after 1 and 2 years. Relative treatment effects &gt; 1 are associated with more ADRs with improving access versus usual practice. </p> <p><sup>‡</sup>Illustrative comparative rates and numbers of ADRs are presented as numbers of ADRs per 1000 practitioner years (for risk ratio) and expected numbers of ADRs after 1 and 2 years in a setting with 1000 practitioners (for the ITS studies). </p> <p>Serious ADRs: resulting in death; is life‐threatening; is a congenital anomaly; requires hospital admission or prolongation of stay in hospital; or results in persistent or great disability, incapacity, or both; high‐causality ADRs: ADRs with attribution of definitive or probable causality; unexpected (previously unknown) ADRs: previously unknown ADRs that are not described in the summary of product characteristics; new‐drug‐related ADRs: ADRs concerning medications that have been on the market for less than five years. </p> <p><sup>1</sup><a href="./references#CD012594-bbs2-0005" title="HanesseB , LegrasB , RoyerRJ , GuilleminF , BrianconS . Adverse drug reactions: comparison of two report methods. Pharmacoepidemiology and Drug Safety1994;3(4):223-9. ">Hanesse 1994</a>: cluster‐RCT (with cross‐over after 8 weeks, plus 2‐week washout period); the two methods for reporting ADRs were the spontaneous reporting method (SR method; usual care) and the standardised discharge form with additional ADR items (DRG method; intervention). </p> <p><sup>2</sup>Downgraded twice for very serious risk of bias (possible contamination effect due to cross‐over design and inability to blind physicians to the intervention; also unclear if the outcome assessors were blinded); no serious inconsistency; no serious indirectness; no serious imprecision; no other considerations </p> <p><sup>3</sup>Two ITS studies; <a href="./references#CD012594-bbs2-0002" title="CastelJM , FiguerasA , PedrosC , LaporteJR , CapellaD . Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads. Drug Safety2003;25(14):1049-55. ">Castel 2003</a>: combined effect of quarterly adverse drug reaction bulletin with ADR yellow card report form (introduced Sept 1985) and a ADR yellow card report form in the prescription pad (introduced January 1991 to December 1994); <a href="./references#CD012594-bbs2-0014" title="Ribeiro-VazI , Santos Cda, Costa-PereiraA , Cruz-CorreiaR . Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal. Drug Safety2012;33(5):387-94. ">Ribeiro‐Vaz 2012</a>: 2006 to 2010 ‐ hyperlinks to the ADR online reporting pharmacovigilance centre form included either in the electronic patient record or on a desktop computer. </p> <p><sup>4</sup>Both studies are observational ITS studies so GRADE starts at low; downgraded once for serious risk of bias (high risk of bias for domain: intervention independent of other changes; there are no compelling arguments that the intervention occurred independently of other changes over time and the outcome was not influenced by other confounding variables or historic events during study period); no serious inconsistency: no serious imprecision: no serious indirectness; no other considerations. </p> <p><sup>5</sup>Total number of ADE reports, including ADR reports and ME reports: number of ADR reports after 2 years of follow‐up: RR1.80 (95% CI 1.08 to 3.01, assumed rate or number with usual practice: 160 ADR reports per 1000 practitioners; corresponding rate or number with improved access: 288 ADR reports per 1000 practitioners (173 to 482); mean study duration for 2 ITS studies<sup>3</sup>: 8.4 years; certainty of the evidence: very low<sup>4</sup> </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012594-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Improving ADE reporting method (new web‐based electronic error reporting system) versus usual practice (existing web‐based electronic error reporting system)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participants:</b> healthcare professionals </p> <p><b>Intervention:</b> September 2010 replace existing electronic error reporting system with new web‐based electronic error reporting system (equipped with a series of standardised screens, drop‐down menu choices, and input fields designed to collect specific information and improve communication with all departments involved); post‐implementation segment (1 September 2010 to 31 October 2012) </p> <p><b>Comparator:</b> pre‐implementation segment (1 January 2009 to 31 August 2010) ‐ web‐based electronic error reporting system </p> <p><b>Setting:</b> hospital </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative numbers of reports (95% CI)<sup>*</sup> </b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative numbers of reports</b><sup>‡</sup><br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Mean study duration (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed number with usual practice</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding number with improved reporting system</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of ADE reports: number of ME reports after one year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.80 (1.15 to 2.80)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 ME reports per 1000 practitioners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144 ME reports per 1000 practitioners (92 to 224)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.75 (1)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We do not know if the re‐engineering the web‐based electronic error reporting system may have increased the number of ME reports after one year because the evidence is very uncertain. </p> <p>Data after two years in footnotes<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of false ADE reports, including false ADR reports and false ME reports</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of serious ADE reports (including serious ADR reports and serious ME reports)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of high‐causality ADE reports (including high‐causality ADR reports and high‐causality ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of unexpected ADE reports (including unexpected ADR reports and unexpected ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of new‐drug‐related ADE reports (including new‐drug‐related ADR reports and new‐drug‐related ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ADE: adverse drug event; ADR: adverse drug reaction; CI: confidence interval; ITS: interrupted time series; ME: medication error; vs: versus </p> <p><sup>*</sup>Relative expected numbers of ME reports &gt; 1 are associated with more ME reports with improving reporting practice versus usual practice. </p> <p><sup>‡</sup>Illustrative comparative rates are presented as expected numbers of ME reports after 1 and 2 years in a setting with 1000 practitioners. </p> <p><sup>1</sup><a href="./references#CD012594-bbs2-0011" title="McKaigD , CollinsC , ElsaidKA . Impact of a reengineered electronic error-reporting system on medication event reporting and care process improvements at an urban medical center. Joint Commission Journal on Quality &amp; Patient Safety2014;40(9):398-407. ">McKaig 2014</a>: ITS; pre‐implementation segment (1 January 2009 to 31 August 2010), replace one web‐based electronic error reporting system with new web‐based electronic error reporting system (equipped with a series of standardised screens, drop‐down menu choices, and input fields designed to collect specific information and improve communication with all departments involved) implemented in September 2010, post‐implementation segment (1 September 2010 to 31 October 2012) </p> <p><sup>2</sup>Observational ITS so GRADE starts at low; downgraded once for serious risk of bias (authors do not appear to have considered seasonal effects and there is no control arm to counter this). Furthermore, there is no compelling argument that the effects of the intervention occurred independently of other changes over time; inconsistency: none; downgraded once for serious imprecision (wide confidence intervals that include little or no effect to substantial effect); indirectness: none; other: none. </p> <p><sup>3</sup>Total number of ADE reports, including ADR reports and ME reports: Relative number of ME reports after 2 years: 2.11 (95% CI 1.03 to 4.33), assumed number with usual practice: 160 ME reports per 1000 practitioners, corresponding number with different web‐based electronic error reporting system: 338 ME reports per 1000 practitioners (165 to 693); 1 study, 3.75 years exposure to intervention; very low certainty of evidence (see footnote<sup>2</sup>) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012594-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Case finding versus spontaneous reporting (usual practice)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participants:</b> healthcare professionals </p> <p><b>Intervention:</b> case finding ‐ clinical pharmacist identified ADEs by joining daily hospital rounds, screening patient charts and interviewing patients, daily meetings with physicians and nurses, comprehensive review of patient charts post‐discharge using specific data extract form to identify in‐hospital ADEs; ADEs were identified by (a) spontaneous or solicited reporting by a physician, (b) spontaneous or solicited reporting by a nurse, (c) detection on regular ward rounds and (d) detection by the clinical pharmacist by chart review after hospital discharge. </p> <p><b>Comparator:</b> usual practice (clinical pharmacist not present; ADEs identified through spontaneous reporting by nurses and physicians) </p> <p><b>Setting:</b> hospital </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p>Relative effect <b>(95% CI)<sup>*</sup> </b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative numbers of ADE</b>s<sup>‡</sup><br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed number with usual practice</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding number with case finding</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of ADE reports (including ADR reports and ME reports): number of ADE reports </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11.07 (6.24 to 21.38)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.4 per 1000 patient‐days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5 (95% CI 8.74 to 29.9) per 1000 patient‐days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1016 (1)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We do not know if having clinical pharmacists actively identifying and encouraging the identification of ADEs in a hospital setting leads to more ADEs being reported per 1000 patient‐days because the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of false ADE reports (including false ADR reports and false ME reports): number of false ADE reports </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of serious ADE reports (including serious ADR reports and serious ME reports)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of high‐causality ADE reports (including high‐causality ADR reports and high‐causality ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of unexpected ADE reports (including unexpected ADR reports and unexpected ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of new‐drug‐related ADE reports (including new‐drug‐related ADR reports and new‐drug‐related ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ADE: adverse drug event; ADR: adverse drug reaction; CI: confidence interval; ME: medication error; vs: versus </p> <p><sup>*</sup>Incidence rate ratio (IRR) of ADEs; IRR &gt; 1 is associated with more ADE reports with case finding (clinical pharmacist present) versus usual practice (spontaneous reporting, no clinical pharmacist present). </p> <p><sup>‡</sup>Illustrative comparative rates are presented as expected numbers of ADEs per 1000 patient‐days. </p> <p>Serious ADRs: resulting in death; is life‐threatening; is a congenital anomaly; requires hospital admission or prolongation of stay in hospital; or results in persistent or great disability, incapacity, or both); high‐causality ADRs: ADRs with attribution of definitive or probable causality; unexpected (previously unknown) ADRs: previously unknown ADRs that are not described in the summary of product characteristics; new‐drug‐related ADRs: ADRs concerning medications that have been on the market for fewer than 5 years. </p> <p><sup>1</sup><a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a>: non‐randomised cross‐over study, without a washout period. To minimise any possible learning effect, we have only included and analysed the data from the first period (1 to 12 months) of the study. In the test units: case finding ‐ clinical pharmacist identified ADEs by joining daily hospital rounds, screening patient charts and interviewing patients, daily meetings with physicians and nurses, comprehensive review of patient charts post‐discharge using specific data extract form to identify in‐hospital ADEs; ADEs were identified by (a) spontaneous or solicited reporting by a physician, (b) spontaneous or solicited reporting by a nurse, (c) detection on regular ward rounds and (d) detection by the clinical pharmacist by chart review after hospital discharge. In control units: clinical pharmacist not present; ADEs identified through spontaneous reporting by nurses and physicians. </p> <p><sup>2</sup>Because it is not a randomised study, the GRADE assessment starts at low; downgraded twice for very serious risk of bias (risk of selection bias as not randomised, risk of performance as no blinding of physicians or nurses, and risk of detection bias as no blinding of outcome assessors); no serious inconsistency: no serious indirectness; no serious imprecision; no other considerations. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012594-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012594-sec-0009"></div> <section id="CD012594-sec-0010"> <h3 class="title" id="CD012594-sec-0010">Description of the condition</h3> <p>Approximately 1.4% of the global Gross Domestic Product (US$1 trillion) is spent on medicines (<a href="./references#CD012594-bbs2-0151" title="World Bank. World Development Indicators (GDP). http://data.worldbank.org/indicator/NY.GDP.MKTP.CD2014.">World Bank</a>). Medicines cure, arrest or prevent disease, ease symptoms or help diagnose illnesses. However, a great deal of morbidity and mortality is associated with unforeseen reactions to and inappropriate use of medicines. Adverse drug events, defined as “any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with this treatment” (<a href="./references#CD012594-bbs2-0144" title="Uppsala Monitoring Center. Glossary of terms used in pharmacovigilance. www.who-umc.org. Accessed 28 January 2024.">Uppsala Monitoring Center</a>), are a global public health issue. </p> <p>Adverse drug events (ADEs) include all adverse drug reactions and medication errors. An adverse drug reaction is “a harmful effect suspected to be caused by a drug at doses normally used in humans for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function” (<a href="./references#CD012594-bbs2-0144" title="Uppsala Monitoring Center. Glossary of terms used in pharmacovigilance. www.who-umc.org. Accessed 28 January 2024.">Uppsala Monitoring Center</a>). A medication error is “any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is controlled by the health care professional, patient, or consumer. Such events may be related to professional practice, health care products, procedures, and systems, including prescribing, order communication, product labelling, packaging, nomenclature, compounding, dispensing, distribution, administration, education, monitoring, and use” (<a href="./references#CD012594-bbs2-0132" title="National Coordinating Council for Medication Error Reporting and Prevention (NCCMERP). What is a medication error?www.nccmerp.org. Accessed 28 February 2024.">NCCMERP 2016</a>). </p> <p>No medicine is without ADEs. While some ADEs are detected during pre‐marketing phase clinical trials, limitations associated with the conduct of these trials make it impossible to identify all ADEs related to a product. Trial characteristics such as small sample size, relatively short follow‐up periods, close monitoring of study participants (to ensure strict adherence to study protocol), and narrowly defined characteristics of study participants and study indications (study indications for a drug are often limited to a particular disease; <a href="./references#CD012594-bbs2-0113" title="GadSC . Postmarketing safety evaluation: monitoring, assessing, and reporting of adverse drug responses. In: Drug Safety Evaluation. Second edition. Hoboken, New Jersey: John Wiley &amp; Sons, 2009:943-44.">Gad 2009</a>) are important for study validity and efficacy but limit the generalisability and effectiveness of the study findings. Continually monitoring the use and effects (both beneficial and harmful) of clinically approved medicines in large numbers of people is therefore important to better understand the effectiveness and safety of medication under everyday circumstances. </p> <p>Pharmacovigilance, which is "the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug‐related problems" (<a href="./references#CD012594-bbs2-0147" title="World Health Organization. The safety of medicines in public health programmes:pharmacovigilance an essential tool. www.who.int/medicines/areas/quality_safety/safety_efficacy/Pharmacovigilance_B.pdf?ua=1 Accessed 2 October 2016. [ISBN 92 4 159391 1]">WHO 2006</a>), aims to improve patient safety related to the use of medicines (<a href="./references#CD012594-bbs2-0112" title="FornasierG , FrancesconS , LeoneR , BaldoP . An historical overview over Pharmacovigilance. International Journal of Clinical Pharmacy2018;40:744–7.">Fornasier 2018</a>). More than 170 countries have pharmacovigilance agencies that collate and manage adverse event reporting (<a href="./references#CD012594-bbs2-0149" title="World Health Organization. Annual meeting of representatives of National Pharmacovigilance Centres participating in the WHO Programme for International Drug Monitoring. www.who.int//medicines/regulation/medicines-safety/npvc-meeting/en/ Accessed 2 October 2016.">WHO 2016</a>). Identifying any adverse drug events associated either with a medication or with the use of a medication, as soon as possible, prevents or minimises any potential harm. These efforts enable healthcare professionals to maximise the benefits of medicines while avoiding or minimising the risks associated with their use. Spontaneous or voluntary reporting of ADEs (i.e. case reports of ADEs that are voluntarily submitted from healthcare professionals and pharmaceutical manufacturers to the national regulatory authority (<a href="./references#CD012594-bbs2-0144" title="Uppsala Monitoring Center. Glossary of terms used in pharmacovigilance. www.who-umc.org. Accessed 28 January 2024.">Uppsala Monitoring Center</a>)) is the cornerstone of effective pharmacovigilance and is considered "usual practice" in most parts of the world. The level of pharmacovigilance and adverse drug event reporting differs greatly based on the regulations established by the respective regulatory agencies. Data collection also varies amongst countries. France, for example, has regional centres for collecting spontaneous reports, while Iran has a single national pharmacovigilance centre to collect data (<a href="./references#CD012594-bbs2-0141" title="ShalviriG , ValadkhaniM , DinarvandR . Ten years pharmacovigilance activities in Iran. Iranian Journal of Public Health2009;38(Suppl 1):162-5.">Shalviri 2009</a>). Although spontaneous reporting of ADEs is the most common method for collecting information on the safety of medicines during the post‐marketing phase (<a href="./references#CD012594-bbs2-0111" title="FigueirasA , TatoF , FontaiñasJ , TakkoucheB , Gestal-OteroJJ . Physicians’ attitudes towards voluntary reporting of adverse drug events. Journal of Evaluation in Clinical Practice2001;7(4):347-54.">Figueiras 2001</a>; <a href="./references#CD012594-bbs2-0136" title="PalS , DuncombeC , FalzonD , OlssonS . WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Safety2013;36(2):75-81.">Pal 2013</a>), it is limited and is associated with gross underreporting of ADEs. According to the WHO Monitoring Center in Uppsala, annual reporting rates of over 200 adverse drug event reports per million inhabitants indicate a healthy national pharmacovigilance system (<a href="./references#CD012594-bbs2-0127" title="LindquistM . The WHO Global ICSR database system: basic facts. Drug Information Journal2008;42:409-19.">Lindquist 2008</a>). Many countries have yet to achieve this goal. It is estimated that only 2% to 4% of non‐serious adverse drug events and 10% of serious ADEs are reported spontaneously by healthcare professionals (<a href="./references#CD012594-bbs2-0118" title="HazellL , ShakirSAW . Under reporting of adverse drug reactions: a systematic review. Drug Safety2006;29(5):385-96.">Hazell 2006</a>; <a href="./references#CD012594-bbs2-0131" title="MorideY , HaramburuF , RequejoA , BégaudB . Under-reporting of adverse drug reactions in general practice. British Journal of Clinical Pharmacology1997;43(2):177-81.">Moride 1997</a>). It should be noted that reports from patients and healthcare students are also valuable contributors to drug‐related data in many countries. However, these populations are not within the scope of this review. </p> </section> <section id="CD012594-sec-0011"> <h3 class="title" id="CD012594-sec-0011">Description of the intervention</h3> <p>Although spontaneous reporting of adverse drug events is the most common method of collecting safety data associated with medications, there are other methods of collecting safety information (<a href="./references#CD012594-bbs2-0147" title="World Health Organization. The safety of medicines in public health programmes:pharmacovigilance an essential tool. www.who.int/medicines/areas/quality_safety/safety_efficacy/Pharmacovigilance_B.pdf?ua=1 Accessed 2 October 2016. [ISBN 92 4 159391 1]">WHO 2006</a>). Some countries have implemented active surveillance systems to complement spontaneous reporting, for example, the prescription event monitoring (PEM) system in New Zealand and the United Kingdom (<a href="./references#CD012594-bbs2-0147" title="World Health Organization. The safety of medicines in public health programmes:pharmacovigilance an essential tool. www.who.int/medicines/areas/quality_safety/safety_efficacy/Pharmacovigilance_B.pdf?ua=1 Accessed 2 October 2016. [ISBN 92 4 159391 1]">WHO 2006</a>). In the European Union, a set of measures called “good pharmacovigilance practices” have been drawn up to facilitate pharmacovigilance (<a href="./references#CD012594-bbs2-0102" title="European Medicines Agency (EMA). Good pharmacovigilance practices. www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp. Accessed 2 October 2016.">EMA 2016</a>). Various interventions have been used in different settings to improve healthcare professionals' spontaneous reporting of ADEs. The most commonly used interventions include the following (<a href="./references#CD012594-bbs2-0114" title="Gonzalez-GonzalezC , Lopez-GonzalezE , HerdeiroMT , FigueirasA . Strategies to improve adverse drug reactions reporting: a critical and systematic review. Drug Safety2013;36(5):317-28.">Gonzalez‐Gonzalez 2013</a>; <a href="./references#CD012594-bbs2-0130" title="MolokhiaM , TannaS , BellD . Improving reporting of adverse drug reactions: systematic review. Clinical Epidemiology2009;1:75-92.">Molokhia 2009</a>). </p> <p> <ul id="CD012594-list-0001"> <li> <p>Educational activities such as training sessions</p> </li> <li> <p>Reminders such as letters, emails or posters</p> </li> <li> <p>Simplification of the adverse drug event reporting form</p> </li> <li> <p>Increased availability of reporting forms</p> </li> <li> <p>Modification of reporting procedures (e.g. reporting by telephone or email)</p> </li> <li> <p>Incentives such as provision of educational credits, awards or financial motivations, or disincentives for not reporting, e.g. fines </p> </li> <li> <p>Assistance from a colleague (e.g. a clinical pharmacist, physician or nurse) with ADE reporting </p> </li> <li> <p>Providing feedback to reporters about adverse drug events</p> </li> <li> <p>Use of computerised monitoring systems to signal changes in laboratory results</p> </li> </ul> </p> <p>Some studies focus specifically on developing interventions to improve medication error reporting. For example, a study in New Zealand designed a web‐based medication error reporting programme (MERP) to supplement pharmacovigilance (<a href="./references#CD012594-bbs2-0122" title="KunacDL , TatleyMV , SeddonME . A new web-based Medication Error Reporting Programme (MERP) to supplement pharmacovigilance in New Zealand--findings from a pilot study in primary care. New Zealand Medical Journal2014;127(1401):69-81.">Kunac 2014</a>). Some studies choose to examine more than one intervention. For example, seven overlapping interventions were used in a study to improve ADE reporting, including a poster displaying days since the last medication error resulting in harm, a continuous slide show in the staff lounge showing performance metrics, multiple didactic curricula, unit‐wide emails providing information on medication errors, computerised physician order entry, introduction of unit‐based pharmacy technicians for medication delivery, and patient safety report form streamlining (<a href="./references#CD012594-bbs2-0096" title="AbstossKM , ShawBE , OwensTA , JunoJL , CommiskeyEL , NiednerMF . Increasing medication error reporting rates while reducing harm through simultaneous cultural and system-level interventions in an intensive care unit. BMJ Quality and Safety2011;20(11):914-22.">Abstoss 2011</a>). </p> </section> <section id="CD012594-sec-0012"> <h3 class="title" id="CD012594-sec-0012">How the intervention might work</h3> <p>Reasons for inadequate spontaneous reporting or underreporting of adverse drug events by healthcare professionals include complacency (e.g. the belief that very serious adverse drug reactions are well documented by the time a drug is marketed), insecurity (e.g. the belief that it is nearly impossible to determine whether a drug is responsible for a particular adverse reaction), diffidence (e.g. healthcare professionals are afraid of looking foolish or over‐reactive by submitting a report for an adverse event that is not severe or not obviously related to a medical product or the use of a medical product), indifference (e.g. some healthcare professionals feel that the one case they might observe could not contribute to medical knowledge), ignorance (e.g. the belief that it is only necessary to report serious or unexpected adverse drug reactions), and lack of time to complete the adverse drug event reporting procedure (<a href="./references#CD012594-bbs2-0129" title="MirbahaF , ShalviriG , YazdizadehB , GholamiK , MajdzadehR . Perceived barriers to reporting adverse drug events in hospitals: a qualitative study using theoretical domains framework approach. Implementation Science2015;10:110. [DOI: 10.1186/s13012-015-0302-5]">Mirbaha 2015</a>; <a href="./references#CD012594-bbs2-0145" title="VaralloFR , Guimarães S deO , AbjaudeSA , Mastroianni P deC . Causes for the underreporting of adverse drug events by health professionals: a systematic review. Revista da Escola de Enfermagem da USP2014;48(4):739-47.">Varallo 2014</a>). Healthcare professionals may also fear being blamed for any adverse event they draw attention to, that acknowledging an adverse reactions may reflect negatively on their competence or put them at risk of litigation (<a href="./references#CD012594-bbs2-0147" title="World Health Organization. The safety of medicines in public health programmes:pharmacovigilance an essential tool. www.who.int/medicines/areas/quality_safety/safety_efficacy/Pharmacovigilance_B.pdf?ua=1 Accessed 2 October 2016. [ISBN 92 4 159391 1]">WHO 2006</a>). </p> <p>Understanding the barriers associated with underreporting of adverse drug events guides the design of interventions to address or minimise the impact of these barriers or reasons for inadequate spontaneous reporting of ADEs. Educational interventions and informational reminders could raise awareness of the importance of reporting adverse drug events. Other interventions aim to simplify or improve the accessibility of the reporting process itself and, in this way, increase the reporting rate. Interventions that reward healthcare professionals with either financial or non‐financial incentives for reporting ADEs may also facilitate increases in the reporting rates of adverse drug events. Incentivised interventions may also lead to false reports, however, so checks and balances in the system are necessary. </p> <p>Results of observational studies seem to suggest that although interventions involving educational sessions (<a href="./references#CD012594-bbs2-0021" title="BäckströmM , MjorndalT , DahlqvistR . Spontaneous reporting of adverse drug reactions by nurses. Pharmacoepidemiology and Drug Safety2002;11(8):647-50. ">Bäckström 2002</a>), improving access to ADR report forms (<a href="./references#CD012594-bbs2-0128" title="McGettiganP , GoldenJ , ConroyRM , ArthurN , FeelyJ . Reporting of adverse drug reactions by hospital doctors and the response to intervention. British Journal of Clinical Pharmacology1997;44(1):98-100.">McGettigan 1997</a>), or financial incentives (<a href="./references#CD012594-bbs2-0110" title="FeelyJ , MoriartyS , O’ConnorP . Stimulating reporting of adverse drug reactions by using a fee. British Medical Journal1990;300(6716):22-3.">Feely 1990</a>) increase the reporting rate of adverse drug events, the effect of these interventions is temporary, and reporting rates decline once the intervention is removed (<a href="./references#CD012594-bbs2-0128" title="McGettiganP , GoldenJ , ConroyRM , ArthurN , FeelyJ . Reporting of adverse drug reactions by hospital doctors and the response to intervention. British Journal of Clinical Pharmacology1997;44(1):98-100.">McGettigan 1997</a>). The ultimate aim of interventions is to create a "culture of reporting" amongst healthcare professionals that is effective and sustained. Integrating the reporting of adverse drug events into existing hospital electronic reporting systems may be one example of a way to achieve this (<a href="./references#CD012594-bbs2-0134" title="OrtegaA , AguinagaldeA , LacasaC , AquerretaI , Fernández-BenítezM , FernándezLM . Efficacy of an adverse drug reaction electronic reporting system integrated into a hospital information system. Annals of Pharmacotherapy2008;42(10):1491-6.">Ortega 2008</a>). </p> </section> <section id="CD012594-sec-0013"> <h3 class="title" id="CD012594-sec-0013">Why it is important to do this review</h3> <p>The World Health Organization (WHO) International Drug Monitoring Program was created in response to the lack of global harmonisation for monitoring of ADEs (<a href="./references#CD012594-bbs2-0147" title="World Health Organization. The safety of medicines in public health programmes:pharmacovigilance an essential tool. www.who.int/medicines/areas/quality_safety/safety_efficacy/Pharmacovigilance_B.pdf?ua=1 Accessed 2 October 2016. [ISBN 92 4 159391 1]">WHO 2006</a>). The programme currently includes over 170 countries as full members and associate members (<a href="./references#CD012594-bbs2-0149" title="World Health Organization. Annual meeting of representatives of National Pharmacovigilance Centres participating in the WHO Programme for International Drug Monitoring. www.who.int//medicines/regulation/medicines-safety/npvc-meeting/en/ Accessed 2 October 2016.">WHO 2016</a>). Despite the numerous pharmacovigilance activities undertaken in many countries, the problem of underreporting adverse drug events is still a major threat to the public's health and well‐being. Adverse drug events are a significant cause of death in many countries (<a href="./references#CD012594-bbs2-0123" title="LazarouJ , PomeranzBH , CoreyPN . Incidence of adverse drug reactions in hospitalized patients. Journal of the American Medical Association1998;279(15):1200-5.">Lazarou 1998</a>; <a href="./references#CD012594-bbs2-0138" title="PirmohamedM , JamesS , MeakinS , GreenC , ScottAK , WalleyTJ , et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. British Medical Journal2004;329(7456):15-9.">Pirmohamed 2004</a>; <a href="./references#CD012594-bbs2-0141" title="ShalviriG , ValadkhaniM , DinarvandR . Ten years pharmacovigilance activities in Iran. Iranian Journal of Public Health2009;38(Suppl 1):162-5.">Shalviri 2009</a>; <a href="./references#CD012594-bbs2-0142" title="ShalviriG , YousefianS , GholamiK . Adverse events induced by ceftriaxone: a 10-year review of reported cases to Iranian Pharmacovigilance Centre. Journal of Clinical Pharmacy and Therapeutics2012;37(4):448-51.">Shalviri 2012</a>; <a href="./references#CD012594-bbs2-0146" title="WesterK , JönssonAK , SpigsetO , DruidH , HäggS . Incidence of fatal adverse drug reactions: a population based study. British Journal of Clinical Pharmacology2008;65(4):573-9.">Wester 2008</a>), and a significant cause of hospital admissions (<a href="./references#CD012594-bbs2-0097" title="Al HamidA , GhalebM , AljadheyH , AslanpourZ . A systematic review of hospitalization resulting from medicine-related problems in adult patients. British Journal of Clinical Pharmacology2014;78(2):202-17.">Al Hamid 2014</a>; <a href="./references#CD012594-bbs2-0150" title="WilsonRM , MichelP , OlsenS , GibberdRW , VincentC , El-AssadyR , et al. Patient safety in developing countries: retrospective estimation of scale and nature of harm to patients in hospital. British Medical Journal2012;344:e832. [DOI: https://doi.org/10.1136/bmj.e832]">Wilson 2012</a>). Furthermore, a substantial portion of healthcare costs are directly related to adverse drug events, with the economic burden amounting to hundreds of billions of dollars each year (<a href="./references#CD012594-bbs2-0098" title="AndelC , DavidowSL , HollanderM , MorenoDA . The economics of health care quality and medical errors. Journal of Health Care Finance2012;39(1):39.">Andel 2012</a>; <a href="./references#CD012594-bbs2-0099" title="ClassenDC , PestotnikSL , EvansRS , LloydJF , BurkeJP . Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. Journal of the American Medical Association1997;277(4):301-6.">Classen 1997</a>; <a href="./references#CD012594-bbs2-0109" title="ErnstFR , GrizzleAJ . Drug-related morbidity and mortality: updating the cost-of-illness model. Journal of the American Pharmaceutical Association2001;41(2):192-199.">Ernst 2001</a>; <a href="./references#CD012594-bbs2-0117" title="GyllenstenH , RehnbergC , JönssonAK , PetzoldM , CarlstenA , Andersson SundellK . Cost-of-illness of patient-reported adverse drug events – a population-based cross-sectional survey. BMJ Open2013;3(6):e002574.">Gyllensten 2013</a>; <a href="./references#CD012594-bbs2-0120" title="JohnsonJA , BootmanJL . Drug-related morbidity and mortality. A cost-of-illness model. Archives of Internal Medicine1995;155(18):1949-56.">Johnson 1995</a>). </p> <p>Many adverse drug events are preventable. Studies have reported that 10% to 80% of all adverse drug events can be prevented (<a href="./references#CD012594-bbs2-0148" title="World Health Organization. Reporting and learning systems for medication errors: the role of pharmacovigilance centres. apps.who.int/iris/bitstream/10665/137036/1/9789241507943_eng.pdf?ua=1 Accessed prior to 28 February 2017. [ISBN 978 92 4 150794 3]">WHO 2014</a>). Improved spontaneous reporting of suspected adverse drug events enables early detection of any patient safety issues associated with the medication itself or with how the medication is used (<a href="./references#CD012594-bbs2-0136" title="PalS , DuncombeC , FalzonD , OlssonS . WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Safety2013;36(2):75-81.">Pal 2013</a>), which can reduce drug‐related morbidity and mortality (<a href="./references#CD012594-bbs2-0136" title="PalS , DuncombeC , FalzonD , OlssonS . WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Safety2013;36(2):75-81.">Pal 2013</a>). Several systematic reviews have assessed the effectiveness of interventions to enhance the reporting of adverse drug events (<a href="./references#CD012594-bbs2-0114" title="Gonzalez-GonzalezC , Lopez-GonzalezE , HerdeiroMT , FigueirasA . Strategies to improve adverse drug reactions reporting: a critical and systematic review. Drug Safety2013;36(5):317-28.">Gonzalez‐Gonzalez 2013</a>; <a href="./references#CD012594-bbs2-0124" title="LiR , ZaidiSTR , ChenT , CastelinoR . Effectiveness of interventions to improve adverse drug reaction reporting by healthcare professionals over the last decade: a systematic review. Pharmacoepidemiology and Drug Safety2019;29:1-8.">Li 2019</a>; <a href="./references#CD012594-bbs2-0135" title="PagottoC , VaralloF , MastroianniF . Impact of educational interventions on adverse drug events reporting. International Journal of Technology Assessment in Health Care2013;29(4):410-17.">Pagotto 2013</a>; <a href="./references#CD012594-bbs2-0137" title="PaudyalV , Al-HamidaA , BowenaM , Abdul HadiM , HasanSS , JalalaZ , StewartD . Interventions to improve spontaneous adverse drug reaction reporting by healthcare professionals and patients: systematic review and meta-analysis. Expert Opinion on Drug Safety2020;19(9):1173–91.">Paudyal 2020</a>). These reviews are limited in their scope in terms of intervention (educational interventions; <a href="./references#CD012594-bbs2-0135" title="PagottoC , VaralloF , MastroianniF . Impact of educational interventions on adverse drug events reporting. International Journal of Technology Assessment in Health Care2013;29(4):410-17.">Pagotto 2013</a>) or outcome (ADRs; <a href="./references#CD012594-bbs2-0114" title="Gonzalez-GonzalezC , Lopez-GonzalezE , HerdeiroMT , FigueirasA . Strategies to improve adverse drug reactions reporting: a critical and systematic review. Drug Safety2013;36(5):317-28.">Gonzalez‐Gonzalez 2013</a>; <a href="./references#CD012594-bbs2-0124" title="LiR , ZaidiSTR , ChenT , CastelinoR . Effectiveness of interventions to improve adverse drug reaction reporting by healthcare professionals over the last decade: a systematic review. Pharmacoepidemiology and Drug Safety2019;29:1-8.">Li 2019</a>; <a href="./references#CD012594-bbs2-0137" title="PaudyalV , Al-HamidaA , BowenaM , Abdul HadiM , HasanSS , JalalaZ , StewartD . Interventions to improve spontaneous adverse drug reaction reporting by healthcare professionals and patients: systematic review and meta-analysis. Expert Opinion on Drug Safety2020;19(9):1173–91.">Paudyal 2020</a>). Furthermore, none of the systematic reviews have provided an assessment of the certainty of the evidence for each of the interventions assessed (see <a href="#CD012594-tbl-0008">Table 1</a>). This Cochrane review aims to identify all interventions directed at healthcare professionals that may improve reporting of adverse drug events, including all ADRs and any MEs. Our review will also systematically assess the certainty of the evidence associated with each type of intervention. </p> <div class="table" id="CD012594-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of published systematic reviews assessing interventions to increase ADE reporting</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD012594-bbs2-0135" title="PagottoC , VaralloF , MastroianniF . Impact of educational interventions on adverse drug events reporting. International Journal of Technology Assessment in Health Care2013;29(4):410-17."><b>Pagotto 2013</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD012594-bbs2-0114" title="Gonzalez-GonzalezC , Lopez-GonzalezE , HerdeiroMT , FigueirasA . Strategies to improve adverse drug reactions reporting: a critical and systematic review. Drug Safety2013;36(5):317-28."><b>Gonzalez‐Gonzalez 2013</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD012594-bbs2-0139" title="Ribeiro-VazI , SilvaAM , Costa SantosC , Cruz-CorreiaR . How to promote adverse drug reaction reports using information systems - a systematic review and meta-analysis. BMC Medical Informatics and Decision Making2016;16(27):1-10. [DOI: 10.1186/s12911-016-0265-8]"><b>Ribeiro‐Vaz 2016</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD012594-bbs2-0124" title="LiR , ZaidiSTR , ChenT , CastelinoR . Effectiveness of interventions to improve adverse drug reaction reporting by healthcare professionals over the last decade: a systematic review. Pharmacoepidemiology and Drug Safety2019;29:1-8."><b>Li 2019</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD012594-bbs2-0137" title="PaudyalV , Al-HamidaA , BowenaM , Abdul HadiM , HasanSS , JalalaZ , StewartD . Interventions to improve spontaneous adverse drug reaction reporting by healthcare professionals and patients: systematic review and meta-analysis. Expert Opinion on Drug Safety2020;19(9):1173–91."><b>Paudyal 2020</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD012594-bbs2-0121" title="KhaliliM , MesgarpourB , SharifiH , Daneshvar DehnaviS , HaghdoostAA . Interventions to improve adverse drug reaction reporting: a scoping review. Pharmacoepidemiology and Drug Safety2020;29(9):965-92."><b>Khalili 2020</b> </a><b>(scoping review)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Objectives</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To identify the techniques of educational intervention for promotion of pharmacovigilance by healthcare professionals and to assess their impact. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To conduct a critical review of papers that assessed the effectiveness of different strategies to increase ADR reporting, regardless of the healthcare professionals or patients included. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To describe the state of the art information systems used to promote ADR reporting.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To determine the features and successes of the various strategies undertaken to improve ADR reporting by healthcare professionals, and propose alternative initiatives that may enhance these existing methods. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To evaluate the effectiveness of interventions used for improving ADR reporting by patients and healthcare professionals. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To systematically map interventions and strategies to improve ADR reporting among health care professionals. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Eligible study designs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All study designs included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐post experimental design; time series; non‐randomised controlled experimental study; randomised controlled experimental study; cluster randomised controlled experimental study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any studies describing or evaluating the use of information systems to promote adverse drug reaction reporting. Studies with data related to the number of ADRs reported before and after each intervention and the follow‐up period were included in the quantitative analysis. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCTs, quasi‐experimental, time series studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All forms of interventional designs were considered. Meta analysis not undertaken for non‐randomised trials </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quantitative methods focused on healthcare professionals</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Eligible participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Healthcare professionals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Professionals to whom the intervention for increasing ADR reporting is addressed: physicians, nurses, pharmacists, young physicians, house officers,<br/>pharmacy students, section head, ‘quality review staff’,<br/>medical students. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Healthcare professionals or patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Healthcare professionals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Healthcare professionals and patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Healthcare professionals</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Eligible interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Educational interventions only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Educational activity, reminders, modification of reporting forms, modifciation of reporying process, incentives, assistance from another professiionl, increased availability of reporting forms, feedback on reporting </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies describing or evaluating the use of information systems to promote adverse drug reaction reports were selected </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any intervention aimed at increasing ADR reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any pharmacovigilence intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any intervention or strategy (such as ones implemented by government policies, applied experimentally or non‐experimentally, or adopted in specific settings) to improve ADR reporting </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Eligible comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes reported on</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADE reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increase in ADR reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of ADR reporting increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADR rporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome: quantity of<br/>ADRs reported as a result of the intervention including<br/>improvement in the number or rate of reporting. <br/>Secondary outcomes: the quality of ADR reporting including the<br/>nature of ADRs reported (e.g. serious, nonserious ADRs) and<br/>completeness of the reports. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADR reporting rate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number and type of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 met the inclusion criteria<br/>6 RCT, 5 quasi‐experimental, 2 case‐ control studies, 2 ecological time series analysis, 1 observational analytic) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 articles were included in the analysis; these articles described 29 different projects.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 studies included (3 cRCTs, 1 RCT, 7 quasi‐experimental, 2 ITS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 studies included in qualitative synthesis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Findings and conclusions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharmacovigilance‐based educational interventions showed positive impacts (quantitative and qualitative) on ADE spontaneous reporting by health professionals. Multifaceted techniques for interventions, included: lectures, placement of yellow cards, distribution of printed educational materials and giveaways, as well as the or‐ ganization of workshops </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple interventions have a greater impact than single.</p> <p>Evidence to show that, when it comes to bringing about changes in professional practice, interventions that boost the active participation of professionals (i.e. workshops) can be more effective than passive didactic sessions.<br/>Another vital factor is the duration of the effect of the intervention. It can be concluded that, as was to be expected, the longer the period from the date of the intervention, the more the latter's effect is progressively reduced. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most projects performed passive promotion of ADR reporting (i.e., facilitating the process). Developed in hospitals and tailored to healthcare professionals. Interventions doubled the number of ADR reports. Authors believe that it would be useful to develop systems to assist healthcare professionals with completing ADR reporting within electronic health records because this approach seems to be an efficient method to increase the ADR reporting rate. When this approach is not possible, it is essential to have a tool that is easily accessible on the web to report ADRs. This tool can be promoted by sending emails or through the inclusion of direct hyperlinks on healthcare professionals’ desktops. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multi‐faceted approach including education, reminders, and electronic reporting would likely to be the most successful. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited evidence showed that active interventions involving face to face educational approaches, financial incentives, and electronic features targeted at healthcare professionals could improve ADR reporting. However, the results need to be interpreted cautiously given the short term evaluation out‐ comes, dominance of observational designs and low quality of included studies. Interventions need to be developed and tested in countries low‐and‐middle income countries. Most of the included studies included educational interventions to improve ADR reporting. A variety of educational methods were used including reminders, face to face educational sessions and newsletters. While most of these studies were reported to have improved ADR reporting, there was a lack of long‐term follow up of the outcomes. The cluster‐ randomized controlled trials included in the study reported that the impact of interventions observed by the difference in the intervention and control group in the ADR reporting rate lasted for only 12 months after which such difference was no longer significant. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Interventions aimed at enhancing ADR reporting have a good chance of producing positive results, although their effect, especially in the case of educational interventions, could be temporary. Multiple inter‐ ventions might cause greater increase in ADR reporting rates compared with single interventions. Further research is warranted to improve the methodological quality using control groups, large sample sizes, longer follow‐up periods, and adjustment for the confounders. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any limits noted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Language limit: English, Portuguese, or Spanish<br/>search for publications from November 2011 to January 2012, updated in March 2013. <br/>Quality assessment of the manuscripts was not carried out. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limit publication date: up to 2010; Language limited to English, French or Spanish</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Language limited to English, Portuguese or French <br/>Excluded articles based on: (1) only focused on medication errors; (2) only focused on ADR detection; (3) studies without any information system implemented; (4) studies concerning data quality; (5) studies focused on website usability; (6) authors’ reflections on the theme; (7) studies only related to incidents that occurred in health institutions; (8) studies concerning signal detection and (9) studies concerning electronic transmission between the authority and other institutions (pharmaceutical companies or regional pharmacovigilance centres). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search limited to studies published from 2010 to 2019; English only; NO medication error reporting </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Educational research with student participants; interventions not including qualified healthcare practitioners or patients were excluded as well as the interventions<br/>related to devices and planned ADR surveillance monitoring programmes, such as those used for mass vaccinations; Abstract<br/>only publications including conference abstracts were excluded. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search date limited from 1999 to February 2019; <br/>no language restrictions; methodological quality or risk of bias of the included articles were not appraised </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADE: adverse drug event; ADR: adverse drug reaction; cRCT: cluster‐randomised controlled trial; ITS:interrupted time series; RCT: randomised controlled trial </p> </div> </div> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012594-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012594-sec-0014"></div> <p>To assess the effectiveness of different interventions aimed at healthcare professionals to improve the reporting of adverse drug events. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012594-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012594-sec-0015"></div> <section id="CD012594-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012594-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included both individually randomised trials and cluster‐randomised trials, non‐randomised controlled studies and controlled before‐after studies. For cluster‐randomised trials, non‐randomised cluster trials and controlled before‐after studies, we included only those with at least two intervention sites and two control sites (<a href="./references#CD012594-bbs2-0104" title="Effective Practice and Organisation of Care (EPOC). What study designs should be included in an EPOC review? EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services; 2013. epoc.cochrane.org/epoc-specific-resources-review-authors Accessed prior to 28 February 2017.">EPOC 2013a</a>). In addition, for controlled before‐after studies, data collection had to be contemporaneous in both the intervention and control groups during the pre‐ and post‐intervention periods, and identical measurement methods had to be used in these periods. We also included interrupted time series and repeated measures studies that had a clearly defined time point when the intervention occurred and at least three data points before and after the intervention (<a href="./references#CD012594-bbs2-0105" title="Effective Practice and Organisation of Care (EPOC). Interrupted time series (ITS) analyses. EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services; 2013. epoc.cochrane.org/epoc-specific-resources-review-authors Accessed prior to 28 February 2017.">EPOC 2013b</a>). We included data from both published (full‐text articles and conference abstracts) and unpublished eligible studies. </p> </section> <section id="CD012594-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included studies in which healthcare professionals (including but not limited to general practitioners, pharmacists, nurses and specialists) from any healthcare setting were the target audience of the intervention. We excluded studies aimed at patients and healthcare students (e.g. medical, nursing, pharmacy) as the target audience. </p> </section> <section id="CD012594-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies assessing any intervention designed to increase adverse drug event reporting, compared with healthcare professionals' usual adverse drug event reporting practice (mainly spontaneous or voluntary reporting) or a different intervention or interventions designed to improve adverse drug event reporting. We excluded studies of interventions targeted at adverse events reporting following immunisation (AEFI) as AEFI monitoring uses different mechanisms and settings. </p> </section> <section id="CD012594-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>An adverse drug event (ADE) is defined as "any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with this treatment" (<a href="./references#CD012594-bbs2-0144" title="Uppsala Monitoring Center. Glossary of terms used in pharmacovigilance. www.who-umc.org. Accessed 28 January 2024.">Uppsala Monitoring Center</a>). ADEs can include both adverse drug reactions (ADRs) and medication errors (MEs). According to the Uppsala Monitoring Center, an adverse drug reaction (ADR) is defined as "a harmful effect suspected to be caused by a drug", including "all kinds of adverse events, many of which are not 'reactions' in the strict sense and have not been subject to any assessment of causality" (<a href="./references#CD012594-bbs2-0144" title="Uppsala Monitoring Center. Glossary of terms used in pharmacovigilance. www.who-umc.org. Accessed 28 January 2024.">Uppsala Monitoring Center</a>). A medication error (ME) is "any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is controlled by the health care professional, patient, or consumer. Such events may be related to professional practice, health care products, procedures, and systems, including prescribing, order communication, product labelling, packaging, nomenclature, compounding, dispensing, distribution, administration, education, monitoring, and use" (<a href="./references#CD012594-bbs2-0132" title="National Coordinating Council for Medication Error Reporting and Prevention (NCCMERP). What is a medication error?www.nccmerp.org. Accessed 28 February 2024.">NCCMERP 2016</a>). </p> <section id="CD012594-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012594-list-0002"> <li> <p>Total number of ADE reports, including ADR reports and ME reports, submitted by healthcare professionals </p> </li> <li> <p>Total number of false ADE reports, including false ADR reports and false ME reports, submitted by health care professionals </p> </li> </ul> </p> </section> <section id="CD012594-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012594-list-0003"> <li> <p>Number of serious ADE reports (including serious ADR reports and serious ME reports)</p> <ul id="CD012594-list-0004"> <li> <p>ADEs that result in death, are life‐threatening, are a congenital anomaly, require hospital admission or prolongation of stay in hospital, or result in persistent or significant disability or incapacity or both </p> </li> </ul> </li> <li> <p>Number of high‐causality ADE reports (including high‐causality ADR reports and high‐causality ME reports) </p> <ul id="CD012594-list-0005"> <li> <p>ADEs with attribution of definitive or probable causality</p> </li> </ul> </li> <li> <p>Number of unexpected ADE reports (including unexpected ADR reports and unexpected ME reports) </p> <ul id="CD012594-list-0006"> <li> <p>Previously unknown ADEs that are not described in the drug's summary of product characteristics</p> </li> </ul> </li> <li> <p>Number of new‐drug‐related ADE reports (including new‐drug‐related ADR reports and new‐drug‐related ME reports) </p> <ul id="CD012594-list-0007"> <li> <p>ADEs relating to medications that have been on the market for less than five years</p> </li> </ul> </li> </ul> </p> </section> </section> </section> <section id="CD012594-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012594-sec-0024"> <h4 class="title">Electronic searches</h4> <p>An EPOC Information Specialist developed the search strategies in consultation with the review authors. We searched the following databases from inception to 14 October 2022. </p> <p> <ul id="CD012594-list-0008"> <li> <p>Cumulative Index to Nursing and Allied Health Literature (CINAHL) via EbscoHost (1980 to 14 October 2022) </p> </li> <li> <p>Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessment (HTA) database, and NHS Economic Evaluation Database (NHS EED) via the Cochrane Library (Issue 10, 2022; searched on 14 October 2022) </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (includes the entirety of the EPOC Group Specialised Register) via the Cochrane Library (Issue 10, 2022; searched on 14 October 2022) </p> </li> <li> <p>Embase via OvidSP (1974 to 14 October 2022)</p> </li> <li> <p>Science Citation Index (SCI), Social Sciences Citation Index (SSCI) via Web of Knowledge (1975 to 14 October 2022) </p> </li> <li> <p>Conference Proceedings Citation Index‐ Science (CPCI‐S) via Web of Science (1990 to 14 October 2022) </p> </li> <li> <p>MEDLINE (In‐Process and other non‐indexed citations) via OvidSP (1946 to 14 October 2022) </p> </li> <li> <p>Dissertations &amp; Theses (COS Conference Papers Index; ProQuest Dissertations &amp; Theses: UK &amp; Ireland; ProQuest Dissertations &amp; Theses Global) via ProQuest (1861 to 11 March 2021) </p> </li> <li> <p>Virtual Health Library (VHL) Regional Portal via <a href="http://pesquisa.bvsalud.org/portal/advanced/?lang=en" target="_blank">pesquisa.bvsalud.org/portal/advanced/?lang=en</a>; search date: 17 October 2022 </p> </li> <li> <p>World Health Organization Library Catalogue (WHOLIS/IRIS) via <a href="https://kohahq.searo.who.int" target="_blank">https://kohahq.searo.who.int</a>; search date: 17 October 2022 </p> </li> </ul> </p> <p>We also searched the following trial registries for potentially eligible ongoing studies on 17 October 2022. </p> <p> <ul id="CD012594-list-0009"> <li> <p>Word Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) via <a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en</a>; </p> </li> <li> <p>ClinicalTrials.gov via <a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>. </p> </li> </ul> </p> <p>Searches were not restricted by language, date or format of publication. The search strategies used are provided in <a href="./appendices#CD012594-sec-0094">Appendix 1</a>. </p> </section> <section id="CD012594-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We conducted a grey literature search of the following databases using key terms "adverse drug event" OR "adverse drug reaction" OR "medication error" to identify additional potentially eligible studies. </p> <p> <ul id="CD012594-list-0010"> <li> <p>OpenGrey via <a href="https://opengrey.eu/" target="_blank">opengrey.eu</a> (last search date 20 August 2018; database no longer updated) </p> </li> <li> <p>Grey Literature Report, New York Academy of Medicine via <a href="https://www.nyam.org/library/collections-and-resources/#greylit" target="_blank">www.nyam.org/library/collections-and-resources/#greylit</a> (last search date 20 August 2018; database no longer updated) </p> </li> <li> <p>Agency for Healthcare Research and Quality (AHRQ) via <a href="https://www.ahrq.gov/" target="_blank">www.ahrq.gov</a> (last search date 20 August 2018); </p> </li> <li> <p>National Institute for Health and Clinical Excellence (NICE) via <a href="https://www.nice.org.uk/" target="_blank">www.nice.org.uk</a> (last search date 20 August 2018) </p> </li> <li> <p>Bielefeld Academic Search Engine (BASE) via <a href="https://www.base-search.net/" target="_blank">www.base-search.net</a> (last search date 20 August 2018) </p> </li> </ul> </p> <p>We also screened the reference lists of all included studies and relevant systematic reviews and primary studies. We contacted authors of relevant studies or reviews to clarify reported published information and to seek unpublished results or other data for potentially eligible studies. We contacted experts in the field for information on additional eligible ongoing or completed studies. </p> </section> </section> <section id="CD012594-sec-0026"> <h3 class="title" id="CD012594-sec-0026">Data collection and analysis</h3> <section id="CD012594-sec-0027"> <h4 class="title">Selection of studies</h4> <p>All references retrieved through electronic searching were downloaded into a reference management database (<a href="./references#CD012594-bbs2-0103" title="EndNote. Version X4. Thomson Reuters, 2013.">EndNote 2013</a>). After removing all duplicate references, the search records were uploaded to the review management programme Covidence (<a href="./references#CD012594-bbs2-0100" title="Covidence. Version accessed prior to 22 October 2024. Melbourne, Australia: Veritas Health Innovation, 2024. Available at https://www.covidence.org.">Covidence</a>). Two review authors (from GS, NM, LG, WYC) independently screened the titles and abstracts for inclusion. We obtained the full texts of all the potentially eligible studies, and two review authors (from GS, NM, LG, WYC) independently screened these for inclusion. We noted the reasons for excluding any potentially eligible full‐text studies, and these are provided in a <a href="./references#CD012594-sec-0123" title="">Characteristics of excluded studies</a> table. Any disagreement between review authors regarding study eligibility was resolved through discussion or, if required, consultation with a third author (KG). We collated multiple reports of the same study so that each study, rather than each report, was the unit of interest in the review. Details about (potentially) eligible ongoing studies are provided in a <a href="./references#CD012594-sec-0125" title="">Characteristics of ongoing studies</a> table. If we were unable to obtain the full text of a potentially eligible study and could not determine the eligibility of the study, we recorded the study details in a <a href="./references#CD012594-sec-0124" title="">Characteristics of studies awaiting classification</a> table. We presented the study selection process in a PRISMA flow diagram (<a href="#CD012594-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD012594-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram" data-id="CD012594-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> </div> </section> <section id="CD012594-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We used a standard data collection form adapted from EPOC (<a href="./references#CD012594-bbs2-0106" title="Effective Practice and Organisation of Care (EPOC). Data collection form. EPOC resources for review authors. Oslo: Norwegian Knowledge Center for the Health Services; 2013. epoc.cochrane.org/epoc-specific-resources-review-authors Accessed prior to 28 February 2017.">EPOC 2013c</a>) to capture study characteristics and outcome data. Two review authors (GS, NM) independently extracted the following study characteristics from all included studies. </p> <p> <ol id="CD012594-list-0011"> <li> <p>Methods: study design, number of study centres and location, study setting, date of the study, length of follow‐up </p> </li> <li> <p>Participants: number, mean age or age range, sex, inclusion and exclusion criteria, withdrawals, loss to follow‐up, type of healthcare professionals, education </p> </li> <li> <p>Interventions: specific components of the intervention; intensity of intervention; duration of intervention </p> </li> <li> <p>Comparison: treatment and contact received by the control or comparison group</p> </li> <li> <p>Outcomes: description of study outcomes reported in the study (including the number of reported ADEs, number and percentage of false reports of ADEs and number of detected ADEs), time points at which outcomes were reported, outcome data for all relevant outcomes reported </p> </li> <li> <p>Notes: additional details about trial funding, notable author conflicts of interest, ethical approval, any outcome data reported in an unusable way and correspondence with study authors for additional data or information. </p> </li> </ol> </p> <p>A third independent author (CR) also extracted and imputed treatment effect estimates (including standard errors or confidence intervals) for the randomised studies, and extracted and re‐analysed data from the interrupted time series (ITS) studies. For randomised studies, we either extracted published risk ratios or imputed rate ratios and exact 95% confidence intervals on the rate ratio from extracted numbers of events and exposures. Because one of the included studies was a three‐arm study in which two interventions were compared to a common comparator (<a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a>), we adjusted the standard errors for this study's comparisons using the exact adjustment method of <a href="./references#CD012594-bbs2-0140" title="RückerG , CatesCJ , G Schwarzer. Methods for including information from multi-arm trials in pairwise meta-analysis. Research Synthesis Methods2017;8(4):392-403.">Rücker 2017</a>. </p> <p>We extracted ITS study data from the time series graphs published in the studies using <a href="https://apps.automeris.io/wpd/" target="_blank">WebPlotDigitizer</a> (accessed in March and April 2020). In some cases, there were apparent discrepancies between the dates of the interruptions shown in graphs versus those stated in the study texts. We chose to use the dates provided in the study texts where possible, which is a conservative approach that, in the case of these studies, is likely to lead to less extreme effect estimates. We re‐analysed all ITS data using piecewise linear regression, adjusted for autocorrelated disturbances and seasonality where possible, using the interrupted time series analysis add‐on command (<a href="./references#CD012594-bbs2-0126" title="LindenA . Conducting interrupted time-series analysis for single- and multiple-group comparisons. Stata Journal2015;15(2):480-500.">Linden 2015</a>) for Stata (StataCorp LLC, College Station, Texas, USA). Specifically, we estimated the pre‐interruption level and slope, post‐interruption change in level, post‐interruption slope and seasonal effects where possible. We adjusted for autocorrelated disturbances by setting the maximum lag option to a value determined by visual inspection of autocorrelation and partial correlation plots, and by using Cumby‐Huizinga general tests for autocorrelation (<a href="./references#CD012594-bbs2-0101" title="CumbyRE , HuizingaJ . Testing the autocorrelation structure of disturbances in ordinary least squares and instrumental variables regressions. Econometrica1992;60(1):185-95.">Cumby 1990</a>), with a significance threshold of 0.05. We adjusted for seasonality by modelling the effect of each quarter as a fixed effect if at least two years of data were available (i.e. each quarter was observed at least twice) and if data were provided monthly or more frequently (i.e. at least three data points were available for each quarter). The included ITS studies generally reported ADR counts. We modelled ITS data on the natural logarithmic scale to constrain the error distribution to positive values (counts cannot be negative), stabilise variance, and facilitate meta‐analysis (see <a href="#CD012594-sec-0030">Measures of treatment effect</a>). None of the included ITS studies included controls in which no intervention (or a substantively different intervention) was used in the post‐interruption period, so we could not adjust for other possible explanations for the observed changes in reporting. </p> <p>At least one other review author (from LG, GS, NM) checked the extracted and imputed effect estimates. Two review authors independently compared extracted time‐series data and model fits (on the count rather than the logarithmic scale) to the graphs published in the included studies. We resolved any disagreements regarding the extracted data by consensus. </p> </section> <section id="CD012594-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (from GS, NM, LG, WYC) independently assessed the risk of bias for each study using the Cochrane risk of bias tool (RoB 1), as outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012594-bbs2-0119" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane2024:Available from www.training.cochrane.org/handbook.">Higgins 2024</a>), and following guidance from the EPOC group (<a href="./references#CD012594-bbs2-0108" title="Effective Practice and Organisation of Care (EPOC). Suggested risk of bias criteria for EPOC reviews. EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services; 2015. epoc.cochrane.org/epoc-specific-resources-review-authors Accessed prior to 28 February 2017.">EPOC 2015b</a>). We resolved any disagreement by discussion or by involving a third review author (KG). </p> <p>The <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012594-bbs2-0119" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane2024:Available from www.training.cochrane.org/handbook.">Higgins 2024</a>) recommends the explicit reporting of the following individual elements for randomised controlled trials, non‐randomised controlled trials and controlled before‐after studies: random sequence generation; allocation sequence concealment; blinding (participants, personnel); blinding (outcome assessment); completeness of outcome data; selective outcome reporting; and any other sources of bias such as contamination. For each domain, we described the relevant information provided by the authors and judged each item as being at high, low or unclear risk of bias based on the criteria provided by <a href="./references#CD012594-bbs2-0119" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane2024:Available from www.training.cochrane.org/handbook.">Higgins 2024</a>. </p> <p>For cluster‐RCTs, we assessed the risk of bias associated with the following additional domains: selective recruitment of participants (recruitment bias); baseline imbalance between clusters; loss of clusters; not accounting for clustering in the analysis; and comparability with individually randomised trials to account for potential "herd effect" seen with cluster‐RCTs (<a href="./references#CD012594-bbs2-0119" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane2024:Available from www.training.cochrane.org/handbook.">Higgins 2024</a>). We added the judgement and rationale for these domains under "Other bias" in the risk of bias tables and figures, and we report them in the <a href="#CD012594-sec-0058">Other potential sources of bias</a> section. </p> <p>For interrupted time series studies (ITS), we assessed the following additional risk of bias domains: was knowledge of the allocated interventions adequately prevented during the study; was the intervention unlikely to affect data collection; was the intervention independent of other changes; and was the shape of the intervention effect prespecified (<a href="./references#CD012594-bbs2-0105" title="Effective Practice and Organisation of Care (EPOC). Interrupted time series (ITS) analyses. EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services; 2013. epoc.cochrane.org/epoc-specific-resources-review-authors Accessed prior to 28 February 2017.">EPOC 2013b</a>)? </p> <p>We judged each potential source of bias as high, low or unclear and provided justification for our judgement in the risk of bias table. We summarised our risk of bias judgements across different studies for each domain. We considered blinding separately for different key outcomes where necessary. Where information on the risk of bias related to unpublished data or correspondence with a trialist, we noted this in the risk of bias table. When considering treatment effects, we took into account the risk of bias in the studies that contributed to that outcome. </p> </section> <section id="CD012594-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We measured relative treatment effects using risk ratios and rate ratios for the included randomised studies. For the ITS studies, we exponentiated change in level and slope (which were estimated on the logarithmic scale; see <a href="#CD012594-sec-0028">Data extraction and management</a>) to obtain estimates of ratios of post‐ to pre‐interruption levels and slopes. These estimates describe the nature of any change in reporting. In principle, however, genuine changes in level and slope can lead to no overall change in reporting (i.e. a change in slope can effectively cancel a change in level). We, therefore, measured change in reporting as the ratio of expected numbers of ADR reports by extrapolating the pre‐interruption curve into the post‐interruption period and treating it as a counterfactual. Because this ratio is a function of time, we estimated it at one and two years post‐intervention. We excluded a study from any meta‐analysis of the data if it would be necessary to extrapolate beyond the end of follow‐up for that study. We used a consistent direction of effect for all measures of treatment effect such that a value greater than one favours the intervention over the comparator. </p> </section> <section id="CD012594-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>A number of eligible studies were cluster‐randomised trials. A statistician (CR) confirmed that the analyses of all these studies were appropriately adjusted for clustering. We, therefore, extracted the data as reported. </p> <p>Two studies used a cross‐over design (<a href="./references#CD012594-bbs2-0005" title="HanesseB , LegrasB , RoyerRJ , GuilleminF , BrianconS . Adverse drug reactions: comparison of two report methods. Pharmacoepidemiology and Drug Safety1994;3(4):223-9. ">Hanesse 1994</a>; <a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a>). After careful consideration, we decided that we would use the data from both periods for <a href="./references#CD012594-bbs2-0005" title="HanesseB , LegrasB , RoyerRJ , GuilleminF , BrianconS . Adverse drug reactions: comparison of two report methods. Pharmacoepidemiology and Drug Safety1994;3(4):223-9. ">Hanesse 1994</a>. However, in <a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a>, due to limitations in the design of the study (i.e. it was non‐randomised; the same clinical pharmacologist implemented the intervention and collected the outcome; and there was no washout between study periods), we felt it prudent to include only data from the first period of the study. </p> </section> <section id="CD012594-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study authors to verify key study characteristics and obtain missing outcome data where possible. We noted all interactions with study authors in the <a href="./references#CD012594-sec-0122" title="">Characteristics of included studies</a> table. We did not approach the authors of ITS studies to obtain the original time series data. </p> </section> <section id="CD012594-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>When we conducted a meta‐analysis of study data, we used the I² statistic to assess heterogeneity amongst the trials in each analysis. We noted the presence of considerable heterogeneity (I<sup>2</sup> = 75% to 100%, <a href="./references#CD012594-bbs2-0119" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane2024:Available from www.training.cochrane.org/handbook.">Higgins 2024</a>) in the text and explored this heterogeneity through the subgroup analyses. Where there were high levels of unexplained heterogeneity, we interpreted meta‐analysis results with caution. </p> </section> <section id="CD012594-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We had planned to use funnel plots to explore possible non‐reporting biases if it were possible to pool results from more than 10 studies (<a href="./references#CD012594-bbs2-0143" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. British Medical Journal2011;343:d4002. [DOI: 10.1136/bmj.d4002]">Sterne 2011</a>). We could not pool results from more than six studies, so we did not generate funnel plots. </p> </section> <section id="CD012594-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We performed random‐effects meta‐analyses following standard Cochrane methods. We used the meta‐analysis commands provided by Stata version 16.1 (StataCorp LLC, College Station, Texas, USA). We performed estimation using restricted maximum likelihood and presented results on forest plots. </p> </section> <section id="CD012594-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>See <a href="#CD012594-sec-0110">Differences between protocol and review</a> </p> </section> <section id="CD012594-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>See <a href="#CD012594-sec-0110">Differences between protocol and review</a> </p> </section> <section id="CD012594-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We summarised the findings for the main comparisons in a summary of findings table for the following primary and secondary outcomes (see <a href="#CD012594-sec-0020">Types of outcome measures</a>). </p> <p> <ol id="CD012594-list-0012"> <li> <p>Total number of ADE reports</p> <ol id="CD012594-list-0013"> <li> <p>Number of ADR reports</p> </li> <li> <p>Number of ME reports</p> </li> </ol> </li> <li> <p>Total number of false ADE reports</p> <ol id="CD012594-list-0014"> <li> <p>Number of false ADR reports</p> </li> <li> <p>Number of false ME reports</p> </li> </ol> </li> <li> <p>Number of serious ADE reports, including serious ADR reports and serious ME reports (i.e. resulting in death; is life‐threatening; is a congenital anomaly; requires hospital admission or prolongation of stay in hospital; or results in persistent or great disability, incapacity, or both). </p> </li> <li> <p>Number of high‐causality ADE reports, including high‐causality ADR reports and high‐causality ME reports (i.e. ADEs with attribution of definitive or probable causality) </p> </li> <li> <p>Number of unexpected ADE reports, including unexpected ADR reports and unexpected ME reports (i.e. previously unknown ADEs that are not described in the summary of product characteristics) </p> </li> <li> <p>Number of new drug‐related ADE reports, including new drug‐related ADR reports and new drug‐related ME reports (i.e. ADEs concerning medications that have been on the market for less than five years) </p> </li> </ol> </p> <p>We re‐expressed meta‐analytical risk and rate ratio estimates as assumed and corresponding numbers of ADE reports per 1000 practitioner years. We used data from study control arms to estimate the "assumed" rate of ADE reports, which necessarily differs with respect to the type of ADE. For example, the total number of ADR reports is larger than that for serious ADRs. We then rounded these estimates to the nearest 10 to aid reasoning. We then calculated the "corresponding" numbers of ADE reports under the intervention by multiplying the assumed rate by the relative treatment estimate and the bounds on its 95% CI. A similar approach was used to re‐express ratios of numbers of ADE reports at one and two years as assumed and corresponding numbers of ADE reports in a setting with 1000 practitioners (for simplicity, the assumed number of ADE reports at two years was taken to be twice the number of ADE reports at one year). </p> <p>Two review authors (from GS, NM, LG, WYC) independently assessed the certainty of the body of evidence (i.e. high, moderate, low and very low) as it relates to these outcomes (<a href="./references#CD012594-bbs2-0115" title="GRADEpro GDT. Version Accessed prior to 28 February 2017. Hamilton (ON): GRADE Working Group, McMaster University, 2015.">GRADEpro GDT 2015</a>; <a href="./references#CD012594-bbs2-0116" title="GuyattGH , OxmanAD , VistG , KunzR , Falck-YtterY , Alonso-CoelloP , et al GRADE Working Group. Rating quality of evidence and strength of recommendations GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. British Medical Journal2008;336(7650):924-6.">Guyatt 2008</a>), using the five GRADE considerations (risk of bias, consistency of effect, imprecision, indirectness and publication bias). We resolved disagreements on certainty ratings by discussion. We provided justification for decisions to downgrade or upgrade the ratings using footnotes in the table, and we added comments to aid readers' understanding of the review where necessary. We used plain language statements to report these findings in the review (<a href="./references#CD012594-bbs2-0107" title="Effective Practice and Organisation of Care (EPOC). EPOC worksheets for preparing a Summary of Findings (SoF) table using GRADE. EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services; 2013. epoc.cochrane.org/epoc-specific-resources-review-authors Accessed prior to 28 February 2017.">EPOC 2013d</a>). </p> <p>We considered whether there was any additional outcome information that could not be incorporated in our meta‐analyses. We noted this in the comments and stated if it supported or contradicted the information from the meta‐analyses. If it was not possible to meta‐analyse the data, we narratively summarised the results in the text. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012594-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012594-sec-0039"></div> <section id="CD012594-sec-0040"> <h3 class="title">Description of studies</h3> <p>Our study selection process is outlined in a PRISMA flow diagram (<a href="./references#CD012594-bbs2-0125" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6:e1000100.">Liberati 2009</a>) ‐ see <a href="#CD012594-fig-0001">Figure 1</a>. </p> <section id="CD012594-sec-0041"> <h4 class="title">Results of the search</h4> <p>A comprehensive search of electronic databases from inception to 14 October 2022 retrieved 17,705 records. We also screened the reference lists of six recently published relevant systematic reviews (see <a href="#CD012594-tbl-0008">Table 1</a> for details). Following de‐duplication, we screened the titles and abstracts of the remaining 11,520 records and retrieved 99 full‐text reports (including trial registrations) to assess for eligibility. Of these 99, 15 studies (17 references) met the review inclusion criteria (<a href="./references#CD012594-bbs1-0001" title="">Included studies</a>), and we excluded 69 studies (70 references), documenting our reasons ‐ see <a href="./references#CD012594-bbs1-0002" title="">Excluded studies</a>. We have eight studies awaiting classification, and three studies are ongoing (<a href="./references#CD012594-bbs2-0093" title="HutchinsonAM , BrottoV , ChapmanA , SalesAE , MohebbiM , BucknallTK . Use of an audit with feedback implementation strategy to promote medication error reporting by nurses. Journal of Clinical Nursing2020;29(21-2):4180-93. HutchinsonAM , SalesAE , BrottoV , BucknallTK . Implementation of an audit with feedback knowledge translation intervention to promote medication error reporting in health care: a protocol. Implementation Science2015;10:70. [DOI: https://dx.doi.org/10.1186/s13012-015-0260-y]">Hutchinson 2020</a>; <a href="./references#CD012594-bbs2-0094" title="Correction: Effectiveness of the med Safety mobile application in improving adverse drug reaction reporting by healthcare professionals in Uganda: a protocol for a pragmatic cluster-randomised controlled trial. BMJ Open2024;14:e061725corr1. [DOI: 10.1136/bmjopen-2022-061725corr1]KigubaR , MwebazaN , SsenyongaR , NdagijeHB , NambasaV , KatureebeC , et al. Effectiveness of the Med Safety mobile application in improving adverse drug reaction reporting by healthcare professionals in Uganda: a protocol for a pragmatic cluster-randomised controlled trial. BMJ Open2022;12(7):e061725. ">Kiguba 2022</a>; <a href="./references#CD012594-bbs2-0095" title="NCT05402254. Impact of a pharmacovigilance program led by advanced practice nursing (IMPACTO). https://www.clinicaltrials.gov/study/NCT05402254 (first received 23 May 2022). ">NCT05402254</a>). We identified an errata paper for one of the ongoing studies during our preparation of the review (<a href="./references#CD012594-bbs2-0094" title="Correction: Effectiveness of the med Safety mobile application in improving adverse drug reaction reporting by healthcare professionals in Uganda: a protocol for a pragmatic cluster-randomised controlled trial. BMJ Open2024;14:e061725corr1. [DOI: 10.1136/bmjopen-2022-061725corr1]KigubaR , MwebazaN , SsenyongaR , NdagijeHB , NambasaV , KatureebeC , et al. Effectiveness of the Med Safety mobile application in improving adverse drug reaction reporting by healthcare professionals in Uganda: a protocol for a pragmatic cluster-randomised controlled trial. BMJ Open2022;12(7):e061725. ">Kiguba 2022</a>). </p> </section> <section id="CD012594-sec-0042"> <h4 class="title">Study design</h4> <p>There were two individually randomised controlled trials (<a href="./references#CD012594-bbs2-0008" title="JohanssonML , BrunlofG , EdwardC , WallerstedtSM . Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports. European Journal of Clinical Pharmacology2009;65(5):511-4. ">Johansson 2009</a>; <a href="./references#CD012594-bbs2-0009" title="JohanssonML , HaggS , WallerstedtSM . Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study. BMC Clinical Pharmacology2011;11:14. ">Johansson 2011</a>), five cluster‐randomised controlled trials (<a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a>; <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a>; <a href="./references#CD012594-bbs2-0010" title="ISRCTN91140684. An educational intervention to improve adverse drug reactions reporting among Galician physicians. https://www.isrctn.com/ISRCTN91140684 (first received 7 May 2009). Lopez-GonzalezE , HerdeiroMT , Pineiro-LamasM , FigueirasA , Grephepi group. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Safety2015;38(2):189-96. ">Lopez‐Gonzalez 2015</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a>) and one cluster‐randomised cross‐over trial (<a href="./references#CD012594-bbs2-0005" title="HanesseB , LegrasB , RoyerRJ , GuilleminF , BrianconS . Adverse drug reactions: comparison of two report methods. Pharmacoepidemiology and Drug Safety1994;3(4):223-9. ">Hanesse 1994</a>). Six were interrupted time series studies (<a href="./references#CD012594-bbs2-0001" title="AliS , EgunsolaO , Al-DossariDS , Al-ZaagiIA . Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Therapeutic Advances in Drug Safety2018;9(10):585-90. [DOI: 10.1177/2042098618790209]">Ali 2018</a>; <a href="./references#CD012594-bbs2-0002" title="CastelJM , FiguerasA , PedrosC , LaporteJR , CapellaD . Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads. Drug Safety2003;25(14):1049-55. ">Castel 2003</a>; <a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>; <a href="./references#CD012594-bbs2-0011" title="McKaigD , CollinsC , ElsaidKA . Impact of a reengineered electronic error-reporting system on medication event reporting and care process improvements at an urban medical center. Joint Commission Journal on Quality &amp; Patient Safety2014;40(9):398-407. ">McKaig 2014</a>; <a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>; <a href="./references#CD012594-bbs2-0014" title="Ribeiro-VazI , Santos Cda, Costa-PereiraA , Cruz-CorreiaR . Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal. Drug Safety2012;33(5):387-94. ">Ribeiro‐Vaz 2012</a>) and one was a non‐randomised cross‐over study (<a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a>). </p> <p>Four of the studies were connected (<a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a>; <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a>). <a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a> and <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a> were conducted in the same 15 Portuguese clusters (which consisted of one reference hospital plus the outpatient centre and any other hospital in the catchment area). <a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a> targeted the physicians in these clusters and <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a> targeted the pharmacists. A second randomisation of the four intervention clusters from <a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a> and <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a> was performed, with two clusters receiving the workshop intervention and two clusters receiving the telephone‐interview intervention, and 11 clusters remaining assigned to the control arm. <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a> targeted the physicians and <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a> targeted the pharmacists in the newly randomised clusters. </p> </section> <section id="CD012594-sec-0043"> <h4 class="title">Study setting</h4> <p>Five of the studies were conducted in Portugal (<a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a>; <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a>; <a href="./references#CD012594-bbs2-0014" title="Ribeiro-VazI , Santos Cda, Costa-PereiraA , Cruz-CorreiaR . Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal. Drug Safety2012;33(5):387-94. ">Ribeiro‐Vaz 2012</a>), three in Spain (<a href="./references#CD012594-bbs2-0002" title="CastelJM , FiguerasA , PedrosC , LaporteJR , CapellaD . Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads. Drug Safety2003;25(14):1049-55. ">Castel 2003</a>; <a href="./references#CD012594-bbs2-0010" title="ISRCTN91140684. An educational intervention to improve adverse drug reactions reporting among Galician physicians. https://www.isrctn.com/ISRCTN91140684 (first received 7 May 2009). Lopez-GonzalezE , HerdeiroMT , Pineiro-LamasM , FigueirasA , Grephepi group. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Safety2015;38(2):189-96. ">Lopez‐Gonzalez 2015</a>; <a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>), two in Sweden (<a href="./references#CD012594-bbs2-0008" title="JohanssonML , BrunlofG , EdwardC , WallerstedtSM . Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports. European Journal of Clinical Pharmacology2009;65(5):511-4. ">Johansson 2009</a>; <a href="./references#CD012594-bbs2-0009" title="JohanssonML , HaggS , WallerstedtSM . Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study. BMC Clinical Pharmacology2011;11:14. ">Johansson 2011</a>) and one in each of the following countries: France (<a href="./references#CD012594-bbs2-0005" title="HanesseB , LegrasB , RoyerRJ , GuilleminF , BrianconS . Adverse drug reactions: comparison of two report methods. Pharmacoepidemiology and Drug Safety1994;3(4):223-9. ">Hanesse 1994</a>), Switzerland (<a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a>), USA (<a href="./references#CD012594-bbs2-0011" title="McKaigD , CollinsC , ElsaidKA . Impact of a reengineered electronic error-reporting system on medication event reporting and care process improvements at an urban medical center. Joint Commission Journal on Quality &amp; Patient Safety2014;40(9):398-407. ">McKaig 2014</a>), China (<a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>) and Saudi Arabia (<a href="./references#CD012594-bbs2-0001" title="AliS , EgunsolaO , Al-DossariDS , Al-ZaagiIA . Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Therapeutic Advances in Drug Safety2018;9(10):585-90. [DOI: 10.1177/2042098618790209]">Ali 2018</a>). Most of the studies were conducted in large tertiary care hospitals. </p> </section> <section id="CD012594-sec-0044"> <h4 class="title">Participants</h4> <p>Approximately 62,389 participants were enroled in the 15 included studies. While some studies reported approximate participant numbers, four (all ITS studies) did not report the number of healthcare professionals exposed to the intervention. In seven studies, the intervention targeted physicians (<a href="./references#CD012594-bbs2-0002" title="CastelJM , FiguerasA , PedrosC , LaporteJR , CapellaD . Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads. Drug Safety2003;25(14):1049-55. ">Castel 2003</a>; <a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>; <a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0005" title="HanesseB , LegrasB , RoyerRJ , GuilleminF , BrianconS . Adverse drug reactions: comparison of two report methods. Pharmacoepidemiology and Drug Safety1994;3(4):223-9. ">Hanesse 1994</a>; <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a>; <a href="./references#CD012594-bbs2-0010" title="ISRCTN91140684. An educational intervention to improve adverse drug reactions reporting among Galician physicians. https://www.isrctn.com/ISRCTN91140684 (first received 7 May 2009). Lopez-GonzalezE , HerdeiroMT , Pineiro-LamasM , FigueirasA , Grephepi group. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Safety2015;38(2):189-96. ">Lopez‐Gonzalez 2015</a>; <a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>). In three studies, the intervention targeted hospital pharmacists (<a href="./references#CD012594-bbs2-0001" title="AliS , EgunsolaO , Al-DossariDS , Al-ZaagiIA . Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Therapeutic Advances in Drug Safety2018;9(10):585-90. [DOI: 10.1177/2042098618790209]">Ali 2018</a>; <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a>). The intervention in <a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a> targeted physicians and nurses. The intervention in <a href="./references#CD012594-bbs2-0008" title="JohanssonML , BrunlofG , EdwardC , WallerstedtSM . Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports. European Journal of Clinical Pharmacology2009;65(5):511-4. ">Johansson 2009</a> and <a href="./references#CD012594-bbs2-0009" title="JohanssonML , HaggS , WallerstedtSM . Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study. BMC Clinical Pharmacology2011;11:14. ">Johansson 2011</a> targeted hospital GPs and nurses. In <a href="./references#CD012594-bbs2-0011" title="McKaigD , CollinsC , ElsaidKA . Impact of a reengineered electronic error-reporting system on medication event reporting and care process improvements at an urban medical center. Joint Commission Journal on Quality &amp; Patient Safety2014;40(9):398-407. ">McKaig 2014</a> and <a href="./references#CD012594-bbs2-0014" title="Ribeiro-VazI , Santos Cda, Costa-PereiraA , Cruz-CorreiaR . Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal. Drug Safety2012;33(5):387-94. ">Ribeiro‐Vaz 2012</a>, the intervention targeted all hospital medical staff (physicians, nurses, and pharmacists). </p> </section> <section id="CD012594-sec-0045"> <h4 class="title">Interventions</h4> <p>Based on the characteristics of the various interventions, the main focus of the interventions and usual practices implemented in the eligible studies, we devised the following overarching categories and comparisons. </p> <section id="CD012594-sec-0046"> <h5 class="title">Educating and informing</h5> <p> <ul id="CD012594-list-0015"> <li> <p>Comparison 1. Education session plus reminder card and ADR report form versus usual practice (<a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a>; <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a>; <a href="./references#CD012594-bbs2-0010" title="ISRCTN91140684. An educational intervention to improve adverse drug reactions reporting among Galician physicians. https://www.isrctn.com/ISRCTN91140684 (first received 7 May 2009). Lopez-GonzalezE , HerdeiroMT , Pineiro-LamasM , FigueirasA , Grephepi group. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Safety2015;38(2):189-96. ">Lopez‐Gonzalez 2015</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a>) </p> </li> <li> <p>Comparison 2. Informational letter and email versus usual practice (<a href="./references#CD012594-bbs2-0008" title="JohanssonML , BrunlofG , EdwardC , WallerstedtSM . Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports. European Journal of Clinical Pharmacology2009;65(5):511-4. ">Johansson 2009</a>; <a href="./references#CD012594-bbs2-0009" title="JohanssonML , HaggS , WallerstedtSM . Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study. BMC Clinical Pharmacology2011;11:14. ">Johansson 2011</a>) </p> </li> </ul> </p> </section> <section id="CD012594-sec-0047"> <h5 class="title">Multifaceted intervention</h5> <p> <ul id="CD012594-list-0016"> <li> <p>Comparison 3. Multifaceted intervention (financial and non‐financial incentives, fines, education, reminders) versus usual practice (<a href="./references#CD012594-bbs2-0001" title="AliS , EgunsolaO , Al-DossariDS , Al-ZaagiIA . Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Therapeutic Advances in Drug Safety2018;9(10):585-90. [DOI: 10.1177/2042098618790209]">Ali 2018</a>; <a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>; <a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>) </p> </li> <li> <p>Comparison 4. Government regulations plus financial incentives versus usual practice (<a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>) </p> </li> </ul> </p> </section> <section id="CD012594-sec-0048"> <h5 class="title">Process improvement</h5> <p> <ul id="CD012594-list-0017"> <li> <p>Comparison 5. Improving access to ADR report forms versus usual practice (<a href="./references#CD012594-bbs2-0002" title="CastelJM , FiguerasA , PedrosC , LaporteJR , CapellaD . Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads. Drug Safety2003;25(14):1049-55. ">Castel 2003</a>; <a href="./references#CD012594-bbs2-0005" title="HanesseB , LegrasB , RoyerRJ , GuilleminF , BrianconS . Adverse drug reactions: comparison of two report methods. Pharmacoepidemiology and Drug Safety1994;3(4):223-9. ">Hanesse 1994</a>; <a href="./references#CD012594-bbs2-0014" title="Ribeiro-VazI , Santos Cda, Costa-PereiraA , Cruz-CorreiaR . Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal. Drug Safety2012;33(5):387-94. ">Ribeiro‐Vaz 2012</a>) </p> </li> <li> <p>Comparison 6. Improving the reporting method versus usual practice (<a href="./references#CD012594-bbs2-0011" title="McKaigD , CollinsC , ElsaidKA . Impact of a reengineered electronic error-reporting system on medication event reporting and care process improvements at an urban medical center. Joint Commission Journal on Quality &amp; Patient Safety2014;40(9):398-407. ">McKaig 2014</a>) </p> </li> </ul> </p> </section> <section id="CD012594-sec-0049"> <h5 class="title">Adverse drug event champion</h5> <p> <ul id="CD012594-list-0018"> <li> <p>Comparison 7. Case finding versus spontaneous reporting (<a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a>) </p> </li> </ul> </p> </section> </section> <section id="CD012594-sec-0050"> <h4 class="title">Outcomes</h4> <p>See <a href="#CD012594-tbl-0009">Table 2</a> for a summary of the outcomes measured and reported on in each study. In terms of our first primary outcome, all but two studies reported the number of ADR reports submitted (<a href="./references#CD012594-bbs2-0011" title="McKaigD , CollinsC , ElsaidKA . Impact of a reengineered electronic error-reporting system on medication event reporting and care process improvements at an urban medical center. Joint Commission Journal on Quality &amp; Patient Safety2014;40(9):398-407. ">McKaig 2014</a>; <a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a>). <a href="./references#CD012594-bbs2-0011" title="McKaigD , CollinsC , ElsaidKA . Impact of a reengineered electronic error-reporting system on medication event reporting and care process improvements at an urban medical center. Joint Commission Journal on Quality &amp; Patient Safety2014;40(9):398-407. ">McKaig 2014</a> (comparison 6 ‐ improving ME reporting method versus usual practice) reported the mean number of monthly medication error reports submitted pre‐ and post‐intervention implementation. <a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a> (comparison 7 ‐ case finding versus spontaneous reporting (usual practice) reported the number of ADE reports per 1000 patient‐days. None of the included studies provided data on our other primary outcome, the total number of false ADE reports (including ADR and ME) submitted by healthcare professionals. </p> <div class="table" id="CD012594-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcomes reported by the included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of ADE reports (including ADR reports and ME reports)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of false ADE reports (including false ADR reports and false ME reports)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of serious ADE reports (including serious ADR reports and serious ME reports)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of high‐causality ADE reports (including high‐causality ADR reports and high‐causality ME reports)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of unexpected (previously unknown) ADE reports (including unexpected ADR reports and unexpected ME reports)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of new drug‐related ADE reports (including drug‐related ADR reports and drug‐related ME reports)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Comparison 1. Education session plus reminder card and report form versus usual practice</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a>; <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a>; <a href="./references#CD012594-bbs2-0010" title="ISRCTN91140684. An educational intervention to improve adverse drug reactions reporting among Galician physicians. https://www.isrctn.com/ISRCTN91140684 (first received 7 May 2009). Lopez-GonzalezE , HerdeiroMT , Pineiro-LamasM , FigueirasA , Grephepi group. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Safety2015;38(2):189-96. ">Lopez‐Gonzalez 2015</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a>; <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a>; <a href="./references#CD012594-bbs2-0010" title="ISRCTN91140684. An educational intervention to improve adverse drug reactions reporting among Galician physicians. https://www.isrctn.com/ISRCTN91140684 (first received 7 May 2009). Lopez-GonzalezE , HerdeiroMT , Pineiro-LamasM , FigueirasA , Grephepi group. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Safety2015;38(2):189-96. ">Lopez‐Gonzalez 2015</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>;<br/><a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a>; <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a>; <a href="./references#CD012594-bbs2-0010" title="ISRCTN91140684. An educational intervention to improve adverse drug reactions reporting among Galician physicians. https://www.isrctn.com/ISRCTN91140684 (first received 7 May 2009). Lopez-GonzalezE , HerdeiroMT , Pineiro-LamasM , FigueirasA , Grephepi group. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Safety2015;38(2):189-96. ">Lopez‐Gonzalez 2015</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a>; <a href="./references#CD012594-bbs2-0010" title="ISRCTN91140684. An educational intervention to improve adverse drug reactions reporting among Galician physicians. https://www.isrctn.com/ISRCTN91140684 (first received 7 May 2009). Lopez-GonzalezE , HerdeiroMT , Pineiro-LamasM , FigueirasA , Grephepi group. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Safety2015;38(2):189-96. ">Lopez‐Gonzalez 2015</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a> (ADR reports) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Comparison 2. Informational letter or email versus usual practice</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0008" title="JohanssonML , BrunlofG , EdwardC , WallerstedtSM . Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports. European Journal of Clinical Pharmacology2009;65(5):511-4. ">Johansson 2009</a>; <a href="./references#CD012594-bbs2-0009" title="JohanssonML , HaggS , WallerstedtSM . Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study. BMC Clinical Pharmacology2011;11:14. ">Johansson 2011</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0008" title="JohanssonML , BrunlofG , EdwardC , WallerstedtSM . Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports. European Journal of Clinical Pharmacology2009;65(5):511-4. ">Johansson 2009</a>; <a href="./references#CD012594-bbs2-0009" title="JohanssonML , HaggS , WallerstedtSM . Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study. BMC Clinical Pharmacology2011;11:14. ">Johansson 2011</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0008" title="JohanssonML , BrunlofG , EdwardC , WallerstedtSM . Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports. European Journal of Clinical Pharmacology2009;65(5):511-4. ">Johansson 2009</a>; <a href="./references#CD012594-bbs2-0009" title="JohanssonML , HaggS , WallerstedtSM . Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study. BMC Clinical Pharmacology2011;11:14. ">Johansson 2011</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0008" title="JohanssonML , BrunlofG , EdwardC , WallerstedtSM . Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports. European Journal of Clinical Pharmacology2009;65(5):511-4. ">Johansson 2009</a>;<br/><a href="./references#CD012594-bbs2-0009" title="JohanssonML , HaggS , WallerstedtSM . Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study. BMC Clinical Pharmacology2011;11:14. ">Johansson 2011</a> (ADR reports) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Comparison 3. Multifaceted intervention versus usual practice</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012594-bbs2-0001" title="AliS , EgunsolaO , Al-DossariDS , Al-ZaagiIA . Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Therapeutic Advances in Drug Safety2018;9(10):585-90. [DOI: 10.1177/2042098618790209]">Ali 2018</a>; <a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>;<br/><a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>; <a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>; <a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a> (ADR reports) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Comparison 4. Government regulations and financial incentives versus usual practice</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Comparison 5. Improving access to ADR report form versus usual practice</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012594-bbs2-0002" title="CastelJM , FiguerasA , PedrosC , LaporteJR , CapellaD . Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads. Drug Safety2003;25(14):1049-55. ">Castel 2003</a>; <a href="./references#CD012594-bbs2-0014" title="Ribeiro-VazI , Santos Cda, Costa-PereiraA , Cruz-CorreiaR . Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal. Drug Safety2012;33(5):387-94. ">Ribeiro‐Vaz 2012</a>; <a href="./references#CD012594-bbs2-0005" title="HanesseB , LegrasB , RoyerRJ , GuilleminF , BrianconS . Adverse drug reactions: comparison of two report methods. Pharmacoepidemiology and Drug Safety1994;3(4):223-9. ">Hanesse 1994</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Comparison 6. Improving reporting method versus usual practice</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012594-bbs2-0011" title="McKaigD , CollinsC , ElsaidKA . Impact of a reengineered electronic error-reporting system on medication event reporting and care process improvements at an urban medical center. Joint Commission Journal on Quality &amp; Patient Safety2014;40(9):398-407. ">McKaig 2014</a> (mean number of monthly ME reports pre‐ and post‐intervention) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Comparison 7. Case finding versus spontaneous reporting (usual practice)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a> (number of ADE reports per 1000 patient‐days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p> <ul id="CD012594-list-0019"> <li> <p>Serious ADRs: adverse drug reactions resulting in death; is life‐threatening; is a congenital anomaly; requires hospital admission or prolongation of stay in hospital; results in persistent or great disability, incapacity or both </p> </li> <li> <p>High‐causality ADRs: adverse drug reactions with attribution of definitive or probable causality; unexpected (previously unknown) </p> </li> <li> <p>ADRs: unknown adverse drug reactions that are not described in the drug's summary of product characteristics </p> </li> <li> <p>New‐drug‐related ADRs: adverse drug reactions relating to medications that have been on the market for less than five years </p> </li> <li> <p>ADE: adverse drug event</p> </li> <li> <p>ME: medication error</p> </li> </ul> </p> </div> </div> </section> <section id="CD012594-sec-0051"> <h4 class="title">Excluded studies</h4> <p>We excluded 69 full‐text articles (70 studies). The most common reason for exclusion was ineligible study design. For more details, see <a href="./references#CD012594-sec-0123" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD012594-sec-0052"> <h3 class="title">Risk of bias in included studies</h3> <p>For a summary of our assessment of the studies' risk of bias, see <a href="#CD012594-fig-0002">Figure 2</a> (controlled studies) and <a href="#CD012594-fig-0003">Figure 3</a> (ITS studies). </p> <div class="figure" id="CD012594-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary for the controlled trials" data-id="CD012594-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary for the controlled trials</p> </div> </div> </div> <div class="figure" id="CD012594-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary for interrupted time series (ITS) studies" data-id="CD012594-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-03.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary for interrupted time series (ITS) studies</p> </div> </div> </div> <section id="CD012594-sec-0053"> <h4 class="title">Allocation</h4> <p>We judged <a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a> to have a high risk of selection bias as it was a non‐randomised study. <a href="./references#CD012594-bbs2-0008" title="JohanssonML , BrunlofG , EdwardC , WallerstedtSM . Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports. European Journal of Clinical Pharmacology2009;65(5):511-4. ">Johansson 2009</a> and <a href="./references#CD012594-bbs2-0009" title="JohanssonML , HaggS , WallerstedtSM . Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study. BMC Clinical Pharmacology2011;11:14. ">Johansson 2011</a> both have an unclear risk of selection bias as they did not describe how the random sequence was generated. However, both studies stated that "a person not involved in the study and without knowledge about the study protocol performed the randomisation procedure". Assuming that the randomisation procedure includes the allocation procedure, it is likely that overall, the risk of selection bias was low in both these studies. We judged <a href="./references#CD012594-bbs2-0005" title="HanesseB , LegrasB , RoyerRJ , GuilleminF , BrianconS . Adverse drug reactions: comparison of two report methods. Pharmacoepidemiology and Drug Safety1994;3(4):223-9. ">Hanesse 1994</a> to have an unclear risk of selection bias. The study authors state that reporting methods were randomly assigned; however, they did not describe how the random sequence was generated or provide details regarding allocation concealment. We judged the remainder of the randomised studies to have a low risk of selection bias (<a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a>; <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a>; <a href="./references#CD012594-bbs2-0010" title="ISRCTN91140684. An educational intervention to improve adverse drug reactions reporting among Galician physicians. https://www.isrctn.com/ISRCTN91140684 (first received 7 May 2009). Lopez-GonzalezE , HerdeiroMT , Pineiro-LamasM , FigueirasA , Grephepi group. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Safety2015;38(2):189-96. ">Lopez‐Gonzalez 2015</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a>). </p> </section> <section id="CD012594-sec-0054"> <h4 class="title">Performance bias</h4> <p>We judged all the studies to have a high risk of performance bias as blinding of the participant or intervention targets was not possible due to the nature of the various interventions implemented. </p> </section> <section id="CD012594-sec-0055"> <h4 class="title">Detection bias</h4> <p>We judged <a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a> to have a high risk of detection bias as the outcome assessor was not blinded to the group allocation. The risk of detection bias was judged unclear in <a href="./references#CD012594-bbs2-0005" title="HanesseB , LegrasB , RoyerRJ , GuilleminF , BrianconS . Adverse drug reactions: comparison of two report methods. Pharmacoepidemiology and Drug Safety1994;3(4):223-9. ">Hanesse 1994</a> as the data on adverse drug reactions were extracted from patients' medical files in the study, and it was unclear who extracted them and if this person was blinded. Although blinding of the outcome assessors was not clearly or explicitly described in most of the studies, we judged the remaining studies to have a low risk of detection bias as the person who extracted the data was likely to be unaware of the intervention allocation. </p> </section> <section id="CD012594-sec-0056"> <h4 class="title">Incomplete outcome data</h4> <p>We judged <a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a> as unclear risk of attrition bias as neither the flow of participants nor the retention of healthcare professionals was described in the published study. We judged all remaining randomised trials as having a low risk of attrition bias. There was no loss of clusters in the cluster‐randomised studies, and even though retention of healthcare professionals (which might affect the number of adverse drug event reports submitted) was not clearly reported, we assumed that any loss or addition of healthcare professionals was just as likely to occur in the intervention and control arms. </p> </section> <section id="CD012594-sec-0057"> <h4 class="title">Selective reporting</h4> <p>We judged all the studies to have a low risk of reporting bias as, even though the protocol was not available for all the studies, all the outcomes mentioned in the methods section were reported on in the results section. Furthermore, all expected outcomes were reported in the studies. Only three studies were registered in a trial registry (<a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a>; <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a>; <a href="./references#CD012594-bbs2-0010" title="ISRCTN91140684. An educational intervention to improve adverse drug reactions reporting among Galician physicians. https://www.isrctn.com/ISRCTN91140684 (first received 7 May 2009). Lopez-GonzalezE , HerdeiroMT , Pineiro-LamasM , FigueirasA , Grephepi group. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Safety2015;38(2):189-96. ">Lopez‐Gonzalez 2015</a>). </p> </section> <section id="CD012594-sec-0058"> <h4 class="title">Other potential sources of bias</h4> <p>We judged <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a> and <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a> as having a high risk of other bias due to a baseline imbalance in adverse drug reaction reporting rate between the intervention and control groups. We judged <a href="./references#CD012594-bbs2-0008" title="JohanssonML , BrunlofG , EdwardC , WallerstedtSM . Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports. European Journal of Clinical Pharmacology2009;65(5):511-4. ">Johansson 2009</a> as having a high risk of other bias due to potential contamination bias. The authors stated: "The intervention may also have spilled over to the control units. Doctors may work in more than one primary health care unit, i.e. both in the intervention group and in the control group. Also, the units all belong to the same organisation, and information may easily be passed on from one unit to another." We judged <a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a> as having an unclear risk of other bias due to an imbalance in the number of males and females in the intervention and control arms, and the effect of this imbalance on the number of reported adverse drug events being unclear. <a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a> is a non‐randomised cross‐over study; to mitigate the potential risk of bias due to the carry‐over effect, we included only data from the first phase of the study prior to cross‐over. </p> </section> <section id="CD012594-sec-0059"> <h4 class="title">Interrupted time‐series (ITS) studies</h4> <section id="CD012594-sec-0060"> <h5 class="title">Incomplete outcome data (attrition bias)</h5> <p>We judged all the ITS studies to have an unclear risk of attrition bias. Most of the studies reported the number of centres and hospitals exposed to the intervention and the number included in the analysis, but they did not report the number of healthcare professionals serving these hospitals or centres or the retention rate of healthcare professionals in the study. </p> </section> <section id="CD012594-sec-0061"> <h5 class="title">Selective reporting (reporting bias)</h5> <p>We judged all the ITS studies to have a low risk of reporting bias. Even though we did not have access to the study protocols, all relevant outcomes in the method section were reported in the results section of the published studies. </p> </section> <section id="CD012594-sec-0062"> <h5 class="title">Other potential sources of bias</h5> <p>We judged <a href="./references#CD012594-bbs2-0001" title="AliS , EgunsolaO , Al-DossariDS , Al-ZaagiIA . Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Therapeutic Advances in Drug Safety2018;9(10):585-90. [DOI: 10.1177/2042098618790209]">Ali 2018</a>, <a href="./references#CD012594-bbs2-0011" title="McKaigD , CollinsC , ElsaidKA . Impact of a reengineered electronic error-reporting system on medication event reporting and care process improvements at an urban medical center. Joint Commission Journal on Quality &amp; Patient Safety2014;40(9):398-407. ">McKaig 2014</a> and <a href="./references#CD012594-bbs2-0014" title="Ribeiro-VazI , Santos Cda, Costa-PereiraA , Cruz-CorreiaR . Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal. Drug Safety2012;33(5):387-94. ">Ribeiro‐Vaz 2012</a> to have a high risk of other bias as none of these studies appeared to adjust for seasonality. Furthermore, there is a probable clustering effect in <a href="./references#CD012594-bbs2-0014" title="Ribeiro-VazI , Santos Cda, Costa-PereiraA , Cruz-CorreiaR . Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal. Drug Safety2012;33(5):387-94. ">Ribeiro‐Vaz 2012</a> (there appears to be a hierarchy of hospitals within centres), which does not seem to be modelled in the analyses. </p> </section> <section id="CD012594-sec-0063"> <h5 class="title">Intervention independent of other changes</h5> <p>We judged <a href="./references#CD012594-bbs2-0001" title="AliS , EgunsolaO , Al-DossariDS , Al-ZaagiIA . Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Therapeutic Advances in Drug Safety2018;9(10):585-90. [DOI: 10.1177/2042098618790209]">Ali 2018</a>, <a href="./references#CD012594-bbs2-0002" title="CastelJM , FiguerasA , PedrosC , LaporteJR , CapellaD . Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads. Drug Safety2003;25(14):1049-55. ">Castel 2003</a>, <a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>, <a href="./references#CD012594-bbs2-0011" title="McKaigD , CollinsC , ElsaidKA . Impact of a reengineered electronic error-reporting system on medication event reporting and care process improvements at an urban medical center. Joint Commission Journal on Quality &amp; Patient Safety2014;40(9):398-407. ">McKaig 2014</a> and <a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a> to have a high risk of bias in this domain as the study authors did not provide any compelling argument that the intervention occurred independently of other changes over time and that the outcome was not influenced by other confounding variables or historic events during the study period. <a href="./references#CD012594-bbs2-0014" title="Ribeiro-VazI , Santos Cda, Costa-PereiraA , Cruz-CorreiaR . Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal. Drug Safety2012;33(5):387-94. ">Ribeiro‐Vaz 2012</a> was the only study to explicitly address this issue: "From the initial 18 centres (31 hospitals), we excluded four hospitals that established other cooperation protocols with UFN to avoid a possible confounder bias. For the other 16 centres, we believe that there were no external interventions that could potentially explain the observed results.” </p> </section> <section id="CD012594-sec-0064"> <h5 class="title">Shape of the intervention effect prespecified</h5> <p>We judged all the ITS studies to have a low risk of bias in this domain as the point of analysis matched the point of intervention and was clearly described in all the studies. </p> </section> <section id="CD012594-sec-0065"> <h5 class="title">Intervention unlikely to affect data collection</h5> <p>We judged all the ITS studies to have a low risk of bias in this domain because we thought that the intervention itself was unlikely to affect data collection as sources and data collection methods were the same before and after the intervention in all studies. </p> </section> <section id="CD012594-sec-0066"> <h5 class="title">Knowledge of the allocated interventions adequately prevented during the study</h5> <p>We judged all the ITS studies to have a low risk of bias in this domain because the outcome is objective. In all the studies, the number of ADE reports were retrieved from central or pharmacovigilance databases. </p> </section> </section> </section> <section id="CD012594-sec-0067"> <h3 class="title" id="CD012594-sec-0067">Effects of interventions</h3> <p>See: <a href="./full#CD012594-tbl-0001"><b>Summary of findings 1</b> Education session plus reminder card and ADR report form versus usual practice</a>; <a href="./full#CD012594-tbl-0002"><b>Summary of findings 2</b> Informational letter or email versus usual practice</a>; <a href="./full#CD012594-tbl-0003"><b>Summary of findings 3</b> Multifaceted interventions versus usual practice</a>; <a href="./full#CD012594-tbl-0004"><b>Summary of findings 4</b> Government regulations plus financial incentives versus usual practice</a>; <a href="./full#CD012594-tbl-0005"><b>Summary of findings 5</b> Improving access to ADR report forms versus usual practice</a>; <a href="./full#CD012594-tbl-0006"><b>Summary of findings 6</b> Improving ADE reporting method (new web‐based electronic error reporting system) versus usual practice (existing web‐based electronic error reporting system)</a>; <a href="./full#CD012594-tbl-0007"><b>Summary of findings 7</b> Case finding versus spontaneous reporting (usual practice)</a> </p> <p>For a summary of the key comparisons and outcomes, see <a href="./full#CD012594-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD012594-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD012594-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD012594-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD012594-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD012594-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD012594-tbl-0007">summary of findings Table 7</a>. </p> <p>None of the included studies reported on our primary outcome 'total number of false ADE reports' (see <a href="#CD012594-sec-0021">Primary outcomes</a>). </p> <section id="CD012594-sec-0068"> <h4 class="title">Comparison 1. Education session plus reminder card and report form versus usual practice</h4> <p>Data for this comparison came from five cluster‐RCTs (<a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a>; <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a>; <a href="./references#CD012594-bbs2-0010" title="ISRCTN91140684. An educational intervention to improve adverse drug reactions reporting among Galician physicians. https://www.isrctn.com/ISRCTN91140684 (first received 7 May 2009). Lopez-GonzalezE , HerdeiroMT , Pineiro-LamasM , FigueirasA , Grephepi group. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Safety2015;38(2):189-96. ">Lopez‐Gonzalez 2015</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a>; see <a href="./full#CD012594-tbl-0001">summary of findings Table 1</a>). All trials assessed the effect of an education session (consisting of 30‐ to 60‐minute long face‐to‐face group workshops or telephone interviews, or both), plus a reminder card (similar to the ADR report form summarising the main points from the education session) and an ADR report form on the number of ADR reports submitted. The effect of the intervention was measured amongst participants (i.e. physicians and pharmacists). </p> <p>At 13 to 16 months after the implementation of the intervention, compared to usual practice, education sessions together with reminder cards and ADR report forms may substantially increase the number of submitted ADR reports (risk ratio 3.00, 95% CI 1.53 to 5.90; <a href="#CD012594-fig-0004">Figure 4</a>), serious ADR reports (risk ratio 3.30, 95% CI 1.51 to 7.21; <a href="#CD012594-fig-0005">Figure 5</a>), high‐causality ADR reports (risk ratio 2.48, 95% CI 1.11 to 5.57; <a href="#CD012594-fig-0006">Figure 6</a>), unexpected or previously unknown ADR reports (risk ratio 4.72, 95% CI 1.75 to 12.76; <a href="#CD012594-fig-0007">Figure 7</a>) and new‐drug‐related ADR reports (risk ratio 8.68, 95% CI 3.40 to 22.13; <a href="#CD012594-fig-0008">Figure 8</a>). The certainty of the evidence was low for all these findings. </p> <div class="figure" id="CD012594-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Comparison 1. Education session plus reminder card and report form versus usual practice. Outcome: total number of adverse drug reaction reports submitted. Education delivered in group sessions, workshops or via telephone. Meta‐analysis of five cluster‐randomised controlled studies." data-id="CD012594-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1. Education session plus reminder card and report form versus usual practice. Outcome: total number of adverse drug reaction reports submitted. Education delivered in group sessions, workshops or via telephone. Meta‐analysis of five cluster‐randomised controlled studies. </p> </div> </div> </div> <div class="figure" id="CD012594-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Comparison 1. Education session plus reminder card and report form versus usual practice. Outcome: number of serious adverse drug reaction reports submitted" data-id="CD012594-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1. Education session plus reminder card and report form versus usual practice. Outcome: number of serious adverse drug reaction reports submitted </p> </div> </div> </div> <div class="figure" id="CD012594-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Comparison 1. Education session plus reminder card and report form versus usual practice. Outcome: high‐causality adverse drug reaction reports submitted" data-id="CD012594-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1. Education session plus reminder card and report form versus usual practice. Outcome: high‐causality adverse drug reaction reports submitted </p> </div> </div> </div> <div class="figure" id="CD012594-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Comparison 1. Education session plus reminder card and report form versus usual practice. Outcome: unexpected adverse drug reaction reports" data-id="CD012594-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1. Education session plus reminder card and report form versus usual practice. Outcome: unexpected adverse drug reaction reports </p> </div> </div> </div> <div class="figure" id="CD012594-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Comparison 1. Education session plus reminder card and report form versus usual practice. Outcome: number of new drug‐related adverse drug reaction reports submitted" data-id="CD012594-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1. Education session plus reminder card and report form versus usual practice. Outcome: number of new drug‐related adverse drug reaction reports submitted </p> </div> </div> </div> </section> <section id="CD012594-sec-0069"> <h4 class="title">Comparison 2. Informational letter or email versus usual practice</h4> <p>Two RCTs provided data for this comparison (<a href="./references#CD012594-bbs2-0008" title="JohanssonML , BrunlofG , EdwardC , WallerstedtSM . Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports. European Journal of Clinical Pharmacology2009;65(5):511-4. ">Johansson 2009</a>; <a href="./references#CD012594-bbs2-0009" title="JohanssonML , HaggS , WallerstedtSM . Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study. BMC Clinical Pharmacology2011;11:14. ">Johansson 2011</a>; see <a href="./full#CD012594-tbl-0002">summary of findings Table 2</a>). The two studies assessed the effectiveness of distributing a series of informative emails or letters to GPs and nurses in primary healthcare units describing the importance of reporting ADRs and instructions on how to do so. The effect of the intervention was measured in primary healthcare unit years of exposure. </p> <p>At the one‐year follow‐up time point following the implementation of the intervention, compared to usual practice, we do not know if sending informational letters or emails to GPs and nurses increases the number of total ADR reports because the certainty of the evidence is very low (rate ratio 1.28, 95% CI 0.42 to 3.91; very low certainty evidence; <a href="#CD012594-fig-0009">Figure 9</a>). Similarly, we do not know if sending informational letters or emails to GPs and nurses increases the number of serious ADR reports (rate ratio 1.79, 95% CI 0.69 to 4.65; very low certainty evidence; <a href="#CD012594-fig-0010">Figure 10</a>), new‐drug‐related ADR reports (rate ratio 2.58, 95% CI 1.12 to 5.92; very low certainty evidence; <a href="#CD012594-fig-0011">Figure 11</a>) or unexpected or previously unknown ADR reports (rate ratio 1.46, 95% CI 0.92 to 2.30; very low certainty evidence; <a href="./references#CD012594-fig-0035" title="">Analysis 1.1</a>). This is because the certainty of the evidence for these outcomes is also very low. </p> <div class="figure" id="CD012594-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Comparison 2. Informational letter or email vs usual practice. Outcome: total number of adverse drug reaction reports submittedd" data-id="CD012594-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2. Informational letter or email vs usual practice. Outcome: total number of adverse drug reaction reports submittedd </p> </div> </div> </div> <div class="figure" id="CD012594-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Comparison 2. Informational letter or email versus usual practice. Outcome: number of serious adverse drug reaction reports submitted" data-id="CD012594-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2. Informational letter or email versus usual practice. Outcome: number of serious adverse drug reaction reports submitted </p> </div> </div> </div> <div class="figure" id="CD012594-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Comparison 2. Informational letter or email versus usual practice. Outcome: number of new drug‐related adverse drug reaction reports submitted" data-id="CD012594-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2. Informational letter or email versus usual practice. Outcome: number of new drug‐related adverse drug reaction reports submitted </p> </div> </div> </div> </section> <section id="CD012594-sec-0070"> <h4 class="title">Comparison 3. Multifaceted interventions (financial incentives, fines, non‐financial incentives, education, reminder) versus usual practice </h4> <p>Three ITS studies assessed the effectiveness of various interventions that included financial and non‐financial (i.e. letters of appreciation, employee of the month award, certificate and a day's leave) incentives for spontaneous reporting of ADRs, fines for not reporting or missing an ADR, education workshops, and periodic reminders to report ADRs (<a href="./references#CD012594-bbs2-0001" title="AliS , EgunsolaO , Al-DossariDS , Al-ZaagiIA . Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Therapeutic Advances in Drug Safety2018;9(10):585-90. [DOI: 10.1177/2042098618790209]">Ali 2018</a>; <a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>; <a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>). The data were presented only in the form of published figures, and thus we extracted and re‐analysed these data (see <a href="#CD012594-fig-0012">Figure 12</a>; <a href="#CD012594-fig-0013">Figure 13</a>; <a href="#CD012594-fig-0014">Figure 14</a>; <a href="#CD012594-fig-0015">Figure 15</a>; <a href="#CD012594-fig-0016">Figure 16</a>; <a href="#CD012594-fig-0017">Figure 17</a>; <a href="#CD012594-fig-0018">Figure 18</a>; <a href="#CD012594-fig-0019">Figure 19</a>). The periods over which the studies were conducted and the lengths of follow‐up differed across the three studies in this comparison as detailed below. </p> <div class="figure" id="CD012594-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Re‐analysis of data from published graph. Ali 2018: Comparison 3. Multifaceted interventions versus usual practice. Outcome: total number of adverse drug reaction reports submitted" data-id="CD012594-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-12.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Re‐analysis of data from published graph. <a href="./references#CD012594-bbs2-0001" title="AliS , EgunsolaO , Al-DossariDS , Al-ZaagiIA . Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Therapeutic Advances in Drug Safety2018;9(10):585-90. [DOI: 10.1177/2042098618790209]">Ali 2018</a>: Comparison 3. Multifaceted interventions versus usual practice. Outcome: total number of adverse drug reaction reports submitted </p> </div> </div> </div> <div class="figure" id="CD012594-fig-0013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 13</div> </div> <hr class="top"/><img alt="Re‐analysis of data from published graph. Chang 2017 Comparison 3. Multifaceted intervention versus usual practice. Outcome: total number of adverse drug reaction reports submitted" data-id="CD012594-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-13.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Re‐analysis of data from published graph. <a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a> Comparison 3. Multifaceted intervention versus usual practice. Outcome: total number of adverse drug reaction reports submitted </p> </div> </div> </div> <div class="figure" id="CD012594-fig-0014"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 14</div> </div> <hr class="top"/><img alt="Re‐analysis of data from published graph. Chang 2017 Comparison 3. Multifaceted intervention versus usual practice. Outcome: number of serious adverse drug reaction reports submitted" data-id="CD012594-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-14.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Re‐analysis of data from published graph. <a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a> Comparison 3. Multifaceted intervention versus usual practice. Outcome: number of serious adverse drug reaction reports submitted </p> </div> </div> </div> <div class="figure" id="CD012594-fig-0015"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 15</div> </div> <hr class="top"/><img alt="Re‐analysis of data from published graph. Chang 2017 Comparison 3. Multifaceted intervention versus usual practice. Outcome: number of new drug‐related adverse drug reaction reports submitted" data-id="CD012594-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-15.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Re‐analysis of data from published graph. <a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a> Comparison 3. Multifaceted intervention versus usual practice. Outcome: number of new drug‐related adverse drug reaction reports submitted </p> </div> </div> </div> <div class="figure" id="CD012594-fig-0016"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 16</div> </div> <hr class="top"/><img alt="Pedrós 2009: re‐analysis of total number of adverse drug reaction reports submitted" data-id="CD012594-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-16.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>: re‐analysis of total number of adverse drug reaction reports submitted </p> </div> </div> </div> <div class="figure" id="CD012594-fig-0017"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 17</div> </div> <hr class="top"/><img alt="Pedrós 2009: re‐analysis of number of serious adverse drug reaction reports submitted" data-id="CD012594-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-17.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>: re‐analysis of number of serious adverse drug reaction reports submitted </p> </div> </div> </div> <div class="figure" id="CD012594-fig-0018"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 18</div> </div> <hr class="top"/><img alt="Pedrós 2009: re‐analysis of number of new‐drug‐related adverse drug reaction reports submitted" data-id="CD012594-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-18.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>: re‐analysis of number of new‐drug‐related adverse drug reaction reports submitted </p> </div> </div> </div> <div class="figure" id="CD012594-fig-0019"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 19</div> </div> <hr class="top"/><img alt="Pedrós 2009: re‐analysis of number of previously unknown adverse drug reaction reports submitted" data-id="CD012594-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-19.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>: re‐analysis of number of previously unknown adverse drug reaction reports submitted </p> </div> </div> </div> <p> <ul id="CD012594-list-0020"> <li> <p><a href="./references#CD012594-bbs2-0001" title="AliS , EgunsolaO , Al-DossariDS , Al-ZaagiIA . Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Therapeutic Advances in Drug Safety2018;9(10):585-90. [DOI: 10.1177/2042098618790209]">Ali 2018</a>: December 2015 (first time point); January 2016 (intervention implemented); November 2016 (last time point); a total of 24 observations </p> </li> <li> <p><a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>: 2006 to 2009 (pre‐intervention); 2009 to 2011 (financial incentive); 2012 to 2014 (financial incentive plus government regulations for antimicrobial agents); December 2014 (last time point); total 108 observations </p> </li> <li> <p><a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>: January 1998 (first point); December 2002 (intervention implemented); December 2005 (last time point); a total of 96 observations </p> </li> </ul> </p> <p><a href="./full#CD012594-tbl-0003">summary of findings Table 3</a> presents the meta‐analysed data from <a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>a and <a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>. <a href="./references#CD012594-bbs2-0001" title="AliS , EgunsolaO , Al-DossariDS , Al-ZaagiIA . Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Therapeutic Advances in Drug Safety2018;9(10):585-90. [DOI: 10.1177/2042098618790209]">Ali 2018</a> data is presented separately (see <a href="#CD012594-tbl-0010">Table 3</a>), as the follow‐up period after the implementation of the intervention was too short to be included in the meta‐analysis. The data for this comparison is generated through ITS studies, in which it is often impossible to know how many people are exposed to the intervention. Therefore, the effectiveness of the intervention is assessed over the mean duration of the contributing studies (i.e. the length of time participants were exposed to the intervention) instead of the number of participants. </p> <div class="table" id="CD012594-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Re‐analysis of data in three included studies (Ali 2018, Chang 2017, Pedros 2009)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative treatment effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>ITS parameter</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% CI</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012594-bbs2-0001" title="AliS , EgunsolaO , Al-DossariDS , Al-ZaagiIA . Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Therapeutic Advances in Drug Safety2018;9(10):585-90. [DOI: 10.1177/2042098618790209]">Ali 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Total number of ADR reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relative change in level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.533</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.658 to 3.408</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in slope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.073 to 0.543</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative expected adverse drug reaction reports<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.43 to 10.54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a> </p> <p>Financial incentives</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total number of ADR reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.084</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.490 to 2.678</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in slope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.005 to 0.126</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a> </p> <p>Government regulations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total number of ADR reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.129 to 1.261</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in slope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.069 to 0.014</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total number of ADR reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.142 to 0.065</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in slope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.059</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.026 to 0.092</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>See <a href="#CD012594-fig-0022">Figure 22</a> for data source </p> <p>ADR: adverse drug reactions; CI: confidence interval; ITS: interrupted time series</p> </div> </div> <p>We do not know if multifaceted interventions (including incentives, fines, education meetings, and reminder cards) increase the total number of ADE reports by physicians and pharmacists at the one‐ and two‐year time points following intervention implementation. This is because the certainty of the evidence is very low (relative number of ADR reports after one year: 4.29, 95% CI 0.32 to 56.76; <a href="#CD012594-fig-0020">Figure 20</a>; after two years: 8.11, 95% CI 0.61 to 107.93; <a href="#CD012594-fig-0021">Figure 21</a>; very low certainty evidence; see <a href="./full#CD012594-tbl-0003">summary of findings Table 3</a>. Although <a href="./references#CD012594-bbs2-0001" title="AliS , EgunsolaO , Al-DossariDS , Al-ZaagiIA . Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Therapeutic Advances in Drug Safety2018;9(10):585-90. [DOI: 10.1177/2042098618790209]">Ali 2018</a> showed an increase in the total number of ADR reports (relative number of ADR reports after one year: 6.99, 95% CI: 3.43 to 10.54; <a href="#CD012594-fig-0022">Figure 22</a> and <a href="#CD012594-tbl-0010">Table 3</a>) following the implementation of incentives (both non‐financial and financial) targeting the hospital’s clinical pharmacists, the certainty of this evidence is very low, so we do not know if this intervention is truly effective or not. </p> <div class="figure" id="CD012594-fig-0020"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 20</div> </div> <hr class="top"/><img alt="Comparison 3 and 4. Outcome: total number of ADR reports submitted after 1 year" data-id="CD012594-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-20.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 and 4. Outcome: total number of ADR reports submitted after 1 year</p> </div> </div> </div> <div class="figure" id="CD012594-fig-0021"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 21</div> </div> <hr class="top"/><img alt="Comparison 3 and Comparison 4. Outcome: total number of ADR reports after 2 years" data-id="CD012594-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-21.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 and Comparison 4. Outcome: total number of ADR reports after 2 years</p> </div> </div> </div> <div class="figure" id="CD012594-fig-0022"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 22</div> </div> <hr class="top"/><img alt="Multifaceted interventions: total number of adverse drug reaction reports submitted. This was the first draft of the analyses. We subsequently took Ali 2018 out of the meta‐analysis as the follow‐up time was too short compared to Chang 2017 and Pedrós 2009." data-id="CD012594-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-22.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Multifaceted interventions: total number of adverse drug reaction reports submitted. This was the first draft of the analyses. We subsequently took Ali 2018 out of the meta‐analysis as the follow‐up time was too short compared to Chang 2017 and Pedrós 2009. </p> </div> </div> </div> <p>Similarly, we do not know if multifaceted interventions directed at physicians and pharmacists increase the total number of serious ADR reports (relative number of ADR reports after one year: 2.10, 95% CI 0.29 to 15.20; <a href="#CD012594-fig-0023">Figure 23</a>; after two years: 2.57, 95% CI 0.22 to 29.93; <a href="#CD012594-fig-0024">Figure 24</a>; very low certainty evidence), the total number of new drug‐related ADR reports (after one year: 1.65, 95% CI 0.20 to 13.77; <a href="#CD012594-fig-0025">Figure 25</a>; after two years: 1.86, 95% CI 0.16 to 21.59; <a href="#CD012594-fig-0026">Figure 26</a>; very low certainty evidence), or the total number of unexpected or previously unknown ADR reports (after one year 0.73, 95% CI 0.02 to 22.75; <a href="#CD012594-fig-0027">Figure 27</a>; after two years: 0.67, 95% CI 0.01 to 61.55; <a href="#CD012594-fig-0028">Figure 28</a>; very low certainty evidence). This is because the certainty of the evidence is very low. The 95% CIs on the relative treatment effect, and the corresponding illustrative comparative numbers of ADEs, likely reflect (a) the limitations of re‐analysis of uncontrolled ITS studies that often reported relatively few data points; (b) highly heterogeneous study results and the effect of the random‐effects assumption; and (c) extrapolation using a relatively simple model. </p> <div class="figure" id="CD012594-fig-0023"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 23</div> </div> <hr class="top"/><img alt="Comparison 3. Multifaceted interventions. Outcome: serious adverse drug reaction reports submitted after 1 year" data-id="CD012594-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-23.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3. Multifaceted interventions. Outcome: serious adverse drug reaction reports submitted after 1 year </p> </div> </div> </div> <div class="figure" id="CD012594-fig-0024"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 24</div> </div> <hr class="top"/><img alt="Comparison 3. Multifaceted interventions. Outcome: serious adverse drug reaction reports submitted after 2 years" data-id="CD012594-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-24.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3. Multifaceted interventions. Outcome: serious adverse drug reaction reports submitted after 2 years </p> </div> </div> </div> <div class="figure" id="CD012594-fig-0025"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 25</div> </div> <hr class="top"/><img alt="Comparison 3. Multifaceted interventions. Outcome: new‐drug‐related adverse drug reaction reports submitted after 1 year" data-id="CD012594-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-25.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3. Multifaceted interventions. Outcome: new‐drug‐related adverse drug reaction reports submitted after 1 year </p> </div> </div> </div> <div class="figure" id="CD012594-fig-0026"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 26</div> </div> <hr class="top"/><img alt="Comparison 3. Multifaceted interventions. Outcome: new‐drug‐related adverse drug reaction reports submitted after 2 years" data-id="CD012594-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-26.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3. Multifaceted interventions. Outcome: new‐drug‐related adverse drug reaction reports submitted after 2 years </p> </div> </div> </div> <div class="figure" id="CD012594-fig-0027"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 27</div> </div> <hr class="top"/><img alt="Comparison 3. Multifaceted interventions. Outcome: unexpected (previously unknown) adverse drug reaction reports submitted after 1 year" data-id="CD012594-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-27.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3. Multifaceted interventions. Outcome: unexpected (previously unknown) adverse drug reaction reports submitted after 1 year </p> </div> </div> </div> <div class="figure" id="CD012594-fig-0028"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 28</div> </div> <hr class="top"/><img alt="Comparison 3. Multifaceted interventions. Outcome: unexpected (previously unknown) adverse drug reaction reports submitted after 2 years" data-id="CD012594-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-28.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3. Multifaceted interventions. Outcome: unexpected (previously unknown) adverse drug reaction reports submitted after 2 years </p> </div> </div> </div> </section> <section id="CD012594-sec-0071"> <h4 class="title">Comparison 4: Government regulations plus financial incentives versus usual practice</h4> <p><a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a> assessed the effect of implementing financial incentives for ADR reporting together with government regulations on the clinical use of antimicrobial agents, which included detailed reporting on the total number of ADR reports by physicians (see <a href="#CD012594-fig-0020">Figure 20</a>; <a href="#CD012594-fig-0021">Figure 21</a>; <a href="./full#CD012594-tbl-0004">summary of findings Table 4</a>). As the data were generated by an ITS study, the effectiveness of the intervention is assessed over the mean duration of the contributing study (i.e. length of time exposed to the intervention) instead of the number of participants. </p> <p>We do not know if government regulations and financial incentives increase the total number of ADR reports by physicians one or two years after the implementation of these interventions as the certainty of the evidence is very low (after one year: 1.43, 95% CI 0.54 to 3.79; <a href="#CD012594-fig-0020">Figure 20</a>; after two years: 1.02, 95% CI 0.24 to 4.32; <a href="#CD012594-fig-0021">Figure 21</a>; very low certainty evidence). <a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a> did not report on the number of serious ADR reports, new drug‐related ADR reports or unexpected or previously unknown ADR reports. </p> </section> <section id="CD012594-sec-0072"> <h4 class="title">Comparison 5: Improving access to ADE report forms versus usual practice</h4> <p>One randomised cross‐over study (<a href="./references#CD012594-bbs2-0005" title="HanesseB , LegrasB , RoyerRJ , GuilleminF , BrianconS . Adverse drug reactions: comparison of two report methods. Pharmacoepidemiology and Drug Safety1994;3(4):223-9. ">Hanesse 1994</a>) and two ITS studies (<a href="./references#CD012594-bbs2-0002" title="CastelJM , FiguerasA , PedrosC , LaporteJR , CapellaD . Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads. Drug Safety2003;25(14):1049-55. ">Castel 2003</a>; <a href="./references#CD012594-bbs2-0014" title="Ribeiro-VazI , Santos Cda, Costa-PereiraA , Cruz-CorreiaR . Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal. Drug Safety2012;33(5):387-94. ">Ribeiro‐Vaz 2012</a>) provided data for this comparison. We extracted the data from the ITS studies from published figures and re‐analysed them (see <a href="#CD012594-fig-0029">Figure 29</a> and <a href="#CD012594-fig-0030">Figure 30</a>). </p> <div class="figure" id="CD012594-fig-0029"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 29</div> </div> <hr class="top"/><img alt="Re‐analysis of data from published graph. Castel 2003 Comparison 4. Improving access to adverse drug reaction report form versus usual practice. Outcome: total number of adverse drug reaction reports submitted" data-id="CD012594-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-29.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Re‐analysis of data from published graph. <a href="./references#CD012594-bbs2-0002" title="CastelJM , FiguerasA , PedrosC , LaporteJR , CapellaD . Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads. Drug Safety2003;25(14):1049-55. ">Castel 2003</a> Comparison 4. Improving access to adverse drug reaction report form versus usual practice. Outcome: total number of adverse drug reaction reports submitted </p> </div> </div> </div> <div class="figure" id="CD012594-fig-0030"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 30</div> </div> <hr class="top"/><img alt="Ribeiro‐Vaz 2012: re‐analysis of total number of adverse drug reaction reports submitted" data-id="CD012594-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-30.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><a href="./references#CD012594-bbs2-0014" title="Ribeiro-VazI , Santos Cda, Costa-PereiraA , Cruz-CorreiaR . Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal. Drug Safety2012;33(5):387-94. ">Ribeiro‐Vaz 2012</a>: re‐analysis of total number of adverse drug reaction reports submitted </p> </div> </div> </div> <p>Data from <a href="./references#CD012594-bbs2-0005" title="HanesseB , LegrasB , RoyerRJ , GuilleminF , BrianconS . Adverse drug reactions: comparison of two report methods. Pharmacoepidemiology and Drug Safety1994;3(4):223-9. ">Hanesse 1994</a> suggests that the use of a standardised discharge form (based on the ‘Diagnosis Related Groups’ (DRG) system and used by physicians for recording patient diagnoses, and medical and surgical acts received during hospital stay) with additional ADR items (addressing time of occurrence and evolution) may slightly improve the number of ADR reports (risk ratio 2.06, 95% CI 1.11 to 3.83; low‐certainty evidence). See <a href="./full#CD012594-tbl-0005">summary of findings Table 5</a> and <a href="#CD012594-tbl-0011">Table 4</a> for more details). </p> <div class="table" id="CD012594-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Comparison 5. Improving access to ADR report forms (Hanesse 1994)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk ratio</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% CI</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0005" title="HanesseB , LegrasB , RoyerRJ , GuilleminF , BrianconS . Adverse drug reactions: comparison of two report methods. Pharmacoepidemiology and Drug Safety1994;3(4):223-9. ">Hanesse 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improving access vs usual practice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of ADR reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.11 to 3.83</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADR: adverse drug reactions; CI: confidence interval; vs: versus</p> </div> </div> <p>We do not know if making it easier to report ADEs by including ADR yellow card report forms in quarterly bulletins and prescription pads or by providing a hyperlink to the reporting form in hospitals' electronic patient records leads to more ADRs being reported because the certainty of this evidence, based on combined data from <a href="./references#CD012594-bbs2-0002" title="CastelJM , FiguerasA , PedrosC , LaporteJR , CapellaD . Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads. Drug Safety2003;25(14):1049-55. ">Castel 2003</a> and <a href="./references#CD012594-bbs2-0014" title="Ribeiro-VazI , Santos Cda, Costa-PereiraA , Cruz-CorreiaR . Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal. Drug Safety2012;33(5):387-94. ">Ribeiro‐Vaz 2012</a>, is very low (after one year: 1.95, 95% CI 1.33 to 2.85; <a href="#CD012594-fig-0031">Figure 31</a>; after two years: 1.80, 95% CI 1.08 to 3.01; <a href="#CD012594-fig-0032">Figure 32</a>; very low certainty evidence). See <a href="./full#CD012594-tbl-0005">summary of findings Table 5</a> and <a href="#CD012594-tbl-0012">Table 5</a> for more details. </p> <div class="figure" id="CD012594-fig-0031"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 31</div> </div> <hr class="top"/><img alt="Comparison 5. Improving access to adverse drug reaction report form versus usual practice. Outcome: total number of adverse drug reaction reports submitted after 1 year" data-id="CD012594-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-31.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 5. Improving access to adverse drug reaction report form versus usual practice. Outcome: total number of adverse drug reaction reports submitted after 1 year </p> </div> </div> </div> <div class="figure" id="CD012594-fig-0032"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 32</div> </div> <hr class="top"/><img alt="Comparision 5. Improving access to adverse drug reaction report form versus usual practice. Outcome: total number of adverse drug reaction reports submitted after 2 years" data-id="CD012594-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-32.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparision 5. Improving access to adverse drug reaction report form versus usual practice. Outcome: total number of adverse drug reaction reports submitted after 2 years </p> </div> </div> </div> <div class="table" id="CD012594-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Comparison 5. Improving access to ADR report forms (Castel 2003 and Ribeiro‐Vaz 2012)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Measure</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>ITS parameter</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% CI</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012594-bbs2-0002" title="CastelJM , FiguerasA , PedrosC , LaporteJR , CapellaD . Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads. Drug Safety2003;25(14):1049-55. ">Castel 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Bulletins and ADR report forms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Total number of ADR reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.734</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.422 to 1.047</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in slope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.022 to 0.008</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative expected ADRs (1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.653</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.263 to 1.043</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relative expected ADRs (2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.050 to 1.093</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012594-bbs2-0014" title="Ribeiro-VazI , Santos Cda, Costa-PereiraA , Cruz-CorreiaR . Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal. Drug Safety2012;33(5):387-94. ">Ribeiro‐Vaz 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Hyperlink to online ADR form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Total number of ADR reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.813</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.302 to 1.324</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in slope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.034</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.281 to 0.348</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative expected ADRs (1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.714 to 2.608</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative expected ADRs (2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.081</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.822 to 3.983</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADR: adverse drug reaction; CI: confidence interval; ITS: interrupted time series</p> </div> </div> </section> <section id="CD012594-sec-0073"> <h4 class="title">Comparison 6. Improving medication error reporting method versus usual practice</h4> <p>One ITS study assessed the effect on the number of ME reports of re‐engineering the web‐based electronic error reporting system (i.e. incorporating a series of standardised screens, drop‐down menu choices, and input fields designed to collect specific information and improve communication with all departments involved) (<a href="./references#CD012594-bbs2-0011" title="McKaigD , CollinsC , ElsaidKA . Impact of a reengineered electronic error-reporting system on medication event reporting and care process improvements at an urban medical center. Joint Commission Journal on Quality &amp; Patient Safety2014;40(9):398-407. ">McKaig 2014</a>). We extracted the data from a published figure and re‐analysed them (see <a href="#CD012594-tbl-0013">Table 6</a> for a detailed re‐analysis of the data). As the data were from an ITS study, the effectiveness of the intervention is assessed over the mean duration of the contributing study (i.e. length of time exposed to the intervention) instead of the number of participants. </p> <div class="table" id="CD012594-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Comparison 6. Improving reporting practice vs usual practice (McKaig 2014)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative treatment effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>ITS parameter</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% CI</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012594-bbs2-0011" title="McKaigD , CollinsC , ElsaidKA . Impact of a reengineered electronic error-reporting system on medication event reporting and care process improvements at an urban medical center. Joint Commission Journal on Quality &amp; Patient Safety2014;40(9):398-407. ">McKaig 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Total number of ME reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.229 to 0.624</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in slope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.010 to 0.037</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative expected ME reports (1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.142 to 1.031</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative expected ME reports (2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.026 to 1.466</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; ITS: interrupted time series; ME: medication error</p> </div> </div> <p>We do not know if the number of ME reports are greater one year or two years after re‐engineering the web‐based electronic error reporting system as the certainty of the evidence is very low for both time points (after one year: 1.80, 95% CI 1.15 to 2.80; <a href="#CD012594-fig-0033">Figure 33</a>; after two years: 2.11, 95% CI 1.03 to 4.33; <a href="#CD012594-fig-0034">Figure 34</a>). See <a href="./full#CD012594-tbl-0006">summary of findings Table 6</a>. </p> <div class="figure" id="CD012594-fig-0033"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 33</div> </div> <hr class="top"/><img alt="Comparison 6. Improving usability of reporting form versus usual practice. Outcome: total number of medication error reports submitted after 1 year" data-id="CD012594-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-33.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6. Improving usability of reporting form versus usual practice. Outcome: total number of medication error reports submitted after 1 year </p> </div> </div> </div> <div class="figure" id="CD012594-fig-0034"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 34</div> </div> <hr class="top"/><img alt="Comparison 6. Improving usability of reporting form versus usual practice. Outcome: total number of medication error reports submitted after 2 years" data-id="CD012594-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-34.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6. Improving usability of reporting form versus usual practice. Outcome: total number of medication error reports submitted after 2 years </p> </div> </div> </div> </section> <section id="CD012594-sec-0074"> <h4 class="title">Comparison 7. Case finding versus spontaneous reporting</h4> <p>A non‐randomised, prospective cross‐over study evaluated the effectiveness of employing a clinical pharmacist to encourage physicians and nurses to identify and report ADEs in hospitalised patients (<a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a>). As <a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a> is a cross‐over study without a washout period, we used only the data from the first period of the study to minimise any possible "learning effect" on the findings. Using data from <a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a> (from Table 3 in the full‐text study report), we imputed the incidence rates and 95% CIs; then we computed the incidence rate ratios (IRRs) to compare the ADE reporting rate with and without the presence of a clinical pharmacist (see <a href="#CD012594-tbl-0014">Table 7</a>). </p> <div class="table" id="CD012594-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Comparison 7. Case finding versus spontaneous reporting (usual practice) (Schlienger 1999)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Incidence rate (95% CI) of ADE reports: period 1 (12 months)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Incidence rate ratio</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With clinical pharmacist</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Without clinical pharmacist</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5 (95% CI 12.87 to 18.51)</p> <p>ADEs per 1000 patient‐days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 (95% CI 0.75 to 2.39)</p> <p>ADEs per 1000 patient‐days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.07 (95% CI 6.24 to 21.38) more ADEs per 1000 patient‐days with clinical pharmacist than without </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADE: adverse drug event; CI: confidence interval</p> <p>As <a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a> is a cross‐over study without a washout period, we only used the data from the first period of the study, prior to the treatment allocation cross‐over. Using data from Table 3 in the full‐text study report (first study period), we imputed the incidence rates and 95% CI; then we computed the incidence rate ratios to compare the rate of ADE reporting rate with and without the presence of a clinical pharmacist actively checking for and submitting reports on any ADEs. </p> </div> </div> <p>We do not know if the presence of a clinical pharmacist actively identifying and encouraging the identification and reporting of ADEs in a hospital setting increases the number of ADE reports as the certainty of the evidence is very low (IRR 11.07, 95% CI 6.24 to 21.38). See <a href="./full#CD012594-tbl-0007">summary of findings Table 7</a>. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012594-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012594-sec-0075"></div> <p>A comprehensive search for published and unpublished evidence identified 15 studies of various designs (enroling approximately 62,389 participants) that addressed the review question. </p> <section id="CD012594-sec-0076"> <h3 class="title" id="CD012594-sec-0076">Educating and informing</h3> <section id="CD012594-sec-0077"> <h4 class="title">Comparison 2. Informational letter or email versus usual practice</h4> <p>Fairly robust evidence from five cluster‐randomised trials suggests that, compared to usual practice, education sessions along with reminder cards, and provision of ADR report forms may increase the number of adverse drug reactions reported (see <a href="./full#CD012594-tbl-0001">summary of findings Table 1</a>). The inconsistency in the effect of educational interventions may be explained by the mode of delivery. Based on the limited data available, outreach group education sessions delivered in‐person, appeared to be more effective in increasing the number of ADR reports submitted compared with delivering similar information in a 3‐ to 8‐minute telephone interview. The different target audience (physicians versus pharmacists) in the studies may also explain the inconsistency in the effect of the education intervention on the number of ADR reports submitted. Participation rates varied between studies and modes of delivering the education intervention. For example, participation rates in the telephone interviews ranged from 7.9% to 36%, whereas participation rates in the education workshops ranged from 27% to 81%. Almost all the studies reported that the effect of the educational interventions lasted no longer than six months, suggesting that education sessions might have to be conducted on a continuous 6‐monthly basis to maintain any benefits. The benefits of the intervention would have to be balanced against the time and human resource costs required to implement the education sessions, which may limit the scalability of the intervention. </p> <p>In contrast, we do not know if sending informational letters or emails to GPs and nurses increases the quantity of ADR reports as the certainty of this evidence is very low (see <a href="./full#CD012594-tbl-0002">summary of findings Table 2</a>). A major limitation of this intervention is not knowing if the informational email or letter reached its target audience. It would be beneficial to know the true effect of this intervention as it is cheap and easy to implement with broad‐reaching potential. </p> </section> </section> <section id="CD012594-sec-0078"> <h3 class="title" id="CD012594-sec-0078">Multifaceted interventions, including educating, informing, incentivising (financial and non‐financial), and reprimanding </h3> <section id="CD012594-sec-0079"> <h4 class="title">Comparison 4. Government regulations plus financial incentives versus usual practice</h4> <p>Based on very low certainty evidence from three ITS studies, we do not know if multifaceted interventions, including incentives, fines, educational meetings, and reminder cards, increase the number of adverse drug reaction reports submitted by physicians and pharmacists one year and two years after the implementation of the intervention (see <a href="./full#CD012594-tbl-0003">summary of findings Table 3</a>). While in most cases, quite dramatic increases in adverse drug reaction reports were noted, wide confidence intervals around the summary estimates of effect, and the corresponding illustrative comparative numbers of adverse drug reactions, reflected the uncertainty in the evidence and the possibility of the results being compatible with both an increase or a decrease in the number of reports, or no difference between them. We do not know if implementing government regulations together with financial incentives increases the number of adverse drug reaction reports submitted by physicians one year or two years after implementing these interventions, as the certainty of the evidence is also very low (see <a href="./full#CD012594-tbl-0004">summary of findings Table 4</a>). Financially and non‐financially incentivising or punishing healthcare professionals based on the number of adverse drug reaction reports submitted may increase the risk of false adverse drug event reports, as healthcare professionals' better judgement might be clouded by greed or fear. Unfortunately, none of the studies included in this review reported the effect of any interventions on the number of false reports of adverse drug events submitted. </p> </section> </section> <section id="CD012594-sec-0080"> <h3 class="title" id="CD012594-sec-0080">Process improvement</h3> <section id="CD012594-sec-0081"> <h4 class="title">Comparison 6. Improving medication error reporting method versus usual practice</h4> <p>While it may seem evident that improving the reporting process should result in an increase in adverse drug event reports being submitted, the certainty of the available evidence is low or very low. Making it easier to report adverse drug reactions by implementing a standardised discharge form (based on the ‘Diagnosis Related Groups’ (DRG) system for recording patient diagnoses, medical and surgical acts received during hospital stay) with additional ADR items (i.e. time of occurrence and evolution) may slightly improve the number of adverse drug reaction reports (<a href="./references#CD012594-bbs2-0005" title="HanesseB , LegrasB , RoyerRJ , GuilleminF , BrianconS . Adverse drug reactions: comparison of two report methods. Pharmacoepidemiology and Drug Safety1994;3(4):223-9. ">Hanesse 1994</a>). However, we do not know if including ADR report forms in quarterly bulletins and prescription pads or providing a hyperlink to the reporting form in hospitals' electronic patient records to improve the ease of adverse drug reaction reporting leads to more adverse drug reaction reports being submitted because the certainty of this evidence is very low (<a href="./references#CD012594-bbs2-0002" title="CastelJM , FiguerasA , PedrosC , LaporteJR , CapellaD . Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads. Drug Safety2003;25(14):1049-55. ">Castel 2003</a>; <a href="./references#CD012594-bbs2-0014" title="Ribeiro-VazI , Santos Cda, Costa-PereiraA , Cruz-CorreiaR . Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal. Drug Safety2012;33(5):387-94. ">Ribeiro‐Vaz 2012</a>; see <a href="./full#CD012594-tbl-0005">summary of findings Table 5</a>). We also do not know if improving the reporting process by re‐engineering the web‐based electronic error reporting system (i.e. incorporating standardised screens, drop‐down menu choices, and input fields to collect specific information and improve communication with all departments involved) will increase the expected number of medication error reports one or two years after implementing the changes as the certainty of the evidence is very low (see <a href="./full#CD012594-tbl-0006">summary of findings Table 6</a>). </p> </section> </section> <section id="CD012594-sec-0082"> <h3 class="title" id="CD012594-sec-0082">Adverse drug event champion</h3> <section id="CD012594-sec-0083"> <h4 class="title">Comparison 7. Case finding versus spontaneous reporting</h4> <p>Finally, we do not know if the presence of a clinical pharmacist actively identifying and encouraging the identification and reporting of adverse drug events in a hospital setting increases the number of adverse drug event reports as the certainty of the evidence is very low (see <a href="./full#CD012594-tbl-0007">summary of findings Table 7</a>). </p> </section> </section> <section id="CD012594-sec-0084"> <h3 class="title" id="CD012594-sec-0084">Overall completeness and applicability of evidence</h3> <p>Although we identified 15 eligible studies investigating the effectiveness of various interventions on the reporting rate of adverse drug events, important gaps in the evidence base remain. </p> <p>All 15 studies included in this review were conducted in high‐income countries with relatively well‐established pharmacovigilance systems. This may limit the applicability of the evidence to countries without established functioning pharmacovigilance systems. For the most part, interventions to improve reporting of adverse drug events (including adverse drug reactions and medication errors) were targeted at hospital physicians. General practitioners, nurses and pharmacists were targeted to a lesser extent. As a result, we are not sure of the transferability of the effectiveness of the various interventions to all health professionals. </p> <p>Most studies assessed the effectiveness of interventions to increase the number of adverse drug reaction reports. Only one study provided data on ways to increase reporting of medication errors (<a href="./references#CD012594-bbs2-0011" title="McKaigD , CollinsC , ElsaidKA . Impact of a reengineered electronic error-reporting system on medication event reporting and care process improvements at an urban medical center. Joint Commission Journal on Quality &amp; Patient Safety2014;40(9):398-407. ">McKaig 2014</a>), and one study provided data on ways to increase adverse drug event reporting (<a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a>). Importantly, none of the studies included in the review investigated the impact of the tested interventions on the number of false adverse event reports submitted. This outcome is of particular concern with interventions offering financial or non‐financial incentives or punishment based on the number of adverse drug reaction reports submitted. </p> </section> <section id="CD012594-sec-0085"> <h3 class="title" id="CD012594-sec-0085">Quality of the evidence</h3> <p>Overall, the certainty of the evidence related to the effectiveness of interventions to improve the reporting of adverse drug events is low to very low. Of the 15 included studies, eight studies incorporated randomisation and a control group. Most of the remaining studies were interrupted time series studies without control populations. Our certainty in the evidence from randomised studies was reduced due to possible risk of bias, inconsistency of effects and imprecision around the effect estimates. We further downgraded the low certainty of the evidence of the observational studies because lack of a control group made it impossible to rule out confounding variables or events as the cause of any effects observed. The inconsistency of the effects between the studies may be explained, but we cannot be certain of our explanations. Lastly, the evidence provided by observational studies was imprecise, including both benefits and harms. </p> </section> <section id="CD012594-sec-0086"> <h3 class="title" id="CD012594-sec-0086">Potential biases in the review process</h3> <p>We used a comprehensive method to identify all eligible studies investigating interventions aimed at healthcare professionals with the intention of increasing the reporting rate of adverse drug events (including adverse drug reactions and medication errors). We used a sensitive search strategy, without date or language limits, to conduct a comprehensive search of a number of electronic databases for both published and unpublished studies. We supplemented our search of electronic databases by hand‐searching the reference lists of relevant systematic reviews and eligible studies for additional eligible studies. We also searched clinical trial registry sites for ongoing studies. </p> <p>Throughout the review process, every effort was made to reduce any potential risk of bias in this review. We consistently adhered to our published review protocol. We have detailed any deviations we made from the published protocol in the <a href="#CD012594-sec-0110">Differences between protocol and review</a> section of this review. At least two review authors independently screened identified records for eligibility and extracted data from eligible studies. At least two review authors independently assessed the certainty of the evidence using GRADE. Any disagreements regarding eligibility, extracted data, or certainty of the evidence were discussed or referred to a third review author for resolution. We could not assess publication bias in our meta‐analyses using funnel plots as we did not have enough studies to do so reliably. </p> </section> <section id="CD012594-sec-0087"> <h3 class="title" id="CD012594-sec-0087">Agreements and disagreements with other studies or reviews</h3> <p>A number of systematic reviews have examined this question in whole or in part. We briefly describe these reviews in <a href="#CD012594-tbl-0008">Table 1</a>. We have included all relevant studies from these reviews in this Cochrane review. The findings of this Cochrane review closely mirror those of the other systematic reviews, which agree that educational sessions, particularly outreach, in‐person group workshops (see <a href="./full#CD012594-tbl-0001">summary of findings Table 1</a>), may improve the number of adverse drug reaction reports by healthcare professionals. This finding is further supported by the findings of a Cochrane review looking at the effectiveness of educational outreach visits on healthcare professionals' practice (<a href="./references#CD012594-bbs2-0133" title="O'BrienMA , RogersS , JamtvedtG , OxmanAD , Odgaard‐JensenJ , KristoffersenDT , et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD000409. [DOI: 10.1002/14651858.CD000409.pub2]">O'Brien 2007</a>). Based on data from 69 studies, educational outreach improved the care delivered to patients through small to moderate changes in practice (<a href="./references#CD012594-bbs2-0133" title="O'BrienMA , RogersS , JamtvedtG , OxmanAD , Odgaard‐JensenJ , KristoffersenDT , et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD000409. [DOI: 10.1002/14651858.CD000409.pub2]">O'Brien 2007</a>). </p> <p>Another key finding of the systematic reviews was that multifaceted interventions are likely to be more effective than single interventions. Our Cochrane review was not designed to test this (i.e. single versus multifaceted interventions), so we cannot make such claims. Most of the interventions assessed in our Cochrane Review were multifaceted, including some form of educational input (even when it was not the focus of the intervention), reminders and ADR report forms. </p> <p>The other systematic reviews also drew attention to the limitations of the current body of evidence; while uncontrolled, observational studies are pragmatic, they do not provide robust data. The evidence is limited to high‐income countries with relatively good pharmacovigilance systems, and there is no long‐term follow‐up data on the degree of the longevity of any intervention effect. </p> <p>A major difference between our Cochrane Review and previous systematic reviews is that we looked for evidence of harm (i.e. an increase in the number of false adverse drug event reports) as a result of the interventions. Unfortunately, we did not find any data on this outcome, but it remains an important aspect for consideration going forward. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012594-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram" data-id="CD012594-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary for the controlled trials" data-id="CD012594-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary for the controlled trials</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary for interrupted time series (ITS) studies" data-id="CD012594-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-03.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary for interrupted time series (ITS) studies</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-03.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1. Education session plus reminder card and report form versus usual practice. Outcome: total number of adverse drug reaction reports submitted. Education delivered in group sessions, workshops or via telephone. Meta‐analysis of five cluster‐randomised controlled studies." data-id="CD012594-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Comparison 1. Education session plus reminder card and report form versus usual practice. Outcome: total number of adverse drug reaction reports submitted. Education delivered in group sessions, workshops or via telephone. Meta‐analysis of five cluster‐randomised controlled studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1. Education session plus reminder card and report form versus usual practice. Outcome: number of serious adverse drug reaction reports submitted" data-id="CD012594-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-05.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Comparison 1. Education session plus reminder card and report form versus usual practice. Outcome: number of serious adverse drug reaction reports submitted </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1. Education session plus reminder card and report form versus usual practice. Outcome: high‐causality adverse drug reaction reports submitted" data-id="CD012594-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-06.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Comparison 1. Education session plus reminder card and report form versus usual practice. Outcome: high‐causality adverse drug reaction reports submitted </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1. Education session plus reminder card and report form versus usual practice. Outcome: unexpected adverse drug reaction reports" data-id="CD012594-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-07.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Comparison 1. Education session plus reminder card and report form versus usual practice. Outcome: unexpected adverse drug reaction reports </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1. Education session plus reminder card and report form versus usual practice. Outcome: number of new drug‐related adverse drug reaction reports submitted" data-id="CD012594-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-08.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Comparison 1. Education session plus reminder card and report form versus usual practice. Outcome: number of new drug‐related adverse drug reaction reports submitted </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2. Informational letter or email vs usual practice. Outcome: total number of adverse drug reaction reports submittedd" data-id="CD012594-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-09.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Comparison 2. Informational letter or email vs usual practice. Outcome: total number of adverse drug reaction reports submittedd </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2. Informational letter or email versus usual practice. Outcome: number of serious adverse drug reaction reports submitted" data-id="CD012594-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-10.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Comparison 2. Informational letter or email versus usual practice. Outcome: number of serious adverse drug reaction reports submitted </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2. Informational letter or email versus usual practice. Outcome: number of new drug‐related adverse drug reaction reports submitted" data-id="CD012594-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-11.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Comparison 2. Informational letter or email versus usual practice. Outcome: number of new drug‐related adverse drug reaction reports submitted </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-12" target="_blank"><b></b></a></p> </div><img alt="Re‐analysis of data from published graph. Ali 2018: Comparison 3. Multifaceted interventions versus usual practice. Outcome: total number of adverse drug reaction reports submitted" data-id="CD012594-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-12.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Re‐analysis of data from published graph. <a href="./references#CD012594-bbs2-0001" title="AliS , EgunsolaO , Al-DossariDS , Al-ZaagiIA . Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Therapeutic Advances in Drug Safety2018;9(10):585-90. [DOI: 10.1177/2042098618790209]">Ali 2018</a>: Comparison 3. Multifaceted interventions versus usual practice. Outcome: total number of adverse drug reaction reports submitted </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-13" target="_blank"><b></b></a></p> </div><img alt="Re‐analysis of data from published graph. Chang 2017 Comparison 3. Multifaceted intervention versus usual practice. Outcome: total number of adverse drug reaction reports submitted" data-id="CD012594-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-13.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Re‐analysis of data from published graph. <a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a> Comparison 3. Multifaceted intervention versus usual practice. Outcome: total number of adverse drug reaction reports submitted </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-14" target="_blank"><b></b></a></p> </div><img alt="Re‐analysis of data from published graph. Chang 2017 Comparison 3. Multifaceted intervention versus usual practice. Outcome: number of serious adverse drug reaction reports submitted" data-id="CD012594-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-14.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p>Re‐analysis of data from published graph. <a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a> Comparison 3. Multifaceted intervention versus usual practice. Outcome: number of serious adverse drug reaction reports submitted </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-15" target="_blank"><b></b></a></p> </div><img alt="Re‐analysis of data from published graph. Chang 2017 Comparison 3. Multifaceted intervention versus usual practice. Outcome: number of new drug‐related adverse drug reaction reports submitted" data-id="CD012594-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-15.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 15</div> <div class="figure-caption"> <p>Re‐analysis of data from published graph. <a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a> Comparison 3. Multifaceted intervention versus usual practice. Outcome: number of new drug‐related adverse drug reaction reports submitted </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-16" target="_blank"><b></b></a></p> </div><img alt="Pedrós 2009: re‐analysis of total number of adverse drug reaction reports submitted" data-id="CD012594-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-16.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 16</div> <div class="figure-caption"> <p><a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>: re‐analysis of total number of adverse drug reaction reports submitted </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-17" target="_blank"><b></b></a></p> </div><img alt="Pedrós 2009: re‐analysis of number of serious adverse drug reaction reports submitted" data-id="CD012594-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-17.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 17</div> <div class="figure-caption"> <p><a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>: re‐analysis of number of serious adverse drug reaction reports submitted </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-18" target="_blank"><b></b></a></p> </div><img alt="Pedrós 2009: re‐analysis of number of new‐drug‐related adverse drug reaction reports submitted" data-id="CD012594-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-18.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 18</div> <div class="figure-caption"> <p><a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>: re‐analysis of number of new‐drug‐related adverse drug reaction reports submitted </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-19" target="_blank"><b></b></a></p> </div><img alt="Pedrós 2009: re‐analysis of number of previously unknown adverse drug reaction reports submitted" data-id="CD012594-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-19.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 19</div> <div class="figure-caption"> <p><a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>: re‐analysis of number of previously unknown adverse drug reaction reports submitted </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-20" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 and 4. Outcome: total number of ADR reports submitted after 1 year" data-id="CD012594-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-20.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 20</div> <div class="figure-caption"> <p>Comparison 3 and 4. Outcome: total number of ADR reports submitted after 1 year</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-21" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 and Comparison 4. Outcome: total number of ADR reports after 2 years" data-id="CD012594-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-21.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 21</div> <div class="figure-caption"> <p>Comparison 3 and Comparison 4. Outcome: total number of ADR reports after 2 years</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-22" target="_blank"><b></b></a></p> </div><img alt="Multifaceted interventions: total number of adverse drug reaction reports submitted. This was the first draft of the analyses. We subsequently took Ali 2018 out of the meta‐analysis as the follow‐up time was too short compared to Chang 2017 and Pedrós 2009." data-id="CD012594-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-22.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 22</div> <div class="figure-caption"> <p>Multifaceted interventions: total number of adverse drug reaction reports submitted. This was the first draft of the analyses. We subsequently took Ali 2018 out of the meta‐analysis as the follow‐up time was too short compared to Chang 2017 and Pedrós 2009. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-23" target="_blank"><b></b></a></p> </div><img alt="Comparison 3. Multifaceted interventions. Outcome: serious adverse drug reaction reports submitted after 1 year" data-id="CD012594-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-23.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 23</div> <div class="figure-caption"> <p>Comparison 3. Multifaceted interventions. Outcome: serious adverse drug reaction reports submitted after 1 year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-24" target="_blank"><b></b></a></p> </div><img alt="Comparison 3. Multifaceted interventions. Outcome: serious adverse drug reaction reports submitted after 2 years" data-id="CD012594-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-24.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 24</div> <div class="figure-caption"> <p>Comparison 3. Multifaceted interventions. Outcome: serious adverse drug reaction reports submitted after 2 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-25" target="_blank"><b></b></a></p> </div><img alt="Comparison 3. Multifaceted interventions. Outcome: new‐drug‐related adverse drug reaction reports submitted after 1 year" data-id="CD012594-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-25.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 25</div> <div class="figure-caption"> <p>Comparison 3. Multifaceted interventions. Outcome: new‐drug‐related adverse drug reaction reports submitted after 1 year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-26" target="_blank"><b></b></a></p> </div><img alt="Comparison 3. Multifaceted interventions. Outcome: new‐drug‐related adverse drug reaction reports submitted after 2 years" data-id="CD012594-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-26.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 26</div> <div class="figure-caption"> <p>Comparison 3. Multifaceted interventions. Outcome: new‐drug‐related adverse drug reaction reports submitted after 2 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-27" target="_blank"><b></b></a></p> </div><img alt="Comparison 3. Multifaceted interventions. Outcome: unexpected (previously unknown) adverse drug reaction reports submitted after 1 year" data-id="CD012594-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-27.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 27</div> <div class="figure-caption"> <p>Comparison 3. Multifaceted interventions. Outcome: unexpected (previously unknown) adverse drug reaction reports submitted after 1 year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-28" target="_blank"><b></b></a></p> </div><img alt="Comparison 3. Multifaceted interventions. Outcome: unexpected (previously unknown) adverse drug reaction reports submitted after 2 years" data-id="CD012594-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-28.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-28.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 28</div> <div class="figure-caption"> <p>Comparison 3. Multifaceted interventions. Outcome: unexpected (previously unknown) adverse drug reaction reports submitted after 2 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-29" target="_blank"><b></b></a></p> </div><img alt="Re‐analysis of data from published graph. Castel 2003 Comparison 4. Improving access to adverse drug reaction report form versus usual practice. Outcome: total number of adverse drug reaction reports submitted" data-id="CD012594-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-29.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-29.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 29</div> <div class="figure-caption"> <p>Re‐analysis of data from published graph. <a href="./references#CD012594-bbs2-0002" title="CastelJM , FiguerasA , PedrosC , LaporteJR , CapellaD . Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads. Drug Safety2003;25(14):1049-55. ">Castel 2003</a> Comparison 4. Improving access to adverse drug reaction report form versus usual practice. Outcome: total number of adverse drug reaction reports submitted </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-30" target="_blank"><b></b></a></p> </div><img alt="Ribeiro‐Vaz 2012: re‐analysis of total number of adverse drug reaction reports submitted" data-id="CD012594-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-30.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-30.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 30</div> <div class="figure-caption"> <p><a href="./references#CD012594-bbs2-0014" title="Ribeiro-VazI , Santos Cda, Costa-PereiraA , Cruz-CorreiaR . Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal. Drug Safety2012;33(5):387-94. ">Ribeiro‐Vaz 2012</a>: re‐analysis of total number of adverse drug reaction reports submitted </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-31" target="_blank"><b></b></a></p> </div><img alt="Comparison 5. Improving access to adverse drug reaction report form versus usual practice. Outcome: total number of adverse drug reaction reports submitted after 1 year" data-id="CD012594-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-31.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-31.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 31</div> <div class="figure-caption"> <p>Comparison 5. Improving access to adverse drug reaction report form versus usual practice. Outcome: total number of adverse drug reaction reports submitted after 1 year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-32" target="_blank"><b></b></a></p> </div><img alt="Comparision 5. Improving access to adverse drug reaction report form versus usual practice. Outcome: total number of adverse drug reaction reports submitted after 2 years" data-id="CD012594-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-32.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-32.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 32</div> <div class="figure-caption"> <p>Comparision 5. Improving access to adverse drug reaction report form versus usual practice. Outcome: total number of adverse drug reaction reports submitted after 2 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-33" target="_blank"><b></b></a></p> </div><img alt="Comparison 6. Improving usability of reporting form versus usual practice. Outcome: total number of medication error reports submitted after 1 year" data-id="CD012594-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-33.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-33.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 33</div> <div class="figure-caption"> <p>Comparison 6. Improving usability of reporting form versus usual practice. Outcome: total number of medication error reports submitted after 1 year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-FIG-34" target="_blank"><b></b></a></p> </div><img alt="Comparison 6. Improving usability of reporting form versus usual practice. Outcome: total number of medication error reports submitted after 2 years" data-id="CD012594-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-34.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-FIG-34.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 34</div> <div class="figure-caption"> <p>Comparison 6. Improving usability of reporting form versus usual practice. Outcome: total number of medication error reports submitted after 2 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-FIG-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012594-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/urn:x-wiley:14651858:media:CD012594:CD012594-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison 2: Informational letter or email versus usual practice, Outcome 1: Number of unexpected (previously unknown) adverse drug reaction reports" data-id="CD012594-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_t/tCD012594-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Comparison 2: Informational letter or email versus usual practice, Outcome 1: Number of unexpected (previously unknown) adverse drug reaction reports </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/references#CD012594-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/media/CDSR/CD012594/image_n/nCD012594-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012594-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Education session plus reminder card and ADR report form versus usual practice</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participants:</b> physicians and pharmacists </p> <p><b>Intervention:</b> education session (in‐person workshop or via telephone), reminder card and ADR report form </p> <p><b>Comparator:</b> usual practice (spontaneous reporting; briefing and standard training given by regional pharmacosurveillance unit) </p> <p><b>Setting:</b> hospitals and outpatient centres in Northern Portugal and Spain </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Risk ratio*</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks<sup>‡</sup> </b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> <p><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk with usual practice</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with education session plus reminder card and report form</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of ADE reports (including ADR reports and ME reports): number of ADR reports </p> <p>Follow‐up: 13 to 16 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.00 (1.53 to 5.90)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 ADR reports per 1000 practitioner years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240 ADR reports per 1000 practitioner years (122 to 472)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21,665 (5 cRCTs)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An education session, together with reminder card and ADR report form, may improve the reporting rate of ADRs. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of false ADE reports (including false ADR reports and false ME reports)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of serious ADE reports (including serious ADR reports and serious ME reports)</p> <p>Follow‐up: 13 to 16 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.30 (1.51 to 7.21)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 ADR reports per 1000 practitioner years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 ADR reports per 1000 practitioner years (15 to 72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21,665 (5 cRCTs)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An education session, together with reminder card and ADR report form, may improve the reporting rate of serious ADRs. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of high‐causality ADE reports (including high‐causality ADR reports and high‐causality ME reports) </p> <p>Follow‐up: 13 to 16 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.48 (1.11 to 5.57)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 ADR reports per 1000 practitioner years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 ADR reports per 1000 practitioner years (22 to 111)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21,665 (5 cRCTs)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An education session, together with reminder card and ADR report form, may improve the reporting rate of high‐causality ADRs. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of unexpected ADE reports (including unexpected ADR reports and unexpected ME reports) </p> <p>Follow‐up: 13 to 16 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4.72 (1.75 to 12.76)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 ADR reports per 1000 practitioner years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 ADR reports per 1000 practitioner years (35 to 255)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,085 (4 cRCTs)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An education session, together with reminder card and ADR report form, may improve the reporting rate of unexpected ADRs </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of new‐drug‐related ADE reports (including drug‐related ADR reports and drug‐related ME reports) </p> <p>Follow‐up: 13 to 16 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8.68 (3.40 to 22.13)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 ADR reports per 1000 practitioner years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 ADR reports per 1000 practitioner years (17 to 111)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7884 (2 cRCTs)<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An education session, together with reminder card and ADR report form, may improve the reporting rate of new‐drug‐related ADRs. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ADE: adverse drug event; ADR: adverse drug reaction; CI: confidence interval; cRCT: cluster‐randomised controlled trial; ME: medication error; vs: versus </p> <p>*Risk ratios &gt; 1 are associated with more ADRs with education session plus reminder card and ADR report form versus usual practice. </p> <p><sup>‡</sup>Illustrative comparative risks are presented as numbers of ADRs per 1000 practitioner years and are rounded to whole numbers. </p> <p><sup>1</sup><a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a> (physicians, education group session); <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a> (pharmacists, education group session); <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a> (physicians; same intervention clusters from <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a> randomised a second time to telephone interview or workshop); <a href="./references#CD012594-bbs2-0010" title="ISRCTN91140684. An educational intervention to improve adverse drug reactions reporting among Galician physicians. https://www.isrctn.com/ISRCTN91140684 (first received 7 May 2009). Lopez-GonzalezE , HerdeiroMT , Pineiro-LamasM , FigueirasA , Grephepi group. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Safety2015;38(2):189-96. ">Lopez‐Gonzalez 2015</a> (physicians, education group session); <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a> (pharmacists, telephone interview or workshop) </p> <p><sup>2</sup><a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a> (physicians); <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a> (pharmacists); <a href="./references#CD012594-bbs2-0010" title="ISRCTN91140684. An educational intervention to improve adverse drug reactions reporting among Galician physicians. https://www.isrctn.com/ISRCTN91140684 (first received 7 May 2009). Lopez-GonzalezE , HerdeiroMT , Pineiro-LamasM , FigueirasA , Grephepi group. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Safety2015;38(2):189-96. ">Lopez‐Gonzalez 2015</a> (physicians); <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a> (pharmacists) </p> <p><sup>3</sup><a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a> </p> <p><sup>4</sup>Downgraded once for serious risk of bias (performance bias and potential selection bias due to baseline differences in reporting rates between intervention and control group; see <a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a>); downgraded once for serious inconsistency: I<sup>2</sup> = 95%. The inconsistency might be explained by the mode of delivery of the education (i.e. telephone vs interactive group session vs workshop) or the different target audience (physicians vs pharmacist), but we are uncertain of this; no serious imprecision; no serious indirectness; no publication bias. </p> <p><sup>5</sup>Downgraded once for serious risk of bias (performance bias and potential selection bias due to baseline differences in reporting rates between intervention and control group; see <a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a>); downgraded once for serious inconsistency: I<sup>2</sup> = 96%. The inconsistency might be explained by the mode of delivery of the education (i.e. telephone vs interactive group session vs workshop) or the different target audience (physicians vs. pharmacist), or both, but we are uncertain of this; no serious imprecision; no serious indirectness; no publication bias. </p> <p><sup>6</sup>Downgraded once for serious risk of bias (performance bias and potential selection bias due to baseline differences in reporting rates between intervention and control group; see <a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a>); downgraded once for serious inconsistency: I<sup>2</sup> = 100%. The inconsistency might be explained by the mode of delivery of the educational outreach (i.e. telephone vs interactive group session vs workshop) or the different target audience (physicians vs pharmacist), but we are uncertain of this; no serious imprecision; no serious indirectness; no publication bias. </p> <p><sup>7</sup>Downgraded once for serious risk of bias (performance bias and potential selection bias due to baseline differences in reporting rates between intervention and control group; see <a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a>); downgraded once for serious inconsistency: I<sup>2</sup> = 64%. The inconsistency might be explained by the mode of delivery of the education (i.e. telephone vs interactive group session vs workshop) or the different target audience (physicians vs pharmacist), but we are uncertain of this; no serious imprecision; no serious indirectness; no publication bias. </p> <p><sup>8</sup>Downgraded once for serious risk of performance bias and potential selection bias due to baseline differences in reporting rates between intervention and control group (see <a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>); no serious inconsistency; downgraded once for serious imprecision (wide confidence intervals so uncertain of the true estimate of effect); no serious indirectness; no publication bias </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Education session plus reminder card and ADR report form versus usual practice</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012594-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Informational letter or email versus usual practice</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participants:</b> general practitioners and nurses </p> <p><b>Intervention:</b> informational letter or email </p> <p><b>Comparator:</b> usual practice (spontaneous reporting) </p> <p><b>Setting:</b> primary healthcare units in Sweden </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Rate ratio<sup>*</sup> </b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative rates</b><sup>‡</sup><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Exposure</b><sup>†</sup><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed rate with usual practice</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding rate with informational letter or email</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of ADE reports (including ADR reports and ME reports): number of ADR reports after one year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.28 (0.42 to 3.91)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 ADR reports per 100 practitioner years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 ADR reports per 100 practitioner years (34 to 313)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>268 primary healthcare unit years (2 RCTs)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if informational letters or emails to GPs and nurses increase the total number of ADR reports because the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of false ADE reports (including false ADR reports and false ME reports)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of serious ADE reports (including serious ADR reports and serious ME reports): number of serious ADR reports after one year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.79 (0.69 to 4.65)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 ADR reports per 100 practitioner years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 ADR reports per 100 practitioner years (7 to 47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>268 primary healthcare unit years (2 RCTs)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if informational letters or emails to GPs and nurses increase serious ADR reports because the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of high‐causality ADE reports (including high‐causality ADR reports and high‐causality ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of unexpected ADE reports (including unexpected ADR reports and unexpected ME reports): number of unexpected ADR reports after one year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.46 (0.92 to 2.30)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 ADR reports per 100 practitioner years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 ADR reports per 100 practitioner years (18 to 46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>268 primary healthcare unit years (2 RCTs)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if informational letters or emails to GPs and nurses increase the number of unexpected ADR reports as the certainty of the evidence is very low. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of new drug‐related ADE reports (including drug‐related ADR reports and drug‐related ME reports): number of new drug‐related ADR reports after one year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.58 (1.12 to 5.92)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 ADR reports per 100 practitioner years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 ADR reports per 100 practitioner years (6 to 30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>268 primary healthcare unit years (2 RCTs)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if informational letters or emails to GPs and nurses increase the total number of new drug‐related ADR reports because the evidence is very uncertain. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ADE: adverse drug event; ADR: adverse drug reaction; CI: confidence interval; RCT: randomised controlled trials; ME: medication error; vs: versus </p> <p><sup>*</sup>Rate ratios &gt; 1 are associated with more ADRs with informational letter or email versus usual practice. </p> <p><sup>†</sup>Unit of exposure is primary healthcare unit years. </p> <p><sup>‡</sup>Illustrative comparative rates are presented as numbers of ADR reports per 100 practitioner years and are rounded to whole numbers. </p> <p><sup>1</sup><a href="./references#CD012594-bbs2-0008" title="JohanssonML , BrunlofG , EdwardC , WallerstedtSM . Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports. European Journal of Clinical Pharmacology2009;65(5):511-4. ">Johansson 2009</a>; <a href="./references#CD012594-bbs2-0009" title="JohanssonML , HaggS , WallerstedtSM . Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study. BMC Clinical Pharmacology2011;11:14. ">Johansson 2011</a> </p> <p><sup>2</sup>Downgraded once for serious risk of bias (performance bias and potential contamination bias); no serious inconsistency; downgraded twice for very serious imprecision: wide confidence intervals that cross the line of no effect (in the case of total number of ADR reports, number of serious ADR reports and number of unexpected ADR reports), small event rate (total of 242 ADR reports from 268 units in 2007 and 2008, total of 35 serious ADR reports from 268 units in 2007 and 2008, total of 85 unexpected ADR reports from 268 units in 2007 and 2008); no serious indirectness; no publication bias </p> <p><sup>3</sup>Downgraded once for serious risk of bias (performance bias and potential contamination bias); no serious inconsistency; downgraded twice for very serious imprecision: wide confidence intervals, small event rate (total of 16 new drug‐related ADRs reported from 268 units in 2007 and 2008); no serious indirectness; no publication bias </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Informational letter or email versus usual practice</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012594-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Multifaceted interventions versus usual practice</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participants:</b> physicians and pharmacists </p> <p><b>Intervention:</b> multifaceted intervention (including financial incentives, fines, non‐financial incentives, education, reminders) </p> <p><b>Comparator:</b> usual practice (spontaneous reporting) </p> <p><b>Setting:</b> hospital </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative numbers of ADES<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative numbers of ADEs</b><sup>‡</sup><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Mean study duration (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed number with usual practice</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding number with multifaceted intervention</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of ADE reports (including ADR reports and ME reports): number of ADR reports after one year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4.29 (0.32 to 56.76)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 ADR reports per 1000 practitioners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>343 ADR reports per 1000 practitioners (26 to 4541)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.5 years (2)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if multifaceted interventions increase the total number of ADR reports in physicians and pharmacists one year after implementation because the evidence is very uncertain.<sup>3</sup> </p> <p>Data after two years in footnotes<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of false ADE reports (including false ADR reports and false ME reports)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of serious ADE reports (including serious ADR reports and serious ME reports): number of serious ADR reports after one year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.10 (0.29 to 15.20)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 ADR reports per 1000 practitioners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 ADR reports per 1000 practitioners (3 to 150)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.5 years (2)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if multifaceted interventions increase the total number of serious ADR reports in physicians and pharmacists one year after implementation because the evidence is very uncertain. </p> <p>Data after two years in footnotes<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of high‐causality ADE reports (including high‐causality ADR reports and high‐causality ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of unexpected ADE reports (including unexpected ADR reports and unexpected ME reports): unexpected or previously unknown ADR reports after one year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.02 to 22.75)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 ADR reports per 1000 practitioners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 ADR reports per 1000 practitioners (0 to 455)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0 years (1)<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if multifaceted interventions increase the total number of unexpected (previously unknown) ADR reports in physicians and pharmacists one year after implementation because the evidence is very uncertain </p> <p>Data after two years in footnotes<sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of new drug‐related ADE reports (including drug‐related ADR reports and drug‐related ME reports): number of new drug‐ related ADR reports after one year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.65 (0.20 to 13.77)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 ADR reports per 1000 practitioners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 ADR reports per 1000 practitioners (1 to 69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.5 years (2)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if multifaceted interventions increase the total number of new‐drug‐related ADR reports in physicians and pharmacists one year after implementation, because the evidence is very uncertain. </p> <p>Data after two years in footnotes<sup>9</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ADE: adverse drug event; ADR: adverse drug reaction; CI: confidence interval; ITS: interrupted time series; ME: medication error; vs: versus </p> <p><sup>*</sup>Relative numbers of ADRs &gt; 1 are associated with more ADRs with multifaceted intervention versus usual practice. </p> <p><sup>‡</sup>Illustrative comparative numbers of ADRs are presented as numbers of ADRs after 1 and 2 years in a setting with 1000 practitioners. </p> <p><sup>1</sup>Meta‐analysis of data from <a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>: financial incentive (1% of physician salary) for spontaneous reporting of ADRs plus fine (double the amount of the incentive) for not reporting or missing an ADR (study timeline ‐ 2006 to 2009 (pre‐intervention), 2009 to 2011 (financial incentive), 2012 to 2014 (financial incentive plus government regulations for antimicrobial agents), December 2014 (last time point), total 108 observations); and <a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>: financial incentives (1% of physicians salary) for spontaneous reporting of ADRs, twice‐yearly education meeting, reminder cards and list of the most important ADRs (study timeline ‐ January 1998 (first point); December 2002 (intervention implemented); December 2005 (last time point); a total of 96 observations) </p> <p><sup>2</sup>Both studies are observational ITS studies, so GRADE starts at low; downgraded once for serious risk of bias (high risk of bias for domain: intervention independent of other changes; there are no compelling arguments that the intervention occurred independently of other changes over time and the outcome was not influenced by other confounding variables or historic events during study period); downgraded once for serious inconsistency (I<sup>2</sup> = 92% for year 1 and 81% for year 2, inconsistency between the studies may be explained by the fact that one study was conducted in China and the other in Spain, but not certain of this); no serious indirectness; downgraded once for serious imprecision (wide confidence intervals that cross the line of no effect); no other considerations. </p> <p><sup>3</sup>Data from <a href="./references#CD012594-bbs2-0001" title="AliS , EgunsolaO , Al-DossariDS , Al-ZaagiIA . Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Therapeutic Advances in Drug Safety2018;9(10):585-90. [DOI: 10.1177/2042098618790209]">Ali 2018</a> (intervention included implementation of financial and non‐financial incentives, i.e. employee of the month award, letters of appreciation, a day's leave, performance excellence award of extra month’s salary and a certificate) could not be included in the meta‐analysis as the length of follow‐up was much shorter (study timelines ‐ 2 years; a total of 24 observations) than <a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a> (8 years; 108 observations) and <a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a> (7 years; 96 observations). Data from <a href="./references#CD012594-bbs2-0001" title="AliS , EgunsolaO , Al-DossariDS , Al-ZaagiIA . Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Therapeutic Advances in Drug Safety2018;9(10):585-90. [DOI: 10.1177/2042098618790209]">Ali 2018</a> shows relative numbers of ADR reports after 1 year: 6.99, 95% CI 3.43 to 10.54; prior to intervention ‐ 80 ADR reports per 1000 practitioners, post intervention implementation ‐ 560 ADR reports per 1000 practitioners (274 to 843); very low certainty evidence as based on observational ITS study, so GRADE starts at low; downgraded once for serious risk of bias (high risk of bias for other bias ‐ seasonality not adjusted for; and intervention independent of other changes <i>‐</i> there are no compelling arguments that the intervention occurred independently of other changes over time and the outcome was not influenced by other confounding variables or historic events during study period); no serious inconsistency; no serious indirectness; no serious imprecision; no other considerations. </p> <p><sup>4</sup>Total number of ADE reports (including ADR reports and ME reports): <b>relative number of ADR reports after 2 years</b> 8.11 (95% CI 0.61 to 107.93); assumed number with usual practice 160 expected ADR reports per 1000 practitioners, corresponding number with multifaceted intervention 1298 expected ADR reports per 1000 practitioners (98 to 17,269), mean study duration 6.5 years, 2 studies<sup>1</sup> ; certainty of the evidence: very low (see footnote<sup>2</sup>) </p> <p><sup>5</sup><b>Relative number of serious ADR reports after 2 years</b>: 2.57 (95% CI 0.22 to 29.93); prior to intervention ‐ 20 ADR reports per 1000 practitioners, post intervention ‐ 51 ADR reports per 1000 practitioners (4 to 599) mean study duration 6.5 years (<a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>; <a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>); very low certainty evidence (see footnote<sup>2</sup>) </p> <p><sup>6</sup><a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a> </p> <p><sup>7</sup>Observational ITS study, so GRADE starts at low; downgraded once for serious risk of bias (high risk of bias for domain: intervention independent of other changes; there are no compelling arguments that the intervention occurred independently of other changes over time and the outcome was not influenced by other confounding variables or historic events during study period); no serious inconsistency; no serious indirectness; downgraded once for serious imprecision (wide confidence intervals that cross the line of no effect); no other considerations. </p> <p><sup>8</sup><b>Relative number of unexpected (previously unknown) ADR reports after 2 years</b>: 0.67 (95% CI 0.01 to 61.55); prior to intervention ‐ 40 ADR reports per 1000 practitioners; post intervention implementation ‐ 27 ADR reports per 1000 practitioners (0 to 2462); mean study duration 7.0 years (<a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>); very low certainty evidence (see footnote<sup>7</sup>) </p> <p><sup>9</sup><b>Relative number of new drug‐related ADR reports after 2 years</b>: 1.86 (95% CI 0.16 to 21.59); prior to intervention ‐ 10 ADR reports per 1000 practitioners; post intervention implementation ‐ 19 ADR reports per 1000 practitioners (2 to 216); mean study duration 6.5 years (<a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>; <a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a>); very low certainty evidence (see footnote<sup>2</sup>) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Multifaceted interventions versus usual practice</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012594-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Government regulations plus financial incentives versus usual practice</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participants:</b> healthcare professionals </p> <p><b>Intervention:</b> financial incentive, fines, plus government regulation, mandatory monitoring, and reporting of ADRs (timeline: 2009 to 2011 (financial incentive or fine); 2012 to 2014 (financial incentive or fine plus government regulations for antimicrobial agents) </p> <p><b>Comparator:</b> spontaneous reporting (2006 to 2009: pre‐intervention) </p> <p><b>Setting:</b> hospital </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative numbers of ADEs<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative numbers of ADEs</b><sup>‡</sup><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Mean study duration (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed number with usual practice</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding number with multifaceted intervention</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of ADE reports (including ADR reports and ME reports): Total number of ADR reports after one year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.43 (0.54 to 3.79)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 ADR reports per 1000 practitioners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114 ADR reports per 1000 practitioners (43 to 303)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0 years (1)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We do not know if government regulations and financial incentives increase the total number of ADR reports by physicians one year after implementation of these interventions because the evidence is very uncertain. </p> <p>Data after two years in footnotes<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of false ADE reports (including false ADR reports and false ME reports)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of serious ADE reports (including serious ADR reports and serious ME reports)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of high‐causality ADE reports (including high‐causality ADR reports and high‐causality ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of unexpected ADE reports (including unexpected ADR reports and unexpected ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of new drug‐related ADE reports (including drug‐related ADR reports and drug‐related ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ADE: adverse drug event; ADR: adverse drug reaction; CI: confidence interval; cRCT: cluster randomised controlled trials; ME: medication error; vs: versus </p> <p><sup>*</sup>Relative numbers of ADRs &gt; 1 are associated with more ADRs with multifaceted intervention versus usual practice. </p> <p><sup>‡</sup>Illustrative comparative numbers of ADRs are presented as numbers of ADRs after 1 and 2 years in a setting with 1000 practitioners. </p> <p><sup>1</sup><a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>: financial incentive (1% of physician salary) for spontaneous reporting of ADRs plus fine (double the amount of the incentive) for not reporting or missing an ADR plus government regulation of antimicrobial use including detailed ADR classification, mandatory monitoring, and reporting of ADRs associated with antimicrobial agents; (timeline ‐ 2006 to 2009 (pre‐intervention); 2009 to 2011 (financial incentive); 2012 to 2014 (financial incentive plus government regulations for antimicrobial agents); December 2014 (last time point); total of 108 observations) </p> <p><sup>2</sup>Observational ITS study so GRADE starts at low; downgraded by one for risk of bias (high risk of bias for domain: Intervention independent of other changes; there are no compelling arguments that the intervention occurred independently of other changes over time and the outcome was not influenced by other confounding variables or historic events during study period); no serious inconsistency; no serious indirectness; downgraded once for serious imprecision (wide confidence intervals that cross the line of no effect); no other considerations. </p> <p><sup>3</sup>Total number of ADE reports, including ADR reports and ME reports: number of ADR reports after 2 years 1.02 (95% CI 0.24 to 4.32, mean study duration: 8 years, 1 study<sup>1</sup>; assumed number of ADR reports with usual practice 160 ADR reports per 1000 practitioners, corresponding number of ADR reports with multifaceted intervention 163 ADR reports per 1000 practitioners (38 to 346); certainty of the evidence: very low<sup>2</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Government regulations plus financial incentives versus usual practice</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012594-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Improving access to ADR report forms versus usual practice</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participants:</b> healthcare professionals </p> <p><b>Intervention:</b> improved access to ADE reporting (standardised discharge form method; yellow card ADR report form in bulletin and prescription pad; online hyperlink to ADR report form) </p> <p><b>Comparator:</b> spontaneous reporting </p> <p><b>Setting:</b> hospital </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)<sup>*</sup> </b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative rates and numbers of ADEs</b><sup>‡</sup><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants or mean study duration (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed rate or number with usual practice</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding rate or number with improving access</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of ADE reports, including ADR reports and ME reports</p> <p>Data from cRCT</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.06 (1.11 to 3.83)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 ADR reports per 1000 practitioner years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165 ADR reports per 1000 practitioner years (89 to 306)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5967 (1)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use of a standardised discharge form (for recording patient diagnoses, medical and surgical acts received during hospital stay; based on the ‘Diagnosis Related Groups’ (DRG) system) with additional ADR items (time of occurrence and evolution) may slightly increase the number of ADR reports. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of ADE reports, including ADR reports and ME reports</p> <p>Data from ITS study after one‐year follow up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.95 (1.33 to 2.85)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 ADR reports per 1000 practitioners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156 ADR reports per 1000 practitioners (106 to 228)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.4 years (2)<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very Low<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if including yellow card ADR report form in quarterly bulletins and prescription pads or providing a hyperlink to the ADR report form in hospitals' electronic patient records may lead to more ADRs being reported after one year because the evidence is very uncertain. </p> <p>Data after two years in footnote<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of false ADE reports (including false ADR reports and false ME reports)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of serious ADE reports (including serious ADR reports and serious ME reports)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of high‐causality ADE reports (including high‐causality ADR reports and high‐causality ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of unexpected ADE reports (including unexpected ADR reports and unexpected ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of new‐drug‐related ADE reports (including new‐drug‐related ADR reports and new‐drug‐related ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ADE: adverse drug event; ADR: adverse drug reaction; CI: confidence interval; cRCT: cluster randomised controlled trial; ITS: interrupted time series; ME: medication error; vs: versus </p> <p><sup>*</sup>Relative treatment effects are expressed as risk ratios and, for ITS analyses, relative expected numbers of ADRs after 1 and 2 years. Relative treatment effects &gt; 1 are associated with more ADRs with improving access versus usual practice. </p> <p><sup>‡</sup>Illustrative comparative rates and numbers of ADRs are presented as numbers of ADRs per 1000 practitioner years (for risk ratio) and expected numbers of ADRs after 1 and 2 years in a setting with 1000 practitioners (for the ITS studies). </p> <p>Serious ADRs: resulting in death; is life‐threatening; is a congenital anomaly; requires hospital admission or prolongation of stay in hospital; or results in persistent or great disability, incapacity, or both; high‐causality ADRs: ADRs with attribution of definitive or probable causality; unexpected (previously unknown) ADRs: previously unknown ADRs that are not described in the summary of product characteristics; new‐drug‐related ADRs: ADRs concerning medications that have been on the market for less than five years. </p> <p><sup>1</sup><a href="./references#CD012594-bbs2-0005" title="HanesseB , LegrasB , RoyerRJ , GuilleminF , BrianconS . Adverse drug reactions: comparison of two report methods. Pharmacoepidemiology and Drug Safety1994;3(4):223-9. ">Hanesse 1994</a>: cluster‐RCT (with cross‐over after 8 weeks, plus 2‐week washout period); the two methods for reporting ADRs were the spontaneous reporting method (SR method; usual care) and the standardised discharge form with additional ADR items (DRG method; intervention). </p> <p><sup>2</sup>Downgraded twice for very serious risk of bias (possible contamination effect due to cross‐over design and inability to blind physicians to the intervention; also unclear if the outcome assessors were blinded); no serious inconsistency; no serious indirectness; no serious imprecision; no other considerations </p> <p><sup>3</sup>Two ITS studies; <a href="./references#CD012594-bbs2-0002" title="CastelJM , FiguerasA , PedrosC , LaporteJR , CapellaD . Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads. Drug Safety2003;25(14):1049-55. ">Castel 2003</a>: combined effect of quarterly adverse drug reaction bulletin with ADR yellow card report form (introduced Sept 1985) and a ADR yellow card report form in the prescription pad (introduced January 1991 to December 1994); <a href="./references#CD012594-bbs2-0014" title="Ribeiro-VazI , Santos Cda, Costa-PereiraA , Cruz-CorreiaR . Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal. Drug Safety2012;33(5):387-94. ">Ribeiro‐Vaz 2012</a>: 2006 to 2010 ‐ hyperlinks to the ADR online reporting pharmacovigilance centre form included either in the electronic patient record or on a desktop computer. </p> <p><sup>4</sup>Both studies are observational ITS studies so GRADE starts at low; downgraded once for serious risk of bias (high risk of bias for domain: intervention independent of other changes; there are no compelling arguments that the intervention occurred independently of other changes over time and the outcome was not influenced by other confounding variables or historic events during study period); no serious inconsistency: no serious imprecision: no serious indirectness; no other considerations. </p> <p><sup>5</sup>Total number of ADE reports, including ADR reports and ME reports: number of ADR reports after 2 years of follow‐up: RR1.80 (95% CI 1.08 to 3.01, assumed rate or number with usual practice: 160 ADR reports per 1000 practitioners; corresponding rate or number with improved access: 288 ADR reports per 1000 practitioners (173 to 482); mean study duration for 2 ITS studies<sup>3</sup>: 8.4 years; certainty of the evidence: very low<sup>4</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Improving access to ADR report forms versus usual practice</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012594-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Improving ADE reporting method (new web‐based electronic error reporting system) versus usual practice (existing web‐based electronic error reporting system)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participants:</b> healthcare professionals </p> <p><b>Intervention:</b> September 2010 replace existing electronic error reporting system with new web‐based electronic error reporting system (equipped with a series of standardised screens, drop‐down menu choices, and input fields designed to collect specific information and improve communication with all departments involved); post‐implementation segment (1 September 2010 to 31 October 2012) </p> <p><b>Comparator:</b> pre‐implementation segment (1 January 2009 to 31 August 2010) ‐ web‐based electronic error reporting system </p> <p><b>Setting:</b> hospital </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative numbers of reports (95% CI)<sup>*</sup> </b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative numbers of reports</b><sup>‡</sup><br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Mean study duration (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed number with usual practice</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding number with improved reporting system</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of ADE reports: number of ME reports after one year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.80 (1.15 to 2.80)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 ME reports per 1000 practitioners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144 ME reports per 1000 practitioners (92 to 224)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.75 (1)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We do not know if the re‐engineering the web‐based electronic error reporting system may have increased the number of ME reports after one year because the evidence is very uncertain. </p> <p>Data after two years in footnotes<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of false ADE reports, including false ADR reports and false ME reports</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of serious ADE reports (including serious ADR reports and serious ME reports)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of high‐causality ADE reports (including high‐causality ADR reports and high‐causality ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of unexpected ADE reports (including unexpected ADR reports and unexpected ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of new‐drug‐related ADE reports (including new‐drug‐related ADR reports and new‐drug‐related ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ADE: adverse drug event; ADR: adverse drug reaction; CI: confidence interval; ITS: interrupted time series; ME: medication error; vs: versus </p> <p><sup>*</sup>Relative expected numbers of ME reports &gt; 1 are associated with more ME reports with improving reporting practice versus usual practice. </p> <p><sup>‡</sup>Illustrative comparative rates are presented as expected numbers of ME reports after 1 and 2 years in a setting with 1000 practitioners. </p> <p><sup>1</sup><a href="./references#CD012594-bbs2-0011" title="McKaigD , CollinsC , ElsaidKA . Impact of a reengineered electronic error-reporting system on medication event reporting and care process improvements at an urban medical center. Joint Commission Journal on Quality &amp; Patient Safety2014;40(9):398-407. ">McKaig 2014</a>: ITS; pre‐implementation segment (1 January 2009 to 31 August 2010), replace one web‐based electronic error reporting system with new web‐based electronic error reporting system (equipped with a series of standardised screens, drop‐down menu choices, and input fields designed to collect specific information and improve communication with all departments involved) implemented in September 2010, post‐implementation segment (1 September 2010 to 31 October 2012) </p> <p><sup>2</sup>Observational ITS so GRADE starts at low; downgraded once for serious risk of bias (authors do not appear to have considered seasonal effects and there is no control arm to counter this). Furthermore, there is no compelling argument that the effects of the intervention occurred independently of other changes over time; inconsistency: none; downgraded once for serious imprecision (wide confidence intervals that include little or no effect to substantial effect); indirectness: none; other: none. </p> <p><sup>3</sup>Total number of ADE reports, including ADR reports and ME reports: Relative number of ME reports after 2 years: 2.11 (95% CI 1.03 to 4.33), assumed number with usual practice: 160 ME reports per 1000 practitioners, corresponding number with different web‐based electronic error reporting system: 338 ME reports per 1000 practitioners (165 to 693); 1 study, 3.75 years exposure to intervention; very low certainty of evidence (see footnote<sup>2</sup>) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Improving ADE reporting method (new web‐based electronic error reporting system) versus usual practice (existing web‐based electronic error reporting system)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012594-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Case finding versus spontaneous reporting (usual practice)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participants:</b> healthcare professionals </p> <p><b>Intervention:</b> case finding ‐ clinical pharmacist identified ADEs by joining daily hospital rounds, screening patient charts and interviewing patients, daily meetings with physicians and nurses, comprehensive review of patient charts post‐discharge using specific data extract form to identify in‐hospital ADEs; ADEs were identified by (a) spontaneous or solicited reporting by a physician, (b) spontaneous or solicited reporting by a nurse, (c) detection on regular ward rounds and (d) detection by the clinical pharmacist by chart review after hospital discharge. </p> <p><b>Comparator:</b> usual practice (clinical pharmacist not present; ADEs identified through spontaneous reporting by nurses and physicians) </p> <p><b>Setting:</b> hospital </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p>Relative effect <b>(95% CI)<sup>*</sup> </b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative numbers of ADE</b>s<sup>‡</sup><br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed number with usual practice</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding number with case finding</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of ADE reports (including ADR reports and ME reports): number of ADE reports </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11.07 (6.24 to 21.38)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.4 per 1000 patient‐days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5 (95% CI 8.74 to 29.9) per 1000 patient‐days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1016 (1)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We do not know if having clinical pharmacists actively identifying and encouraging the identification of ADEs in a hospital setting leads to more ADEs being reported per 1000 patient‐days because the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of false ADE reports (including false ADR reports and false ME reports): number of false ADE reports </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of serious ADE reports (including serious ADR reports and serious ME reports)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of high‐causality ADE reports (including high‐causality ADR reports and high‐causality ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of unexpected ADE reports (including unexpected ADR reports and unexpected ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of new‐drug‐related ADE reports (including new‐drug‐related ADR reports and new‐drug‐related ME reports) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies included in this comparison reported on this outcome.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ADE: adverse drug event; ADR: adverse drug reaction; CI: confidence interval; ME: medication error; vs: versus </p> <p><sup>*</sup>Incidence rate ratio (IRR) of ADEs; IRR &gt; 1 is associated with more ADE reports with case finding (clinical pharmacist present) versus usual practice (spontaneous reporting, no clinical pharmacist present). </p> <p><sup>‡</sup>Illustrative comparative rates are presented as expected numbers of ADEs per 1000 patient‐days. </p> <p>Serious ADRs: resulting in death; is life‐threatening; is a congenital anomaly; requires hospital admission or prolongation of stay in hospital; or results in persistent or great disability, incapacity, or both); high‐causality ADRs: ADRs with attribution of definitive or probable causality; unexpected (previously unknown) ADRs: previously unknown ADRs that are not described in the summary of product characteristics; new‐drug‐related ADRs: ADRs concerning medications that have been on the market for fewer than 5 years. </p> <p><sup>1</sup><a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a>: non‐randomised cross‐over study, without a washout period. To minimise any possible learning effect, we have only included and analysed the data from the first period (1 to 12 months) of the study. In the test units: case finding ‐ clinical pharmacist identified ADEs by joining daily hospital rounds, screening patient charts and interviewing patients, daily meetings with physicians and nurses, comprehensive review of patient charts post‐discharge using specific data extract form to identify in‐hospital ADEs; ADEs were identified by (a) spontaneous or solicited reporting by a physician, (b) spontaneous or solicited reporting by a nurse, (c) detection on regular ward rounds and (d) detection by the clinical pharmacist by chart review after hospital discharge. In control units: clinical pharmacist not present; ADEs identified through spontaneous reporting by nurses and physicians. </p> <p><sup>2</sup>Because it is not a randomised study, the GRADE assessment starts at low; downgraded twice for very serious risk of bias (risk of selection bias as not randomised, risk of performance as no blinding of physicians or nurses, and risk of detection bias as no blinding of outcome assessors); no serious inconsistency: no serious indirectness; no serious imprecision; no other considerations. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Case finding versus spontaneous reporting (usual practice)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012594-tbl-0008"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of published systematic reviews assessing interventions to increase ADE reporting</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD012594-bbs2-0135" title="PagottoC , VaralloF , MastroianniF . Impact of educational interventions on adverse drug events reporting. International Journal of Technology Assessment in Health Care2013;29(4):410-17."><b>Pagotto 2013</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD012594-bbs2-0114" title="Gonzalez-GonzalezC , Lopez-GonzalezE , HerdeiroMT , FigueirasA . Strategies to improve adverse drug reactions reporting: a critical and systematic review. Drug Safety2013;36(5):317-28."><b>Gonzalez‐Gonzalez 2013</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD012594-bbs2-0139" title="Ribeiro-VazI , SilvaAM , Costa SantosC , Cruz-CorreiaR . How to promote adverse drug reaction reports using information systems - a systematic review and meta-analysis. BMC Medical Informatics and Decision Making2016;16(27):1-10. [DOI: 10.1186/s12911-016-0265-8]"><b>Ribeiro‐Vaz 2016</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD012594-bbs2-0124" title="LiR , ZaidiSTR , ChenT , CastelinoR . Effectiveness of interventions to improve adverse drug reaction reporting by healthcare professionals over the last decade: a systematic review. Pharmacoepidemiology and Drug Safety2019;29:1-8."><b>Li 2019</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD012594-bbs2-0137" title="PaudyalV , Al-HamidaA , BowenaM , Abdul HadiM , HasanSS , JalalaZ , StewartD . Interventions to improve spontaneous adverse drug reaction reporting by healthcare professionals and patients: systematic review and meta-analysis. Expert Opinion on Drug Safety2020;19(9):1173–91."><b>Paudyal 2020</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD012594-bbs2-0121" title="KhaliliM , MesgarpourB , SharifiH , Daneshvar DehnaviS , HaghdoostAA . Interventions to improve adverse drug reaction reporting: a scoping review. Pharmacoepidemiology and Drug Safety2020;29(9):965-92."><b>Khalili 2020</b> </a><b>(scoping review)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Objectives</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To identify the techniques of educational intervention for promotion of pharmacovigilance by healthcare professionals and to assess their impact. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To conduct a critical review of papers that assessed the effectiveness of different strategies to increase ADR reporting, regardless of the healthcare professionals or patients included. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To describe the state of the art information systems used to promote ADR reporting.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To determine the features and successes of the various strategies undertaken to improve ADR reporting by healthcare professionals, and propose alternative initiatives that may enhance these existing methods. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To evaluate the effectiveness of interventions used for improving ADR reporting by patients and healthcare professionals. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To systematically map interventions and strategies to improve ADR reporting among health care professionals. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Eligible study designs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All study designs included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐post experimental design; time series; non‐randomised controlled experimental study; randomised controlled experimental study; cluster randomised controlled experimental study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any studies describing or evaluating the use of information systems to promote adverse drug reaction reporting. Studies with data related to the number of ADRs reported before and after each intervention and the follow‐up period were included in the quantitative analysis. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCTs, quasi‐experimental, time series studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All forms of interventional designs were considered. Meta analysis not undertaken for non‐randomised trials </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quantitative methods focused on healthcare professionals</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Eligible participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Healthcare professionals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Professionals to whom the intervention for increasing ADR reporting is addressed: physicians, nurses, pharmacists, young physicians, house officers,<br/>pharmacy students, section head, ‘quality review staff’,<br/>medical students. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Healthcare professionals or patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Healthcare professionals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Healthcare professionals and patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Healthcare professionals</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Eligible interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Educational interventions only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Educational activity, reminders, modification of reporting forms, modifciation of reporying process, incentives, assistance from another professiionl, increased availability of reporting forms, feedback on reporting </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies describing or evaluating the use of information systems to promote adverse drug reaction reports were selected </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any intervention aimed at increasing ADR reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any pharmacovigilence intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any intervention or strategy (such as ones implemented by government policies, applied experimentally or non‐experimentally, or adopted in specific settings) to improve ADR reporting </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Eligible comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes reported on</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADE reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increase in ADR reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of ADR reporting increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADR rporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome: quantity of<br/>ADRs reported as a result of the intervention including<br/>improvement in the number or rate of reporting. <br/>Secondary outcomes: the quality of ADR reporting including the<br/>nature of ADRs reported (e.g. serious, nonserious ADRs) and<br/>completeness of the reports. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADR reporting rate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number and type of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 met the inclusion criteria<br/>6 RCT, 5 quasi‐experimental, 2 case‐ control studies, 2 ecological time series analysis, 1 observational analytic) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 articles were included in the analysis; these articles described 29 different projects.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 studies included (3 cRCTs, 1 RCT, 7 quasi‐experimental, 2 ITS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 studies included in qualitative synthesis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Findings and conclusions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharmacovigilance‐based educational interventions showed positive impacts (quantitative and qualitative) on ADE spontaneous reporting by health professionals. Multifaceted techniques for interventions, included: lectures, placement of yellow cards, distribution of printed educational materials and giveaways, as well as the or‐ ganization of workshops </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple interventions have a greater impact than single.</p> <p>Evidence to show that, when it comes to bringing about changes in professional practice, interventions that boost the active participation of professionals (i.e. workshops) can be more effective than passive didactic sessions.<br/>Another vital factor is the duration of the effect of the intervention. It can be concluded that, as was to be expected, the longer the period from the date of the intervention, the more the latter's effect is progressively reduced. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most projects performed passive promotion of ADR reporting (i.e., facilitating the process). Developed in hospitals and tailored to healthcare professionals. Interventions doubled the number of ADR reports. Authors believe that it would be useful to develop systems to assist healthcare professionals with completing ADR reporting within electronic health records because this approach seems to be an efficient method to increase the ADR reporting rate. When this approach is not possible, it is essential to have a tool that is easily accessible on the web to report ADRs. This tool can be promoted by sending emails or through the inclusion of direct hyperlinks on healthcare professionals’ desktops. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multi‐faceted approach including education, reminders, and electronic reporting would likely to be the most successful. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited evidence showed that active interventions involving face to face educational approaches, financial incentives, and electronic features targeted at healthcare professionals could improve ADR reporting. However, the results need to be interpreted cautiously given the short term evaluation out‐ comes, dominance of observational designs and low quality of included studies. Interventions need to be developed and tested in countries low‐and‐middle income countries. Most of the included studies included educational interventions to improve ADR reporting. A variety of educational methods were used including reminders, face to face educational sessions and newsletters. While most of these studies were reported to have improved ADR reporting, there was a lack of long‐term follow up of the outcomes. The cluster‐ randomized controlled trials included in the study reported that the impact of interventions observed by the difference in the intervention and control group in the ADR reporting rate lasted for only 12 months after which such difference was no longer significant. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Interventions aimed at enhancing ADR reporting have a good chance of producing positive results, although their effect, especially in the case of educational interventions, could be temporary. Multiple inter‐ ventions might cause greater increase in ADR reporting rates compared with single interventions. Further research is warranted to improve the methodological quality using control groups, large sample sizes, longer follow‐up periods, and adjustment for the confounders. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any limits noted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Language limit: English, Portuguese, or Spanish<br/>search for publications from November 2011 to January 2012, updated in March 2013. <br/>Quality assessment of the manuscripts was not carried out. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limit publication date: up to 2010; Language limited to English, French or Spanish</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Language limited to English, Portuguese or French <br/>Excluded articles based on: (1) only focused on medication errors; (2) only focused on ADR detection; (3) studies without any information system implemented; (4) studies concerning data quality; (5) studies focused on website usability; (6) authors’ reflections on the theme; (7) studies only related to incidents that occurred in health institutions; (8) studies concerning signal detection and (9) studies concerning electronic transmission between the authority and other institutions (pharmaceutical companies or regional pharmacovigilance centres). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search limited to studies published from 2010 to 2019; English only; NO medication error reporting </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Educational research with student participants; interventions not including qualified healthcare practitioners or patients were excluded as well as the interventions<br/>related to devices and planned ADR surveillance monitoring programmes, such as those used for mass vaccinations; Abstract<br/>only publications including conference abstracts were excluded. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search date limited from 1999 to February 2019; <br/>no language restrictions; methodological quality or risk of bias of the included articles were not appraised </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ADE: adverse drug event; ADR: adverse drug reaction; cRCT: cluster‐randomised controlled trial; ITS:interrupted time series; RCT: randomised controlled trial </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of published systematic reviews assessing interventions to increase ADE reporting</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012594-tbl-0009"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcomes reported by the included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of ADE reports (including ADR reports and ME reports)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of false ADE reports (including false ADR reports and false ME reports)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of serious ADE reports (including serious ADR reports and serious ME reports)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of high‐causality ADE reports (including high‐causality ADR reports and high‐causality ME reports)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of unexpected (previously unknown) ADE reports (including unexpected ADR reports and unexpected ME reports)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of new drug‐related ADE reports (including drug‐related ADR reports and drug‐related ME reports)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Comparison 1. Education session plus reminder card and report form versus usual practice</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a>; <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a>; <a href="./references#CD012594-bbs2-0010" title="ISRCTN91140684. An educational intervention to improve adverse drug reactions reporting among Galician physicians. https://www.isrctn.com/ISRCTN91140684 (first received 7 May 2009). Lopez-GonzalezE , HerdeiroMT , Pineiro-LamasM , FigueirasA , Grephepi group. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Safety2015;38(2):189-96. ">Lopez‐Gonzalez 2015</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a>; <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a>; <a href="./references#CD012594-bbs2-0010" title="ISRCTN91140684. An educational intervention to improve adverse drug reactions reporting among Galician physicians. https://www.isrctn.com/ISRCTN91140684 (first received 7 May 2009). Lopez-GonzalezE , HerdeiroMT , Pineiro-LamasM , FigueirasA , Grephepi group. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Safety2015;38(2):189-96. ">Lopez‐Gonzalez 2015</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>;<br/><a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a>; <a href="./references#CD012594-bbs2-0007" title="HerdeiroMT , Ribeiro-VazI , FerreiraM , PoloniaJ , FalcaoA , FigueirasA . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Safety2012;35(8):655-65. ">Herdeiro 2012</a>; <a href="./references#CD012594-bbs2-0010" title="ISRCTN91140684. An educational intervention to improve adverse drug reactions reporting among Galician physicians. https://www.isrctn.com/ISRCTN91140684 (first received 7 May 2009). Lopez-GonzalezE , HerdeiroMT , Pineiro-LamasM , FigueirasA , Grephepi group. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Safety2015;38(2):189-96. ">Lopez‐Gonzalez 2015</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a>; <a href="./references#CD012594-bbs2-0010" title="ISRCTN91140684. An educational intervention to improve adverse drug reactions reporting among Galician physicians. https://www.isrctn.com/ISRCTN91140684 (first received 7 May 2009). Lopez-GonzalezE , HerdeiroMT , Pineiro-LamasM , FigueirasA , Grephepi group. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Safety2015;38(2):189-96. ">Lopez‐Gonzalez 2015</a>; <a href="./references#CD012594-bbs2-0013" title="Ribeiro-VazI , HerdeiroMT , PoloniaJ , FigueirasA . Strategies to increase the sensitivity of pharmacovigilance in Portugal [Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal]. Revista Saude Publica2011;45(1):129-35. ">Ribeiro‐Vaz 2011</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0004" title="FigueirasA , HerdeiroMT , PoloniaJ , Gestal-OteroJJ . An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Journal of the American Medical Association2006;296(9):1086-93. [DOI: 10.1001/jama.296.9.1086]">Figueiras 2006</a>; <a href="./references#CD012594-bbs2-0006" title="HerdeiroMT , PoloniaJ , Gestal-OteroJJ , FigueirasA . Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Safety2008;31(4):335-44. ISRCTN45894687. An educational intervention to improve adverse drug reactions reporting: a cluster-randomised trial among Portuguese physicians and pharmacists. https://www.isrctn.com/ISRCTN45894687 (first received 7 June 2006). ">Herdeiro 2008</a> (ADR reports) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Comparison 2. Informational letter or email versus usual practice</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0008" title="JohanssonML , BrunlofG , EdwardC , WallerstedtSM . Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports. European Journal of Clinical Pharmacology2009;65(5):511-4. ">Johansson 2009</a>; <a href="./references#CD012594-bbs2-0009" title="JohanssonML , HaggS , WallerstedtSM . Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study. BMC Clinical Pharmacology2011;11:14. ">Johansson 2011</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0008" title="JohanssonML , BrunlofG , EdwardC , WallerstedtSM . Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports. European Journal of Clinical Pharmacology2009;65(5):511-4. ">Johansson 2009</a>; <a href="./references#CD012594-bbs2-0009" title="JohanssonML , HaggS , WallerstedtSM . Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study. BMC Clinical Pharmacology2011;11:14. ">Johansson 2011</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0008" title="JohanssonML , BrunlofG , EdwardC , WallerstedtSM . Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports. European Journal of Clinical Pharmacology2009;65(5):511-4. ">Johansson 2009</a>; <a href="./references#CD012594-bbs2-0009" title="JohanssonML , HaggS , WallerstedtSM . Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study. BMC Clinical Pharmacology2011;11:14. ">Johansson 2011</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0008" title="JohanssonML , BrunlofG , EdwardC , WallerstedtSM . Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports. European Journal of Clinical Pharmacology2009;65(5):511-4. ">Johansson 2009</a>;<br/><a href="./references#CD012594-bbs2-0009" title="JohanssonML , HaggS , WallerstedtSM . Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study. BMC Clinical Pharmacology2011;11:14. ">Johansson 2011</a> (ADR reports) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Comparison 3. Multifaceted intervention versus usual practice</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012594-bbs2-0001" title="AliS , EgunsolaO , Al-DossariDS , Al-ZaagiIA . Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Therapeutic Advances in Drug Safety2018;9(10):585-90. [DOI: 10.1177/2042098618790209]">Ali 2018</a>; <a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>;<br/><a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>; <a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a>; <a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a> (ADR reports) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Comparison 4. Government regulations and financial incentives versus usual practice</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Comparison 5. Improving access to ADR report form versus usual practice</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012594-bbs2-0002" title="CastelJM , FiguerasA , PedrosC , LaporteJR , CapellaD . Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads. Drug Safety2003;25(14):1049-55. ">Castel 2003</a>; <a href="./references#CD012594-bbs2-0014" title="Ribeiro-VazI , Santos Cda, Costa-PereiraA , Cruz-CorreiaR . Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal. Drug Safety2012;33(5):387-94. ">Ribeiro‐Vaz 2012</a>; <a href="./references#CD012594-bbs2-0005" title="HanesseB , LegrasB , RoyerRJ , GuilleminF , BrianconS . Adverse drug reactions: comparison of two report methods. Pharmacoepidemiology and Drug Safety1994;3(4):223-9. ">Hanesse 1994</a> (ADR reports) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Comparison 6. Improving reporting method versus usual practice</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012594-bbs2-0011" title="McKaigD , CollinsC , ElsaidKA . Impact of a reengineered electronic error-reporting system on medication event reporting and care process improvements at an urban medical center. Joint Commission Journal on Quality &amp; Patient Safety2014;40(9):398-407. ">McKaig 2014</a> (mean number of monthly ME reports pre‐ and post‐intervention) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Comparison 7. Case finding versus spontaneous reporting (usual practice)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a> (number of ADE reports per 1000 patient‐days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p> <ul id="CD012594-list-0019"> <li> <p>Serious ADRs: adverse drug reactions resulting in death; is life‐threatening; is a congenital anomaly; requires hospital admission or prolongation of stay in hospital; results in persistent or great disability, incapacity or both </p> </li> <li> <p>High‐causality ADRs: adverse drug reactions with attribution of definitive or probable causality; unexpected (previously unknown) </p> </li> <li> <p>ADRs: unknown adverse drug reactions that are not described in the drug's summary of product characteristics </p> </li> <li> <p>New‐drug‐related ADRs: adverse drug reactions relating to medications that have been on the market for less than five years </p> </li> <li> <p>ADE: adverse drug event</p> </li> <li> <p>ME: medication error</p> </li> </ul> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcomes reported by the included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012594-tbl-0010"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Re‐analysis of data in three included studies (Ali 2018, Chang 2017, Pedros 2009)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative treatment effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>ITS parameter</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% CI</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012594-bbs2-0001" title="AliS , EgunsolaO , Al-DossariDS , Al-ZaagiIA . Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Therapeutic Advances in Drug Safety2018;9(10):585-90. [DOI: 10.1177/2042098618790209]">Ali 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Total number of ADR reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relative change in level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.533</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.658 to 3.408</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in slope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.073 to 0.543</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative expected adverse drug reaction reports<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.43 to 10.54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a> </p> <p>Financial incentives</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total number of ADR reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.084</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.490 to 2.678</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in slope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.005 to 0.126</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012594-bbs2-0003" title="ChangF , XiY , ZhaoJ , ZhangX , LuY . A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. Journal of Evaluation Clinical Practice2017;23(6):1316-21. ">Chang 2017</a> </p> <p>Government regulations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total number of ADR reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.129 to 1.261</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in slope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.069 to 0.014</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012594-bbs2-0012" title="PedrósC , VallanoA , CerezaG , Mendoza-AranG , AgustiA , AguileraC , et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Safety2009;32(1):77-83. ">Pedrós 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total number of ADR reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.142 to 0.065</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in slope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.059</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.026 to 0.092</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>See <a href="#CD012594-fig-0022">Figure 22</a> for data source </p> <p>ADR: adverse drug reactions; CI: confidence interval; ITS: interrupted time series</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Re‐analysis of data in three included studies (Ali 2018, Chang 2017, Pedros 2009)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012594-tbl-0011"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Comparison 5. Improving access to ADR report forms (Hanesse 1994)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk ratio</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% CI</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0005" title="HanesseB , LegrasB , RoyerRJ , GuilleminF , BrianconS . Adverse drug reactions: comparison of two report methods. Pharmacoepidemiology and Drug Safety1994;3(4):223-9. ">Hanesse 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improving access vs usual practice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of ADR reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.11 to 3.83</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>ADR: adverse drug reactions; CI: confidence interval; vs: versus</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Comparison 5. Improving access to ADR report forms (Hanesse 1994)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012594-tbl-0012"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Comparison 5. Improving access to ADR report forms (Castel 2003 and Ribeiro‐Vaz 2012)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Measure</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>ITS parameter</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% CI</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012594-bbs2-0002" title="CastelJM , FiguerasA , PedrosC , LaporteJR , CapellaD . Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads. Drug Safety2003;25(14):1049-55. ">Castel 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Bulletins and ADR report forms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Total number of ADR reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.734</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.422 to 1.047</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in slope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.022 to 0.008</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative expected ADRs (1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.653</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.263 to 1.043</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relative expected ADRs (2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.050 to 1.093</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012594-bbs2-0014" title="Ribeiro-VazI , Santos Cda, Costa-PereiraA , Cruz-CorreiaR . Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal. Drug Safety2012;33(5):387-94. ">Ribeiro‐Vaz 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Hyperlink to online ADR form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Total number of ADR reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.813</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.302 to 1.324</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in slope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.034</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.281 to 0.348</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative expected ADRs (1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.714 to 2.608</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative expected ADRs (2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.081</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.822 to 3.983</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>ADR: adverse drug reaction; CI: confidence interval; ITS: interrupted time series</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Comparison 5. Improving access to ADR report forms (Castel 2003 and Ribeiro‐Vaz 2012)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012594-tbl-0013"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Comparison 6. Improving reporting practice vs usual practice (McKaig 2014)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative treatment effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>ITS parameter</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% CI</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012594-bbs2-0011" title="McKaigD , CollinsC , ElsaidKA . Impact of a reengineered electronic error-reporting system on medication event reporting and care process improvements at an urban medical center. Joint Commission Journal on Quality &amp; Patient Safety2014;40(9):398-407. ">McKaig 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Total number of ME reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.229 to 0.624</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative change in slope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.010 to 0.037</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative expected ME reports (1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.142 to 1.031</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative expected ME reports (2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.026 to 1.466</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CI: confidence interval; ITS: interrupted time series; ME: medication error</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Comparison 6. Improving reporting practice vs usual practice (McKaig 2014)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012594-tbl-0014"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Comparison 7. Case finding versus spontaneous reporting (usual practice) (Schlienger 1999)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Incidence rate (95% CI) of ADE reports: period 1 (12 months)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Incidence rate ratio</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With clinical pharmacist</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Without clinical pharmacist</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5 (95% CI 12.87 to 18.51)</p> <p>ADEs per 1000 patient‐days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 (95% CI 0.75 to 2.39)</p> <p>ADEs per 1000 patient‐days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.07 (95% CI 6.24 to 21.38) more ADEs per 1000 patient‐days with clinical pharmacist than without </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>ADE: adverse drug event; CI: confidence interval</p> <p>As <a href="./references#CD012594-bbs2-0015" title="SchliengerRG , LuscherTF , SchoenenbergerRA , HaefeliWE . Academic detailing improves identification and reporting of adverse drug events. Pharmacy World &amp; Science1999;21(3):110-5. ">Schlienger 1999</a> is a cross‐over study without a washout period, we only used the data from the first period of the study, prior to the treatment allocation cross‐over. Using data from Table 3 in the full‐text study report (first study period), we imputed the incidence rates and 95% CI; then we computed the incidence rate ratios to compare the rate of ADE reporting rate with and without the presence of a clinical pharmacist actively checking for and submitting reports on any ADEs. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Comparison 7. Case finding versus spontaneous reporting (usual practice) (Schlienger 1999)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/full#CD012594-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012594-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Comparison 2: Informational letter or email versus usual practice</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Number of unexpected (previously unknown) adverse drug reaction reports <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.92, 2.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Comparison 2: Informational letter or email versus usual practice</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012594.pub2/references#CD012594-tbl-0015">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012594.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012594-note-0019">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012594-note-0027">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012594-note-0025">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012594-note-0026">Français</a> </li> <li class="section-language"> <a class="" href="ko#CD012594-note-0024">한국어</a> </li> <li class="section-language"> <a class="" href="ru#CD012594-note-0022">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD012594-note-0023">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012594-note-0020">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012594-note-0021">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012594\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012594\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012594\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012594\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012594\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012594\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012594\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012594\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012594\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012594\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012594\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012594\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012594\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012594\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012594\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012594\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012594\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012594\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012594.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012594.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012594.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012594.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012594.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728518116"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012594.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728518120"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012594.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec66dab6af431',t:'MTc0MDcyODUxOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 